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Genetic studies have led to the identification of several candidate genes, some novel and 
others established, that may contribute to the risk of developing neuropsychiatric disorders.  
For example, dopamine receptor genes are established candidates for a number of psychiatric 
disorders such as Parkinson’s Disease, alcohol addiction and mood disorders. On the other 
hand, a gene of unknown function, AUTS2 (Autism susceptibility candidate 2), has recently 
been associated with alcohol consumption in a GWAS meta-analysis performed by our group. 
Interestingly, it has been associated with a broad range of neuropsychiatric disorders including 
autism, epilepsy and schizo-affective disorders. This thesis looked to address two broad aims: 
to establish lentiviral-mediated gene delivery technique in vivo by delineating the role of two 
well characterised Dopamine receptors D2R and D3R and to functionally characterise the role 
of AUTS2. By successfully establishing lentiviral mediated gene manipulation in vitro and in 
vivo, this thesis presents data for a similar role of nucleus accumbens D2R and D3R in novelty-
induced locomotion while these receptors have a differential function in the regulation of 
light-induced locomotor behaviour in rats. Additionally, using molecular biology and in silico 
methods, this thesis demonstrates that AUTS2 is a nuclear protein and presents indications of 
its function as a neurodevelopmental gene with a potential role in neural migration, although 
its specific role has yet to be corroborated. Collectively, findings from this thesis will increase 
our understanding of the genetic link with brain function and behavioural traits. This will 
therefore have implications for overall neuropsychiatric research, as it will help understand 
molecular mechanisms underlying these conditions and possibly direct in the identification of 
potential therapeutic targets.  
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Brief summary of thesis chapters 
 
Chapter One provides an overview of current literature concerned with the use of various 
strategies used in the identification and validation of candidate genes involved in the aetiology 
of neuropsychiatric disorders in general. 
 
Chapter Two describes generalised methods and materials used in the data chapters that 
follow. 
 
Chapter Three presents findings from establishing lentiviral mediated gene delivery in vitro 
and in vivo by targeting two Dopamine receptors D2 and D3 in the rat nucleus accumbens to 
distinguish their roles on locomotor function. 
 
Chapter Four presents findings that contribute to the regional and cellular characterisation of 
AUTS2 (Autism susceptibility candidate 2) whose gene function is largely unknown.  
 
Chapter Five attempts to investigate the neurodevelopmental role for AUTS2 using lentiviral 
mediated gene silencing in a human foetal neural stem cell line, given its characterisation as a 
neurodevelopmental gene and its implications in a broad range of neuropsychiatric disorders.   
 
Chapter Six will discuss the above findings and its implications for scientific research. This 






I would like to thank my first supervisor, Dr. Sylvane Desrivières for the supervision and 
guidance offered throughout the duration of my study and my second supervisor Prof. Gunter 
Schumann, for giving me the opportunity to study for a PhD. 
 
I would also like to acknowledge all the members of the Schumann group (past and present) 
for their support and friendship, especially Dr David Stacey for his time and advice and Dr 
Barbara Ruggeri. I would also like to express my sincere gratitude to all the staff and students 
(past and present) of the MRC Social, Genetic and Developmental Psychiatry Research Centre 
for their support and encouragement throughout the time I have known them. A special 
mention goes to Dr Conrad Iyegbe, Dr Cathy Fernandes, Dr Louise Arsenault and Dr Anbarasu 
Lourdusamy for their time and advice. 
 
I would like to thank the following individuals for their contribution towards this thesis: 
Prof. Christian P. Müller (Psychiatrische und Psychotherapeutische Klinik Universitätsklinikum 
Erlangen,  Germany) 
Alanna Easton (MRC Social, Genetic and Developmental Psychiatry Research Centre, Institute 
of Psychiatry, King’s College London)  
 
Finally, but most importantly, I am eternally grateful to my mum and dad for their motivation 
and constant encouragement throughout my life and my siblings, Andrea and Adrian for just 




Statement of independent work  
 
Chapter 1 
This chapter is entirely my own work. 
 
Chapter 2 
This chapter is entirely my own work. 
 
Chapter 3 
My contribution included the generation of plasmids overexpressing and silencing D2R and 
D3R, as well as lentiviral production, ultacentrifugation, quantification and testing expression/ 
silencing efficiency of these constrcuts in vitro. I have also performed all the histological 
analysis in this chapter. Animal handling, behavioural testing, culling and brain extraction 
which were carried out by Dr Alanna Easton. 
 
Chapter 4 
My contribution involved the generation of plasmids overexpressing AUTS2 and V5-tagged 
AUTS2, tranfecting these plasmids in various cell lines as well as carrying out RNA and protein 




My contribution included the production, ultracentrifugation, quantification of AUTS2-
sielcning lentiviruses. In addition, I performed the transduction of 293T cells to assess knock 
down efficiencies of lentiviruses silencing AUTS2, as well as carried out RNA extraction for 
microarrays. Microarray experiments were performed by Eric Nasser, Biomedical Research 
Centre (BRC) genomics facility, King’s College London. The data analysis was done by Dr Venu 
Pullabhatla, NIHR GSTFT/KCL Comprehensive Biomedical Research Centre.  
 
Chapter 6 





TABLE OF CONTENTS 
BRIEF SUMMARY OF THESIS CHAPTERS ................................................................................................. 5 
ACKNOWLEDGEMENTS ......................................................................................................................... 6 
STATEMENT OF INDEPENDENT WORK ................................................................................................... 7 
CHAPTER 1 INTRODUCTION .................................................................................................................21 
1.1 THE PREVALENCE OF NEUROPSYCHIATRIC DISORDERS............................................................................. 22 
1.2 GENETIC CONTRIBUTION TO NEUROPSYCHIATRIC DISORDERS ................................................................... 22 
1.3 GENE IDENTIFICATION APPROACHES IN NEUROPSYCHIATRIC DISORDERS ..................................................... 23 
1.3.1 Linkage studies ..................................................................................................................... 24 
1.3.2 Candidate gene approach .................................................................................................... 24 
1.3.3 Genome Wide Association Studies (GWAS) .......................................................................... 28 
1.4 OVERLAPPING GENETIC AETIOLOGY OF NEUROPSYCHIATRIC DISORDERS AND AUTS2 ................................... 29 
1.5 FUNCTIONAL GENETIC APPROACHES – GENE MANIPULATION................................................................. 33 
1.5.1 Gene silencing....................................................................................................................... 33 
1.5.1.1 RNA interference (RNAi) .............................................................................................................33 
RNAi mechanism .......................................................................................................................................33 
Application of RNAi ...................................................................................................................................36 
1.5.2 Generation of genetically altered mice ................................................................................ 37 
1.6 GENE DELIVERY METHODS ............................................................................................................... 39 
1.6.1 Non viral method - Transfection ........................................................................................... 39 
1.6.2 Lentiviruses as vectors for gene delivery .............................................................................. 40 
1.6.2.1 The lentiviral life cycle ................................................................................................................42 
1.6.2.2 Modification of lentiviral features for use in research................................................................43 
1.6.2.3 Advantages and applications of lentiviral mediated gene delivery ............................................46 
1.7 THESIS AIMS ................................................................................................................................. 48 
CHAPTER 2 MATERIALS AND METHODS ...............................................................................................49 
2.1 TISSUE CULTURE ............................................................................................................................ 50 
2.1.1 Materials .............................................................................................................................. 50 
2.1.1.1 Cell lines ......................................................................................................................................50 
2.1.1.2 Media and supplements .............................................................................................................50 
2.1.1.3 SPC-O4 media and reagents........................................................................................................52 
2.1.1.4 RMM without growth factor and 4-OHT (RMM-) .......................................................................53 
2.1.1.5 Preparation of differentiation inducing agents ...........................................................................53 
2.1.1.6 Preparation of trypsin inhibitor solution (Trit)............................................................................53 




2.1.2 Methods ............................................................................................................................... 53 
2.1.2.1 Maintenance of all cells lines ......................................................................................................53 
2.1.2.2 Passaging SPC-04 ........................................................................................................................54 
2.1.2.3 Inducing differentiation of SPC-04 ..............................................................................................54 
2.1.2.4 Passaging other adherent cell lines ............................................................................................55 
2.1.2.5 Cell counting ...............................................................................................................................55 
2.2 TRANSFECTION .............................................................................................................................. 56 
2.2.1 Materials .............................................................................................................................. 56 
2.2.1.1 Hepes Buffered Saline (HBS), 2x .................................................................................................56 
2.2.1.2 CaCl2, 2.5M .................................................................................................................................56 
2.2.2 Methods ............................................................................................................................... 56 
2.2.2.1 Calcium phosphate transfection .................................................................................................56 
2.2.2.2 Determining transfection efficiency ...........................................................................................57 
2.3 LENTIVIRAL PRODUCTION, TRANSDUCTION AND CONCENTRATION ............................................................ 58 
2.3.1 Materials .............................................................................................................................. 58 
2.3.1.1 Polybrene, 1000x ........................................................................................................................58 
2.3.1.2 Chloroquine, 100mM ..................................................................................................................58 
2.3.2 Methods ............................................................................................................................... 58 
2.3.2.1 Lentiviral production ...................................................................................................................58 
2.3.2.2 Lentiviral Transduction ...............................................................................................................58 
2.3.2.3 Concentration of lentivirus .........................................................................................................59 
2.3.2.4 Lentiviral quantification ..............................................................................................................59 
2.3.2.5 Infection of SPC-04 with lentivirus ..............................................................................................60 
2.4 BACTERIAL TRANSFORMATIONS AND CULTURES .................................................................................... 61 
2.4.1 Materials .............................................................................................................................. 61 
2.4.1.1 Ampicillin stock solution .............................................................................................................61 
2.4.1.2 Lennox L Broth base (LB).............................................................................................................61 
2.4.1.3 LB Agar ........................................................................................................................................61 
2.4.1.4 Bacterial strains ..........................................................................................................................61 
2.4.2 Methods ............................................................................................................................... 62 
2.4.2.1 Transformation of E.coli with plasmid DNA ................................................................................62 
2.5 QUANTIFICATION OF DNA AND RNA ................................................................................................ 63 
2.6 DNA EXTRACTION AND ANALYSIS ...................................................................................................... 63 
2.6.1 Materials .............................................................................................................................. 63 
2.6.1.1 DNA Agarose gel .........................................................................................................................63 
2.6.1.2 Gel loading buffer .......................................................................................................................63 
2.6.2 Methods ............................................................................................................................... 64 
2.6.2.1 Mini- and Maxi- preps .................................................................................................................64 
2.6.2.2 Agarose gel electrophoresis ........................................................................................................64 
2.6.2.3 DNA extraction from gels ............................................................................................................64 
10 
 
2.6.2.4 DNA Sequencing .........................................................................................................................65 
2.7 RNA EXTRACTION AND REVERSE TRANSCRIPTION.................................................................................. 67 
2.7.1 Materials .............................................................................................................................. 67 
2.7.1.1 Lysis buffer for RNA extraction ...................................................................................................67 
2.7.2 Methods ............................................................................................................................... 67 
2.7.2.1 Harvesting cells for RNA extraction ............................................................................................67 
2.7.2.2 RNA extraction ............................................................................................................................67 
2.7.2.3 Reverse transcription and complementary DNA (cDNA) synthesis ............................................67 
2.8 REAL TIME QUANTITATIVE PCR ........................................................................................................ 68 
2.9 PROTEIN ANALYSIS ......................................................................................................................... 69 
2.9.1 Materials .............................................................................................................................. 69 
2.9.1.1 Buffers and reagents for Immunocytochemistry and Immunohistochemistry ...........................69 
Phosphate Buffer Saline (PBS) ...................................................................................................................69 
Paraformaldehyde, 4% in 0.1M PBS pH7.4 ................................................................................................69 
PBS-Triton (PBST) ......................................................................................................................................69 
2.9.1.2 Buffers for SDS-PAGE, Western Blot and Co-Immunoprecipitation ............................................69 
Radioimmunoprecipitation (RIPA) buffer .......................................................................................................69 
SDS-PAGE running buffer (National Diagnostic Ltd, UK) ................................................................................70 
SDS-PAGE transfer buffer ...............................................................................................................................70 
SDS-PAGE sample buffer, Laemmli 6x ............................................................................................................70 
Stock acrylamide ............................................................................................................................................70 
SDS-PAGE gel constituents .............................................................................................................................71 
Tris- Buffered Saline (TBS), 1 x .......................................................................................................................71 
TBS containing Tween-20 (TBST) ....................................................................................................................71 
Blocking buffers..............................................................................................................................................71 
2.9.1.3 Primary and secondary antibodies .............................................................................................71 
2.9.2 Methods ............................................................................................................................... 73 
2.9.2.1 Immunocytochemistry ................................................................................................................73 
2.9.2.2 Immunohistochemistry ...............................................................................................................73 
2.9.2.3 Protein extraction .......................................................................................................................74 
2.9.2.4 Protein quantification .................................................................................................................74 
2.9.2.5 SDS-PAGE and Western Blot .......................................................................................................75 
i) SDS-page gel preparation .....................................................................................................................75 
ii) Sample preparation for loading and running .......................................................................................75 
iii) Semidry Transfer ..................................................................................................................................75 
iv) Antibody incubations ............................................................................................................................76 






CHAPTER 3 ...........................................................................................................................................81 
DELINEATING THE ROLE OF DOPAMINE D2 AND D3 RECEPTORS IN VITRO AND IN VIVO USING 
LENTIVIRAL-MEDIATED GENE DELIVERY ...............................................................................................81 
3.1 INTRODUCTION ............................................................................................................................. 82 
3.1.1 The current project and aims ................................................................................................ 82 
3.1.2 Dopamine receptors ............................................................................................................. 83 
3.1.3 Distribution of D2R and D3R in the brain ............................................................................. 85 
3.1.4 The neural circuitry of the ventral striatum and the nucleus accumbens ............................ 86 
3.1.5 D2R and D3R regulation of locomotor behaviour ................................................................ 88 
3.2 METHODS AND MATERIALS ............................................................................................................. 90 
3.2.1 Materials .............................................................................................................................. 90 
3.2.1.1 Cloning plasmids LeGO - iG2 and LeGO-G ...................................................................................90 
3.2.2 Construction of D2R and D3R overexpression vectors .......................................................... 93 
3.2.2.1 PCR Amplification of D2R and D3R .............................................................................................93 
3.2.2.2 Agarose gel electrophoresis ........................................................................................................94 
3.2.2.3 Restriction enzyme digest ...........................................................................................................94 
3.2.2.4 Ligation of the PCR products into the LeGO-iG2 lentiviral expression vector .............................95 
3.2.2.5 Screening for positive clones ......................................................................................................95 
3.2.2.6 DNA sequencing of positive clones .............................................................................................95 
3.2.3 Construction of D2R and D3R shRNA recombinant lentiviruses ........................................... 97 
3.2.3.1 D2R and D3R shRNA design ........................................................................................................97 
3.2.3.2 Annealing shRNA oligos ..............................................................................................................97 
3.2.3.3 Restriction enzyme digest of LeGO-G and LeGO-C plasmids ......................................................98 
3.2.3.4 Ligation of annealed shRNA into the LeGO-G plasmid vector.....................................................98 
3.2.3.5 Screening for positive clones ......................................................................................................98 
3.2.3.6 DNA sequencing of ligated LeGO-G vector .................................................................................99 
3.2.4 Production and titration of lentiviruses ................................................................................ 99 
3.2.5 Transduction of 293T cells with lentiviruses either expressing or silencing D2R and D3R . 100 
3.2.6 Quantification of D2R and D3R transcripts levels............................................................... 100 
3.2.7 Stereotaxic surgery and lentivirus injection........................................................................ 101 
3.2.8 Behavioural testing............................................................................................................. 101 
3.2.8.1 Open field .................................................................................................................................101 
3.2.8.2 Light-induced activity ................................................................................................................104 
3.2.9 Extraction of rat brains and fixation ................................................................................... 104 
3.2.10 Histological analysis ....................................................................................................... 104 
3.2.11 Statistics ......................................................................................................................... 105 
Quantification of D2R and D3R expression in HEK293T cells .......................................................................105 




3.3 RESULTS..................................................................................................................................... 106 
3.3.1 Generation of lentiviruses altering expression of D2R and D3R ......................................... 106 
3.3.2 Stereotaxic lentivirus injections and immunohistochemical analysis ................................. 108 
3.3.3 Reduction of novelty-induced locomotor activity by either NAcc D2R or D3R knockdown 110 
3.3.4 Light-induced activity is controlled by NAcc D2R and D3R ................................................. 114 
3.4 DISCUSSION ................................................................................................................................ 118 
3.4.1 Summary of results ............................................................................................................. 118 
3.4.2 Novelty - induced locomotor activity .................................................................................. 118 
3.4.3 Light-induced activity ......................................................................................................... 121 
3.4.4 Further consideration, limitations and conclusion ............................................................. 122 
CHAPTER 4 ......................................................................................................................................... 124 
CELLULAR CHARACTERISATION OF AUTS2 .......................................................................................... 124 
4.1 CHAPTER AIMS ............................................................................................................................ 125 
4.2 INTRODUCTION ........................................................................................................................... 125 
4.2.1 AUTS2 – molecular function ............................................................................................... 126 
4.3 METHODS AND MATERIALS ........................................................................................................... 128 
4.3.1.1 Construction of human AUTS2 overexpression vectors ............................................................128 
Primer design for AUTS2 amplification ........................................................................................................128 
PCR Amplification of human AUTS2 .............................................................................................................130 
Addition of 3’ A-Overhangs Post-Amplification............................................................................................130 
Ligation of AUTS2 into pLenti7.3/V5 TOPO expression vector .....................................................................131 
Verification of correct DNA inserts ..............................................................................................................131 
4.3.1.2 Production of lentiviruses overexpressing AUTS2 ....................................................................132 
4.3.1.3 Transduction of 293T cells with lentiviruses expressing AUTS2 ...............................................132 
4.3.1.4 Transient transfection of 293T cells with plasmid DNA ............................................................133 
4.3.1.5 qPCR and analysis .....................................................................................................................133 
4.3.1.6 Western Blot .............................................................................................................................134 
4.3.1.7 Immunocytochemistry ..............................................................................................................134 
4.3.1.8 Co-Immunoprecipitation (Co-IP) ...............................................................................................134 
4.3.2 Results ................................................................................................................................ 135 
4.3.2.1 Subcellular localisation of AUTS2 ..............................................................................................135 
Overexpression of AUTS2 and assessment of a commercially available anti-AUTS2 primary antibody ......135 
AUTS2 is expressed in mouse whole brain extracts and Neuro2a cell line ..................................................139 
AUTS2 is localised in the nucleus .................................................................................................................140 
Figure 26 : Nuclear sub-cellular localisation of AUTS2. ................................................................................143 
4.3.2.2 Potential interacting partners of AUTS2 ...................................................................................144 
Co-Immunoprecipitation (Co-IP) of AUTS2 ..................................................................................................144 
4.3.2.3 Summary and discussion...........................................................................................................146 
13 
 
CHAPTER 5 ......................................................................................................................................... 152 
LENTIVIRAL MEDIATED GENE SILENCING OF AUTS2 IN HUMAN FOETAL NEURAL STEM CELLS, SPC04 152 
5.1 PROJECT AIMS ............................................................................................................................ 153 
5.2 INTRODUCTION ........................................................................................................................... 155 
5.2.1 Neural stem cells (NSCs) as an in vitro model to study neurodevelopment ....................... 155 
5.3 METHODS AND MATERIALS ........................................................................................................... 157 
5.3.1 Lentiviral constructs for AUTS2 silencing ............................................................................ 157 
5.3.2 Lentiviral production and ultracentrifugation .................................................................... 159 
5.3.3 Lentiviral transduction of 293T and SPC-04 cell lines ......................................................... 159 
5.3.4 qPCR analysis ...................................................................................................................... 159 
5.3.5 Microscopy and imaging .................................................................................................... 160 
5.3.6 RNA quantification, labelling and Microarrays .................................................................. 161 
5.3.7 Statistics ............................................................................................................................. 161 
5.4 RESULTS..................................................................................................................................... 162 
5.4.1 Silencing of AUTS2 in 293T cell line .................................................................................... 162 
5.4.2 SPC-04 cell line differentiation upon lentiviral mediated silencing of AUTS2 ..................... 164 
5.4.3 Silencing of AUTS2 in undifferentiated and differentiated SPC-04 cell line ........................ 167 
5.5 SUMMARY AND DISCUSSION .......................................................................................................... 171 
CHAPTER 6 DISCUSSION ..................................................................................................................... 175 
6.1 SUMMARY AND DISCUSSION OF DATA CHAPTERS ................................................................................ 176 
6.2 PROJECT LIMITATIONS AND FUTURE DIRECTIONS ................................................................................. 180 
6.3 CONCLUDING REMARKS................................................................................................................. 183 




Table of Tables 
 
Table 1: Comparision of viral vectors for gene delivery. dsDNA = double stranded DNA; ssDNA = single 
stranded DNA.................................................................................................................................... 41 
Table 2:  List of cell lines and details of the media required for their culture ........................................... 51 
Table3: RMM+ media preparation for SPC-04 cell line. ............................................................................. 51 
Table 4: Stock solutions prepared for some of the components in RMM+ ............................................... 52 
Table 4: Details of reagents and cell for CaCl2 – mediated transfection. ................................................... 57 
Table 5: Thermal cycling conditions for DNA sequencing reaction ............................................................ 66 
Table 7: Modified RIPA buffer ingredients. ................................................................................................ 70 
Table 8: Components for an SDS-PAGE gel ................................................................................................ 71 
Table 9: List of Primary and secondary antibodies used in this thesis. ...................................................... 72 
Table 10: Primers used to amplify D2R and D3R for cloning into the LeGO- IG2 vector. .......................... 93 
Table 11: Thermal cycling conditions for touchdown PCR to amplify rat D2R and D3R. ........................... 94 
Table 12: Primers used to sequence D2R and D3R positive clones. .......................................................... 96 
Table 13: PCR thermal cycling for the DNA sequencing reaction............................................................... 96 
Table 14: Sense target sequence of shRNAs targeting D2R and D3R ......................................................... 97 
Table 15: qPCR primers for rat D2R, D3R and human β−ACTIN ............................................................... 100 
Table 16: Primary and secondary antibodies used in histological analysis of rat brains ......................... 105 
Table 19: PCR thermal cycling conditions used for amplifying human AUTS2 ......................................... 130 
Table 20: Primers used for sequencing of the human AUTS2 open-reading frame cloned into pLenti 
7.3/V5 TOPO® TA vector ................................................................................................................. 131 
Table 21: Primers used to amplify the AUTS2 and β -ACTIN for qPCR ..................................................... 133 
Table 22: Primary and secondary antibodies, dilutions and blocking buffer used for western blot. ...... 134 
Table 23: Dilutions of primary and secondary antibodies used for immunoytochemistry. ..................... 134 
Table 25: qPCR primers used to amplify AUTS2, ACTIN and the control gene RPL18 in SPC-04. ............. 160 
Table 26: Microarray analysis of selected genes involved in neurodevelopment for 7 days SPC-04 




Table of Figures 
Figure 1: Heritability estimates for psychiatric disorders or traits  and behavioural disorders. ................ 23 
Figure 2: The dopaminergic neural circuitry in the brain ........................................................................... 26 
Figure 3 RNA interference (RNAi) mechanism . ......................................................................................... 35 
Figure 4:  Lipoplex-mediated transfection and endocytosis ...................................................................... 40 
Figure 5: The lentiviral life cycle  ................................................................................................................ 43 
Figure 6: Genetic elements required for third generation lentiviral vector co-transfection system for 
lentiviral production. ........................................................................................................................ 45 
Figure 7: Co-immunoprecipitation method ............................................................................................... 78 
Figure 8: The dopamine receptor structure. .............................................................................................. 84 
Figure 9: An anatomical localisation of the nucleus accumbens core and shell in a rat brain coronal 
section. ............................................................................................................................................. 87 
Figure 10: LeGO-G and LeGO-C lentiviral vectors for gene silencing. ........................................................ 91 
Figure 11: The lentiviral overexpression vector LeGO-iG2. ........................................................................ 92 
Figure 12: Open field paradigm ................................................................................................................ 102 
Figure 13: Rearing behaviour in rats ........................................................................................................ 103 
Figure 14: Effects of D2R- and D3R-targeting lentiviral constructs on D2R (A) and D3R (B) expression in 
vitro. ................................................................................................................................................ 107 
Figure 15:  Immunohistochemical analysis of lentiviral-mediated gene delivery in the NAcc ................. 109 
Figure 16: The effects of NAcc D2R and D3R overexpression and knockdown on locomotor activity and 
rearing behaviour. .......................................................................................................................... 112 
Figure 17: Effect of nucleus accumbens D2R and D3R over-expression and knock down on anxiety-
related behaviour in the elevated-plus-maze test.  . ...................................................................... 113 
Figure 18: The effect of nucleus accumbens D2R and D3R overepression on light-induced locomotor 
activity . .......................................................................................................................................... 116 
Figure 19: The effect of nucleus accumbens D2R and D3R knock down on light-induced locomotor 
activity ............................................................................................................................................ 117 
Figure 20: The different isoforms of human AUTS2 on Genome Browser. .............................................. 126 
Figure 21: The pLenti7.3/ V5 – TOPO vector. ........................................................................................... 128 
Figure 22: AUTS2 mRNA expression in 293T cells transfected with either empty vector or vector 
overexpressing AUTS2. ................................................................................................................... 136 
Figure 23: Western blot to determine the level of exogenous AUTS2 expression in 293T cell line 
transiently transfected with plasmids overexpressing AUTS2. ...................................................... 138 
Figure 24: SDS-PAGE analysis to determine the level of AUTS2 protein expression in whole mouse brain 
lysate and Neuro2a cell line............................................................................................................ 140 
Figure 25: Nuclear sub-cellular localisation of AUTS2. ............................................................................. 142 
16 
 
Figure 26 : Nuclear sub-cellular localisation of AUTS2. ............................................................................ 143 
Figure 27: Western blot to assess the efficacy of the anti-AUTS2 antibody and anti-V5 antibody for 
immunoprecipitation of AUTS2 protein. ........................................................................................ 145 
Figure 28: In silico analysis of potential protein-protein interactions involving human AUTS2 protein. . 149 
Figure 29:  A brief overview of the methods used to investigate the functional role of AUTS2 using 
human foetal neural stem cell line, SPC-04. ................................................................................... 154 
Figure 30: Features of pGIPZ lentiviral vector and siRNA design. ............................................................ 158 
Figure 31: RT-qPCR to confirm endogenous AUTS2 mRNA expression in three human cell lines. .......... 163 
Figure 32: Effects of the AUTS2-targeting lentiviral constructs on AUTS2 expression in vitro. ............... 164 
Figure 33: Representative images of SPC-O4 morphology before and after differentiation. .................. 166 
Figure 34:  Effect of the AUTS2-targeting lentiviral construct on AUTS2 expression in undifferentiated 







List of Abbreviations  
 
°C Degrees Centigrade 





ADHD Attention Deficit Hyperactivity Disorder 
4-OHT 4-hydroxy-tamoxifen 
ASD Autism Spectrum Disorders 
ATCC American Type Culture Collection  
ATRA All-trans retinoic acid 
AUTS2/ Auts2 Autism susceptibility candidate 2 
bp Base pairs 
BSA Bovine serum albumin  
cDNA Complementary DNA  
chr Chromosome 
CaCl2 Calcium chloride 
c-MYC  V-myc avian myelocytomatosis viral oncogene homolog 
CNV Copy Number Variant 
Co-IP Co-immunoprecipitation 
Ct  Cycle threshold 
DA Dopamine 
DR Dopamine receptor 
D2R Dopamine D2 receptor 
D3R Dopamine D3 receptor 
DAPI 4'-6-Diamidino-2-phenylindole 
DAPT 3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester 
dATP DeoxyAdenosine-5'-triphosphate  
d.f. Degrees of Freedom 
dH2O Distilled water (molecular biology grade) 
ddH2O Double Distilled water 
18 
 
DMEM Dubelcco’s modified Eagles Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acids 
dNTP Deoxynucleotide triphosphate  
dsDNA Double-stranded deoxyribonucleic acids 
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M Molar 
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mg Milligram 
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NaCl Sodium chloride 
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NCBI National Centre for Biotechnology Information 
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NSCs Neural stem cells 
nt nucleotide 
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OMIM Online Mendelian Inheritance in Man 
ONS Office for National Statistics 
OR Odds ratio 
ORF Open Reading Frame 
p Short arm of chromosome 
PPI Protein-protein interaction 
PBS Phosphate buffered saline 
PBST PBS-Triton 
PCR Polymerase chain reaction 
q Long arm of chromosome 
qPCR Quantitative polymerase chain reaction (RT-PCR) 
rcf Relative centrifugal force 
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RIPA buffer Radioimmunoprecipitation Assay Buffer 
RMM+ Reduced Modified Medium with growth factors 
RMM- Reduced Modified Medium without growth factors 
RNA Ribonucleic acids 
rpm Revolutions per minute 
RT Room temperature 
RT-PCR Real Time - PCR 
SD Standard deviation 
SDS Sodium dodecyl sulphate  
SDS-PAGE SDS- polyacrylamide gel electrophoresis 
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Chapter 1  Introduction 
 
The field of psychiatric genetics is rapidly expanding since the discovery that behaviour and 
psychiatric traits are, to some extent, explained by genetic influences, in addition to 
environmental factors. Gene identification methods, including candidate gene studies, linkage 
studies, and more recently, genome wide association studies are currently proving to be key 
contributors to the identification of novel gene and gene variants associated with several 
neuropsychiatric disorders. These studies have also revealed that a wide range of 
neuropsychiatric disorders have overlapping genetic aetiology with many of the genes involved 
in neurodevelopment. Subsequent functional genetic research complements findings from 
linkage and association studies by elucidating the molecular mechanisms by which these genes 
exert their effect on behaviour and psychiatric traits. Gaining insight into the underlying genetic 
basis of neuropsychiatric disorders and mechanisms through which genes exert their effects on 
behaviour will contribute significantly to the development of efficient prevention strategies and 
providing personalized treatments. It is thus imperative to identify susceptibility genes and 
elucidate the mechanisms by which genetic variation alters molecular function, thus 
predisposing to psychiatric disorders. This thesis is split into two themes: it investigates the role 
of two dopamine receptors (D2R and D3R) in locomotor behaviour by establishing lentiviral 
mediated gene delivery technique; and functionally characterise the role of AUTS2, a gene of 
unknown function associated with various neuropsychiatric disorders including autism, 
depression, epilepsy and schizo-affective disorders. This chapter will provide an overview of the 
approaches and techniques used in gene identification and gene function studies relevant to 






1.1 The prevalence of neuropsychiatric disorders  
The term neuropsychiatric disorders encompasses a broad range of mental disorders including 
substance abuse and dependence, schizophrenia, depression and other mood disorders, as 
well as neurological diseases like dementia, autism and epilepsy. These diseases present a 
large burden on families and society. In the EU alone, the three major contributors to the 
overall disease burden in 2010, were depression (7.2%), dementia (3.7%) and alcohol abuse 
(3.4%) (Wittchen et al., 2011). The overall disease burden is mainly due to disability, resulting 
in the inability to carry out daily routines, making neuropsychiatric disorders accountable for 
work disability and economic loss.  
 
1.2 Genetic contribution to neuropsychiatric disorders 
It has been extensively documented that genetic factors strongly influence the aetiology of 
neuropsychiatric disorders. Family, twin and adoption studies have provided evidence of 
genetic predisposition to many neuropsychiatric disorders with variation in the extent of 
genetic influence across disorders as depicted in Figure 1. Depression and anxiety are reported 
to be least heritable i.e. <40% (Hettema et al., 2001; Bienvenu et al., 2011), while heritability 
estimates for alcohol abuse and dependence is moderate ranging from 30% to 60% (Agrawal et 
al., 2008). Schizophrenia, bipolar and autism spectrum disorders are highly heritable with 
estimates of 80% or more (Muhle et al., 2004; Bienvenu et al., 2011) indicating that the major 
underlying susceptibility of these disorders are genetic. These findings also show that disease 
susceptibility is also influenced by environmental factors as concordance rates in monozygotic 
twins do not reach 100%. In fact, environmental risk factors have been examined for 
interaction with specific genes in some neuropsychiatric conditions (Caspi et al., 2003; Lesch, 
2004; Bukh et al., 2009; Clarke & Schumann, 2009) establishing that environmental triggers 
such as stress and childhood abuse are important determinants of disease susceptibility in 
genetically predisposed individuals.   
It is now widely agreed that psychiatric disorders are of multifactorial aetiology, with several 
genetic and environmental factors contributing to disease development. Determinants of 
complexity are likely to include genetic heterogeneity, polygenicity, phenocopies, gene vs 
environment interaction and incomplete penetrance. Despite the intricate genetic 
heterogeneity of neuropsychiatric disorders, a number of gene identification approaches have 
been successful in uncovering susceptibility genes as described in the following subsections.   
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Figure 1: Heritability estimates for psychiatric disorders or traits (black) and behavioural 
disorders (white).  
This figure was taken from (Bienvenu et al., 2011). Bipolar disorder, Schizophrenia and Alzheimer’s 
disease have the highest heritability, compared to substance use disorders which are moderately 





1.3 Gene identification approaches in neuropsychiatric disorders 
Over the past few years, strategies aiming to identify genes that contribute to disease 
susceptibility have employed either linkage and association analysis or candidate gene 
approach. Briefly, linkage and association studies are two complementary approaches used to 
identify genetic loci or genes associated with a particular behavioural trait or disorder, usually 
in a hypothesis free fashion. On the other hand, candidate gene approach, involves the 




1.3.1 Linkage studies  
This approach enables the identification of genomic regions that contain genes or genetic 
markers that predispose to diseases in families with multiple affected members, which occur 
more often than expected by chance. Markers that co-segregate with the disease indicate 
which genomic regions contain disease susceptibility genes. Using this hypothesis-neutral 
approach, relatively few genetic markers are necessary to distinguish which chromosome 
segments are shared among relatives with a common phenotype. Most linkage studies are 
performed in a collection of many families, each with few affected individuals. For linkage 
analysis to succeed, markers that flank the disease gene must segregate with the disease in 
families, hence this method is largely successful with diseases following monogenic Mendelian 
inheritance. Large numbers of samples are required as this approach is not very powerful for 
the detection of susceptibility loci with a small contribution to the total disease risk which is 
the case for many neuropsychiatric disorders (Risch & Merikangas, 1996). Nonetheless, this 
method has been successful in identifying susceptibility genes for non-psychiatric disorders, 
such as evidence for linkage to chromosomal regions 6p, 8p and 13q has been consistently 
reported for schizophrenia (Gill et al., 2010). Extensive fine mapping of these regions led to the 
discovery of three susceptibility genes: the dysbindin gene at 6p (DTNBP1), NRG1 at 8p and 
protein G72 at 13q, all of which linkage have been confirmed by independent studies (Maier et 
al., 2003; Benson et al., 2004).  
 
1.3.2 Candidate gene approach 
Genetic association studies on candidate genes have been a popular alternative to genetic 
linkage studies because families with multiple affected individuals are not necessary for this 
approach. These studies are based on a priori knowledge concerning the pathophysiology of 
the disease or phenotype in question. Not surprisingly, particular emphasis has been directed 
towards studying genes involved in the serotonergic and dopaminergic mechanisms, pivotal in 
neurobiological function regulating several emotional, cognitive, motor and reward processes. 
Hence, mood and personality disorders, anxiety, psychosis, substance abuse among other 
psychiatric conditions have been associated with dysfunction of these systems.    
 
The serotonin transporter SLC6A4 is a promising candidate gene for its involvement in a variety 
of psychiatric disorders and it is also a target for drugs (serotonin selective reuptake inhibitors) 
that are used for the treatment of mood and anxiety disorders. The long and short allele of the 
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serotonin transporter results from a polymorphism in the promoter region of the serotonin 
transporter gene (5-HTTLPR; 5-hydroxytryptophan transporter linked polymorphic region) 
which was shown to be associated with different levels of gene expression (Heils et al., 1996). 
The alleles are caused by a 44bp insertion/deletion approximately 1kb upstream of the SLC6A4 
gene; homozygosity of the short allele results in lower mRNA and protein expression (Lesch et 
al., 1996). Numerous studies have reported an association of this polymorphism with several 
psychiatric disorders (Lazary; Caspi et al., 2003; Feinn et al., 2005; Roy et al., 2007). Among the 
14 serotonin receptor subtypes, a substantial portion of studies have looked at association of 
5HTR1A and 5HTR2A polymorphisms and mood disorders and schizophrenia (Verga et al., 
1997; Spurlock et al., 1998; Tsai et al., 1999; Oswald et al., 2003; Abdolmaleky et al., 2004; 
Hettema et al., 2008; Kishi et al., 2011). Another serotonergic component shown to be 
relevant for depression in particular is the monoamine oxydase (MAO) enzyme that catabolises 
the serotonin neurotransmitter. There are two forms MAO-A and MAO-B, of which it has been 
suggested that MAO-A has higher activity (Shih & Chen, 1999). Accordingly, MAO-A gene 
polymorphisms and SNPs have been identified as possible risk factors for major depression and 
bipolar disorder (Schulze et al., 2000; Caspi et al., 2002; Du et al., 2004; Muller et al., 2007b).  
 
Likewise, the dopaminergic system is known to be essential in the regulation of several 
behavioural functions including locomotion, feeding, sleep, attention, cognition, emotion as 
well as  neuroendocrine functions (Lindvall et al., 1983). This system comprises of four major 
neuronal pathways.  One of these is the nigrostriatal pathway which consists of the 
dopaminergic neurons in the substantia nigra neurons which project to the striatum and play a 
prominent role in controlling motor function (Figure 2). Accordingly, dysfunction in this 
pathway principally results in Parkinson’s disease (Strange, 1993b). Other pathways are the 
mesocortical and mesolimbic pathways (also called mesocorticolimbic pathway) connect the 
neurons of the ventral tegmental area (VTA) to the cortex and the limbic system. The 
mesolimbic system includes dopaminergic innervations in the VTA that project mainly to the 
NAcc as well as the olfactory tubercle. While the mesocortical dopaminergic system also 
includes the VTA, it extends its fibres in the prefrontal cortex, cingulate and peririhinal cortex 
(Wise, 2004; 2005). These pathways regulate cognitive functions, emotion and reward (Yim & 
Mogenson, 1980; D'Ardenne et al., 2008; Phillips et al., 2008). It has been reported that 
alterations in the mesocorticolimbic pathway contribute to the development of psychosis 
(Liston et al.; Kapur & Mamo, 2003; Phillips et al., 2003; Seeman et al., 2006; Laviolette, 2007), 
ADHD (Iversen & Iversen, 2007), and addiction (Kalivas & Volkow, 2005; Koob & Le Moal, 2008) 
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among many other psychiatric conditions. Lastly, the tuberoinfundibular pathway regulates 
prolactin secretion from the anterior pituitary gland through dopamine released from a 
population of neurons that are present in the 'tuberal region' of the hypothalamus. 
 
Figure 2: The dopaminergic neural circuitry in the brain  
This figure taken from (Arias-Carrion et al., 2010), depicts the three main dopaminergic pathways 
through which the neurotransmitter dopamine exerts its effect on various psychomotor behaviours: 






Due to the multiple pathways it is involved in, it is not surprising that the dopamine hypothesis 
of schizophrenia and psychosis prompted a large number of studies to focus on association of 
genes involved in the dopaminergic system and psychosis (Ni et al., 2002; Severino et al., 2005; 
Dmitrzak-Weglarz et al., 2006; Del Zompo et al., 2007). This model attributes symptoms of 
schizophrenia and other psychosis to hyperactive dopaminergic signalling originating from 
observations of dopamine blocking effects of antipsychotic drugs (Moncrieff, 2009). 
Additionally, due to its involvement in the reward pathway, a substantial portion of studies 
have aimed to reveal associations between dopamine receptors and alcohol addiction. There 
are 5 different isoforms for the dopamine receptors: DRD1, D2D2, DRD3, DRD4, and DRD5. 
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One of the first candidate gene studies in alcoholism was the dopamine receptor gene DRD2 
with its Taq1-A1 polymorphism (Blum et al., 1990; Parsian et al., 1991; Noble, 2000). DRD4 is 
also implicated in a recent study (Hack et al., 2011) while the same study also reported that 
DRD3 and DRD5 are typically not associated with alcohol dependence, indicating that 
receptors encoded by these genes may not be associated with alcohol dependence. Other 
genes in the dopaminergic system have also been implicated as candidate genes such as the 
dopamine transporter (DAT), encoded by the SLC6A3 gene which initiates the reuptake of 
extracellular synaptic dopamine by the pre-synaptic neurons, thus regulating dopaminergic 
signalling (Alves et al., 2011). The most widely studied variant in SLC6A3 has been the variable 
number tandem repeat (VNTR) region located in the 3’ UTR, with alleles having between 3-16 
repeats (van der Zwaluw et al., 2009).  
 
Notably, the most robust of all allelic variations relevant for psychiatric disorders is the 
association between the genes encoding hepatic enzymes alcohol dehydrogenase (ADH; 
coverts alcohol to acetaldehyde) and aldehyde dehydrogenase (ALDH; converts acetaldehyde 
to acetate). Indeed, these are excellent candidate genes as a priori knowledge indicates that 
they are clearly involved in regulating the levels of alcohol in the bloodstream and the amount 
of alcohol that reaches the brain. There are seven different ADH genes in the human genome 
that form a cluster on chromosome 4q (5’-ADH7-ADH1C-ADH1B-ADH6-ADH4-ADH5-3’) and 
two main ALDH genes (ALDH1A1 and ALDH2) (Chen et al., 2009). Genetic variants that confer a 
protective effect on the development of alcoholism include a high activity isoform of ADH 
(referred to as ADH1B*2) leading to an accumulation of acetaldehyde in the blood 
consequently producing adverse effects like nausea, hypotension and headache. This 
polymorphism (His47Arg) conferring this protective effect is commonly found in population of 
Asian descent. Furthermore, linkage studies have shown that the ADH gene cluster is within a 
susceptibility region for alcohol-related phenotypes in European populations (Reich, 1996; 
Reich et al., 1998; Cichon et al., 2009). Several other independent linkage studies have 
replicated this finding using different populations such as Irish sibling pairs (Prescott et al., 
2006); and South Western Native American population (Long et al., 1998). In fact, this gene is 
one of the most consistently replicated finding in both linkage and association studies. 
Although this approach is very useful, other approaches are clearly required to discover novel 





1.3.3 Genome Wide Association Studies (GWAS) 
GWAS offer the possibility to identify specific genes that influence the development of a given 
psychiatric disorder, using a hypothesis-free approach. It is based on comparing the genotypes 
of affected vs unaffected individuals in a population to find genetic variation associated with 
the disease or the trait. Unlike linkage studies, GWAS enable the detection of ‘small risk’ 
genetic variation. In just the last few years, GWAS have successfully revealed associations of 
common DNA variants (both previously established and novel) with over 80 diseases and traits 
including schizophrenia, bipolar, major depression, attention deficit disorder (ADD), autism 
and alcohol dependence (Hirschhorn & Daly, 2005; Cichon et al., 2009). Recently, our group in 
collaboration with others have identified Autism susceptibility candidate 2, AUTS2, as a 
possible candidate gene for alcohol consumption.  
 
Previous  studies did not find particular gene(s) that consistently showed significant 
associations across studies (Nurnberger et al., 2001; Schuckit et al., 2001; Treutlein et al., 
2009; Bierut et al., 2010; Edenberg et al., 2010). A possible reason for this could be due to the 
varied ethnic backgrounds of the participants resulting in genetic heterogeneity as mentioned 
earlier. Also, the alcohol phenotype described may have differed among the studies. 
Additionally, the few GWAS findings reported have not been confirmed by functional studies. 
As previously suggested, a large meta-analysis would arguably provide enough power to detect 
SNPs significantly associated with alcohol dependence (Kimura & Higuchi, 2011). Indeed, our 
group has conducted a meta-analysis of GWAS on alcohol consumption based on more than 
28,000 drinkers plus a replication sample of around 21,000 drinkers of European ancestry. 
Most notably, Autism susceptibility candidate 2, AUTS2 attained genome wide significance 
overall (discovery and replication samples combined) p= 4.2x10
-08
 (Schumann et al., 2011). In 
the same study, evidence from Drosophila functional studies in which the AUTS2 homologue 
was silenced showed reduced alcohol sensitivity; though Drosophila studies have their 
limitations in interpreting this kind of behaviour. This study points to a possible role of AUTS2 
in alcohol consumption. Interestingly, this gene has been implicated in several other 




1.4 Overlapping genetic aetiology of neuropsychiatric disorders and 
AUTS2 
It is now clear that the underlying genetic causality for neuropsychiatric disorders can be 
explained by the effects of many different alleles at various loci, each conferring a small effect. 
Following on from this, is the emerging idea that there is substantial overlap in the genetic 
aetiology of some neuropsychiatric disorders with a small number of publications vindicating 
this concept until now. For example, molecular genetic studies have revealed that several large 
copy number variants (CNVs) substantially increase the risk of schizophrenia, autism spectrum 
disorders (ASDs), ADHD and epilepsy (Owen et al., 2011). Additionally, genetic studies indicate 
that the chromosome 16p13.11 heterozygous deletion is associated with these disorders 
(Ramalingam et al., 2011). Further supporting this idea is the existence of co-morbidity among 
psychiatric disorders might be caused to some extent by genetic overlap (Schulze et al., 2012). 
Large-scale epidemiological studies have shown individual and familial comorbidity between 
schizophrenia, ASDs, epilepsy, bipolar disorder, major depression, ADHD and other psychiatric 
diagnoses (Qin et al., 2005; Daniels et al., 2008; Steinhausen et al., 2009). Moreover, a recent 
large scale study has shown that relatives of individuals affected with schizophrenia have 
increased risks of bipolar disorder and vice versa (Lichtenstein et al., 2009). Several other 
studies have pointed out the idea that there exists a fundamental aetiological genetic overlap 
between what have largely been defined clinically as distinct disorders (Rzhetsky et al., 2007; 
Friedman et al., 2008; Mefford et al., 2008; Guilmatre et al., 2009; Sebat et al., 2009; Ching et 
al., 2010). Further research exploring the overlapping genetic aetiologies of psychiatric 
disorders is no doubt warranted. 
 
Recent findings on AUTS2 association with a number of neuropsychiatric disorders have also 
supported the view of their overlapping genetic aetiology. AUTS2 was initially identified as an 
autism susceptibility candidate gene in a pair of monozygotic twins (MZ) with autism who had 
identical balanced chromosomal translocation at t(7;20) (q11.2; p11.2) which disrupted this 
gene (Sultana et al., 2002). Similarly, other studies have also identified AUTS2 disruptions in 
patients with different severities of ASD and/or mental retardation (MR).  For example, three 
unrelated patients with MR had AUTS2 truncated by a de novo balanced translocation of 
7q11.2 (Kalscheuer et al., 2007), while a similar de novo 7q inversion breakpoint disrupting 
AUTS2 and CNTNAP2 (contactin associated protein-like 2) genes were discovered in a patient 
with ASD/MR (Bakkaloglu et al., 2008). Recently, a patient with ASD was found to have a de 
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novo balanced translocation  that disrupted AUTS2 (Huang et al., 2010b). These reports 
demonstrate that AUTS2 plays a significant role in human brain function, especially the 
aetiology of ASDs.  
 
AUTS2 has also been implicated in the aetiology of other neuropsychiatric disorders. 
Association studies using 65 nuclear multiplex autism families suggest that AUTS2 may not be a 
candidate gene (Sultana et al., 2002). Although, rare variants of this gene has been identified 
in cases of autism (Richler et al., 2006) and ADHD (Elia et al., 2010; Girirajan et al., 2011). 
Interestingly, this gene has also been associated with schizoaffective disorder (Hamshere et al., 
2009) and epilepsy (Komoike et al., 2010; Mefford et al., 2010). Recently, our group has also 
found an association of AUTS2 with alcohol consumption (Schumann et al., 2011) which has 
also been replicated in another study (Zuo et al., 2012). Additionally, expression analysis in 
post mortem hippocampal samples from patients with Alzheimer’s disease (AD) showed that 
the AUTS2 gene was upregulated compared to controls (Dahmcke et al., 2008). Interestingly, 
AUTS2 was one of the genes found to be hypermethylated in post mortem frontal cortical 
samples from schizophrenic males compared to matched controls (Mill et al., 2008). 
Intriguingly, AUTS2 is one of several genes originated from such molecular genetic studies that 
is thought to be involved in neurodevelopmental processes (Walsh et al., 2008; Raychaudhuri 
et al., 2009; Elia et al., 2010; Glessner et al., 2010; Mefford et al., 2010; Pinto et al., 2010; Piton 
et al., 2011), which could explain its involvement in the aetiology of a broad range of 
neuropsychiatric disorders. Aberrant developmental processes such as increased neurogenesis 
and decreased neural apoptosis can contribute to brain abnormalities in neuropsychiatric 
disorders. These developmental aberrations may be a result of gene mutations or 
environmental factors which together or independently affect brain development leading to 
pathological phenotypes (Talkowski et al., 2012). An example of one such gene is DISC1, a 
susceptibility gene for a wide range of mental disorders. It is expressed in neuronal progenitor 
cells and post-mitotic neurons in the developing cerebral cortex and is thought to play a key 
role in the transition from progenitor proliferation to post-mitotic neuron migration (Ishizuka 
et al., 2011). Studies in mice show that overexpression of G-protein α subunit, Gαs, either 
during development or in adulthood, result in enlarged lateral ventricles and smaller dorsal 
and ventral striatum (Kelly et al., 2009). Intriguingly, GABAA receptors in particular are reported 
to play a crucial role in the maturation of cortical circuits and synaptogenesis (Cancedda et al., 
2007). While in adulthood, GABA receptors are responsible for the majority of inhibitory 
transmissions, in embryonic and neonatal brains, these are excitatory. Deficiency in GABAA 
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receptor β3 subunit (GABRB3), which is highly expressed in the developing brain, is thought to 
contribute to neurodevelopmental disorders like epilepsy and autism (Tanaka et al., 2010). In 
fact, GABRB3 knockout mice display neurological deficits and are proposed to be models for 
autism (Pizzarelli & Cherubini, 2011). Evidently, the abnormal alteration in essential cellular 
processes such as cell proliferation, differentiation, migration and apoptosis may lead to 
pathological consequences on brain development and therefore function.  
 
Genetic and neuroimaging studies are beginning to broaden our understanding on genetic 
differences on brain function between normal and disease populations. Perhaps a striking 
finding, which is now well established, is that whole brain, gray matter and white matter 
volumes are highly heritable (Peper et al., 2007) with 90%, 82% and 88% heritability estimates 
respectively (Baare et al., 2001). Further expansion on this finding comes from a report 
revealing a strong relationship between genes, anatomical brain structure and behaviour 
(Thompson et al., 2001). Many studies have shown that aetiology of several psychiatric 
disorders may arise due to aberrant processes in brain development resulting in anomalous 
brain structure (Lainhart & Lange, 2011). Several independent studies have reported increased 
total brain volumes in individuals with autism as well as increased cerebellar hemisphere 
volumes (Brambilla et al., 2003). A recent preliminary study showed that brain overgrowth in 
autistic males was due to an augmented number of neurons in the prefrontal cortex 
(Courchesne et al., 2011) and is supported by another finding that reported increased neuron 
number and larger brain volume in individuals with autism (Lainhart & Lange, 2011). On the 
contrary, a number of MRI studies have shown that patients with schizophrenia possess 
reduced brain volume (Andreasen et al., 1994; Gur et al., 1994) reduced grey matter volume 
(Shelton et al., 1988; Woods & Yurgeluntodd, 1991; Zipursky et al., 1992),reduced cortical 
volume (Glahn et al., 2008; Arnone et al., 2009; Ellison-Wright & Bullmore, 2010) which may 
be a direct result of cortical thinning (Rimol, 2012) due to reduced synaptic density 
(Huttenlocher, 1979; Huttenlocher & Dabholkar, 1997). This may, to some extent, be due to 
decreased neural stem cell proliferation during adult neurogenesis (Reif et al., 2006). Indeed, 
knockdown of DISC1, in adult and embryonic mouse stem cells revealed reduced neural 
progenitor proliferation and subsequent premature differentiation (Mao et al., 2009). 
Interestingly, there is reportedly substantial overlap in the underlying brain morphological 
abnormalities in cerebral cortex and subcortical structures of schizophrenia and bipolar 
disorder patients. Both groups showed substantial sub cortical volume reductions in the 
hippocampus and the brain stem as well as ventricular enlargements (Rimol et al., 2010; Rimol, 
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2012). Other neuropsychiatric disorders, although, not extensively researched report brain 
anatomy differences. White matter abnormalities in depression patients have also been 
evident from post-mortem and genetic studies (Tham et al., 2011). Abnormal brain structure 
specifically enlarged medial temporal lobe and basal ganglia has been implicated in drug 
addiction (Ersche et al., 2012) although it can be argued that this may be as a result of 
neuroadaptations occurring due to drug intake. A commonality emerging from the above 
findings is that defects in brain development contribute to the aetiology of a broad range of 
neuropsychiatric disorders. Abnormalities in brain development could be a result of genetic 
dysfunction. Thus there is an increasing need to study the function of neurodevelopmental  
genes such as  AUTS2. 
 
Of course as mentioned earlier, the aetiology of psychiatric disorders stems from the aberrant 
alteration of several genes rather than just one. It is important to consider epigenetic 
mechanisms such as DNA methylation and chromatin remodelling which change the gene 
expression without altering the DNA sequence of a gene. Indeed, vital neurodevelopmental 
processes, such as cell differentiation and neurogenesis, are highly regulated at the level of 
chromatin remodelling, histone acetylation and methylation. Dysfunction of MeCP2, a 
transcriptional repressor that binds to methylated DNA, is associated with several 
neurodevelopmental disorders as it is thought to cause a premature arrest in neuronal 
development (Gonzales & LaSalle, 2010). Another example, histone deacetylase (HDAC) 
inhibitors induce neural differentiation in embryonic cortical cells. Additionally, histone 
deacetylation is crucial for the timing of oligodendrocyte differentiation and myelination: 
administration of valproate (a non-selective HDAC inhibitor) leads to hypomyelination, delayed 
expression of differentiation markers and prolonged expression of progenitor markers in these 
cells. Abnormal DNA methylation as a result of deficiency in the DNA methyltransferase 
DNMT1, or the methyl-CpG binding protein MBD1, causes abnormal neuronal function and 
postnatal death or decreased neurogenesis respectively. It may be that AUTS2 gene 
dysregulation, in addition to other genes, could play a role in mediating abnormal brain 
development and function consequently associating it with various neuropsychiatric disorders. 
Obviously, this argument is speculative and as very little is known about AUTS2 and its 






1.5 Functional Genetic Approaches – Gene Manipulation 
Although genetic studies have led to the identification of susceptibility genes, functional 
genetic studies have provided convincing evidence to support the involvement of specific 
genes in disease development as well as contributed to elucidating their mechanisms of action. 
This will not only uncover the genetic architecture of disease pathology but may also lead to a 
better identification of therapeutic targets for treatment of psychiatric conditions.  
 
1.5.1 Gene silencing 
1.5.1.1 RNA interference (RNAi) 
RNA interference (RNAi) was coined after the landmark discovery that injection of double-
stranded RNA (dsRNA) molecules into the nematode Caenorhabditis elegans (C.elegans), 
whereby one strand is complementary to the coding region of the target gene, resulted in 
specific gene silencing (Fire et al., 1998; Montgomery et al., 1998).  It is an evolutionary 
conserved molecular mechanism involved in several biological processes in all species 
(Waterhouse et al., 1998; Wianny & Zernicka-Goetz, 2000; Caplen et al., 2001; Yang et al., 
2001). In recent years, the discovery of RNAi has led to its wide use as a tool for studying gene 
functionality (Hommel et al., 2003). The RNAi pathway is mediated by double stranded non-
coding RNA molecules of around 21 nucleotides called small regulatory RNAs, which silence a 
specific target gene of interest and with high potency (Hannon & Rossi, 2004). 
 
RNAi mechanism 
In humans, there are two main classes of small regulatory RNAs: short interfering RNAs which 
mediate RNAi by downregulating gene expression through cleavage resulting in RNA 
degradation and microRNAs which results in gene silencing by transcriptional repression 
(Figure 3). A comprehensive description of both classes of RNAi-mediating molecules is given 
below: 
(1) Short interfering RNAs (siRNAs) are derived from long dsRNA molecules. The process of 
targeted gene silencing initiates with an RNase III enzyme complex Dicer, which cleaves 
the dsRNA at 21-25 nucleotide intervals generating a siRNA molecule that is characterized 
by 5′ phosphorylated end, a 19- nucleotide duplexed region and 2 nucleotide overhang 
and unphosphorylated 3′ end. This distinct dsRNA molecule is recognized by the 
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multiprotein complex RISC (RNA-Induced Silencing Complex), which unwinds the siRNA 
duplex and incorporates the single stranded antisense strand. The antisense strand guides 
RISC to the target mRNA, driving its endonucleolytic cleavage. The resultant antisense 
strand binds to the mRNA with sequence homology where nuclease Argonaute 2 (Ago2) 
cuts the mRNA leading to its degradation and resulting in targeted gene silencing (Hannon 
& Rossi, 2004; Meister & Tuschl, 2004).  
Short hairpin RNA (shRNA) is another example of a long dsRNA and has long been used to 
confer sustained gene silencing for functional studies (Carmell et al., 2003; Seibler et al., 
2005; Rubinson et al., 2007). shRNA sequence comprises of the siRNA sequence (sense) 
followed by a loop structure and a reverse complement of the siRNA sequence 
(antisense). These are exported from the nucleus and are recognised and cleaved by the 
endonuclease Dicer, to form double stranded RNA similar to siRNA. For in vitro and in vivo 
experiments, the shRNA can be produced by the transcription of the shRNA plasmid 
construct mediated by Pol II or more commonly Pol III promoters (Paddison et al., 2002; 
Singer & Verma, 2008 ).  
 
(2) MicroRNA (miRNA) is encoded in the host genome and is transcribed as long primary 
transcripts called pri-miRNA from Pol II promotors (Kim & Kim, 2007). The pri-miRNA 
contains a hairpin structure that is cleaved by the nuclear enzyme Drosha and another 
dsRNA binding protein complex called diGeorge Critical region 8 (DGRC8) generating a 
≈70nt miRNA precursor called pre-miRNA which is then transported to the cytoplasm and 
processed by Dicer, which generates the primiRNA to 19-25 nucleotide miRNA.  These 
mature miRNAs are then incorporated in the miRNA-protein complex (miRNP) which 
includes RISC to induce silencing. Unlike siRNAs, the miRNAs pair with partial sequence 
complementarity to the target mRNA and lead to translational repression or decrease 
mRNA stability (Couto & High, 2010).  
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Figure 3 RNA interference (RNAi) mechanism taken from (Jinek & Doudna, 2009).  
RNAi is mediated either via short interfering RNA (siRNA) or microRNA (miRNA). siRNA- mediated gene 
silencing involves degradation of mRNA whose sequence is complementary to the target sequence. On 






Application of RNAi 
Given that RNAi-mediated gene knockdown can achieve high knockdown efficiencies in 
mammalian cells, this technology holds great potential for gene function analysis in vitro and in 
vivo (Mittal, 2004). Effective gene silencing using RNAi has been demonstrated in neuronal cell 
lines (Gan et al., 2002), neural stem cells (Wood et al., 2003), primary mammalian neurons 
(Krichevsky & Kosik, 2002) and astrocytes (Frigeri et al., 2002; Nicchia et al., 2003). In vitro, 
shRNAs and miRNAs are widely used to induce loss of gene function to address neurobiological 
questions (Elbashir et al., 2001; Harborth et al., 2001; Tiscornia et al., 2003; Dorsett & Tuschl, 
2004; Parsi et al., 2012). For example, in vitro RNAi-mediated gene silencing pointed out to the 
involvement of specific genes in embryonic developmental processes such as cell 
differentiation (Desclaux et al., 2009), cell survival (Dickey et al., 2011) and proliferation 
(Foskolou et al., 2012), as well as the development of neural networks (MacLaren et al., 2011). 
These will be covered in more details in a later section. 
 
Sustained gene silencing is achieved from viral vector plasmids expressing shRNA which is 
processed into siRNA in the cytoplasm. As discussed later, the silencing effects are sustained 
due to the recombinant viral DNA being permanently integrated into the host cell genome 
(Manjunath et al., 2009). Interestingly, although the introduction of long double stranded RNA 
will elicit an interferon immune response in mammals, siRNA can circumvent this response 
(Manjunath et al., 2009) making it applicable for in vivo studies. RNAi studies in various animal 
model such as Drosophila and C.elegans have contributed to our understanding at the cellular 
level of neural plasticity (Billuart et al., 2001), axon guidance (Schindelholz et al., 2001; 
Georgiou & Tear, 2002), synaptic endocytosis (Harris et al., 2001) and neurodegeneration 
(Syntichaki et al., 2002). At the behavioural level, rodents in particular, have been instrumental 
in unravelling the genetic underpinnings of many behavioural traits relating to addiction-like 
phenotype (Lasek et al., 2007; Rewal et al., 2009; Johnson & Kenny, 2010; Lasek & Azouaou, 
2010), Parkinson’s disease (Gorbatyuk et al., 2010), Alzheimer’s disease (Singer et al., 2005) 
and anxiety-like behaviour (Eren-Kocak et al., 2011). Most of these studies use viral vector for 




1.5.2 Generation of genetically altered mice 
Mutant mice have proved invaluable to our understanding of molecular mechanisms that 
govern various behavioural and psychiatric traits. These studies have complemented and 
expanded on pharmacological approaches by enabling to investigate the role of specific genes 
(Grant et al., 1992; Silva et al., 1992; Phillips et al., 1998; Wood & Toth, 2001; Blednov et al., 
2010). This approach has also considerably contributed to delineating the role of complex 
receptors for neurotransmitters through generation of mice with loss of function of individual 
isoforms to study behavioural phenotypes (Crabbe et al., 1996; Phillips et al., 1998; Ralph et 
al., 1999; Scearce-Levie et al., 1999; Loh & Ball, 2000; Wood & Toth, 2001; Jacobson et al., 
2007). The fact that the gestation times of mice are relatively short and the complete 
sequencing of the mouse genome also offer benefits to further understanding the function of 
any given gene. Briefly, to generate knockout or knockin mice, initially, the transgene, either a 
cDNA  encoding a particular protein or an antisense fragment designed to silence the level of 
endogenous mRNA, is cloned downstream of a suitable promoter element to drive its 
expression. It is introduced into a pronucleus of a fertilized egg. Once inside the pronucleus, 
the transgene either integrates into the genome in a random fashion or is degraded by 
exonuclease activity. As the transgene insertion occurs early in the developmental process, 
most of the cells, if not all, will contain the transgene. However, if the transgene is integrated 
later in development, this will generate a mosaic transgenic. 
Alternatively, transgenic mice may be obtained by a second route, using embryonic stem (ES) 
cells. These cells, which are derived directly from the culture of blastocysts, retain the ability to 
continue with embryonic development once injected back into an early mouse embryo. 
Introduction of exogenous DNA into the cultured ES cells allows one to generate transgenic 
mice via the production of germ-line chimeras. The gene of interest is modified in the ES cells 
by homologous recombination using a targeting vector that consists of a modified version of 
the endogenous gene. These targeting vectors also contain a gene conferring drug resistance 
(e.g. neomycin phosphotransferase, neo) for selection of recombinant ES cells.  The advantage 
of this method, in contrast to the transgene pronuclear injection, is that desirable and low-
frequency genetic alterations may be selected and veriﬁed in the ES clones maintained in 
culture and then reintroduced in the animal.  
 
The downside of ‘whole body’ gene knockout/knockin is that all tissues express the transgene 
so it is difficult to separate the phenotype resulting from overexpression/ silencing a specific 
tissue, say the brain and other tissues. Thus methods such as conditional/ inducible 
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technologies are now available that allow in vivo gene manipulation at specific time periods 
and tissue specifically during or after development. The Cre/loxP recombination system is a 
widely used approach in which Cre is a recombinase that recognises and mediates 
recombination between loxP sites, excising the sequences in between. Two requirements need 
to be fulﬁlled for conditional targeting with the Cre–loxP system: (a) a ‘ﬂoxed’ allele must be 
created in such a way that two loxP sites ﬂank an essential region of the gene, without altering 
its normal activity; (b) targeting of Cre expression must be tightly controlled: to that end, 
either transgenic mice by pronuclear microinjection or, better, knockin mice may be used. 
This scenario allows spatial control of the occurrence of a mutation and therefore insight into 
the function of a gene in a particular cell type or tissue. There are a few limitations to this 
approach; it is an irreversible one-off event as well as it can be expensive and time-consuming 
to generate.  
In vivo, a number of inducible systems have been developed to allow temporal and spatial 
regulation of transgene expression including the tet regulatory system which is widely used in 
transgenic mice. Briefly, the process involves a dual-transgene system whereby a specific 
promoter controls the expression of tTA (tet controlled Transcriptional Activator) and a second 
transgene encodes for a gene of interest under the control of tTA-responsive TetOp promoter. 
Thus, in the presence of tetracycline or its derivitive doxycycline, tTA is unable to bind to the 
TetOp promoter and expression is turned ‘off’.  A disadvantage of this system is that if the 
induction of the transgene is required only in adulthood, then the mice have to be persistently 
exposed to the tetracycline or doxycycline from conception, which can be very expensive and 
may also results in behavioural side effects. In fact, one study demonstrated that exposure to 
doxycycline resulted in impaired spatial memory and fear conditioning (Mayford et al., 1996). 
Another disappointing feature of this approach is that transgene induction is limited by the 
rate at which the tetracycline or doxycycline is cleared from the body and can be variable 
between tissues (Kistner et al., 1996; Chen et al., 1998). Due to their limitations, gene delivery 










1.6 Gene delivery methods 
1.6.1 Non viral method - Transfection  
Transfection can be attained by introduction of nucleic acids into cells, which is essential for 
the study of gene and protein function. Different transfection methods are available for gene 
transfer although efficiencies differ especially in neural-derived cell lines which are often 
difficult to transfect.  
One of the best established and commonly used methods of transfection is calcium phosphate 
DNA co-precipitation in vitro. Basically, it entails the formation of DNA crystals with calcium 
ions which precipitate onto the cells and is subsequently taken up by endocytosis. In 
proliferating cells the DNA can enter the nucleus when the nuclear envelope breaks down 
during mitosis. However, in postmitotic cells such as neurons, entry into the nucleus is more 
difficult and transfection efficiencies are low although attempts have been made to improve 
this (Goetze et al., 2004). An advantage is that when optimised, calcium phosphate/ DNA co-
precipitation results in good cell viability compared to other transfection methods (Karra & 
Dahm, 2010) such as electroporation.  
 
Another transfection method that is widely used in vitro is lipofection which involves DNA and 
other genetic elements being complexed with a ‘carrier’ called liposomes that facilitate its 
uptake by the cells Figure 4. These are cationic lipids that, like cell membranes, possess long 
hydrophobic chains and a positively charged head group. DNA-liposome complex (lipoplex) 
formation results due to a negatively charged DNA molecule being encapsulated by a lipid 
bilayer not only protecting it from enzymatic degradation but also permitting its efficient 
uptake by endocytosis (Gao et al., 2011). Indeed these carriers are among the most efficient 
non-viral vectors and have been used extensively to transfect various cell lines owing to the 
ability to transfect large nucleic acids and their ease of use. Yet again, in the case of neuronal 
transfection efficiencies remain to be low (Dalby et al., 2004). Very few studies have used non-
viral methods for gene delivery in vivo. Another important consideration is the duration of 
transgene expression as even the most efficient carrier such as PEI-mediated transfection in 
neuronal transfection results in expression in neurons that only lasts several days to few weeks 
(Abdallah et al., 1996; Wang et al., 2001). While some viral vectors have been demonstrated to 
have stable transgene expression in neurons that lasts for up to 6 months (Finiels et al., 1995; 





Figure 4:  Lipoplex-mediated transfection and endocytosis  
Figure adapted from Parker et al. (2003). Negatively charged DNA and positively charged liposomes are 
combined to give a lipoplex, which enters the cell through endocytosis. The resulting endosome is either 






1.6.2 Lentiviruses as vectors for gene delivery  
To circumvent the abovementioned challenges and limitations, viral mediated gene delivery 
offer a highly efficient and sustained transgene expression in a variety of cell types, and is now 
increasingly being used to study gene function. Accordingly, viruses are used as gene vehicles 
that can be engineered for delivery of the desired sequences into host cells making it a useful 
tool for research and therapy. A range of viruses are available for transduction of genetic 
material in vitro and in vivo including herpes simplex virus derived vectors, adenoviruses, 
retroviruses (γ-retroviruses and lentiviruses), poxviruses and adeno-associated viruses. They 
have advantages and disadvantages as described in Table 1 below. For example, adenoviral 
vectors have very high transduction efficiency and can infect both dividing and non-dividing 
cells. They are also able to deliver large DNA particles of up to 38kb, however transgene 
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expression is shortterm as their DNA does not integrate into the host genome and they are 
highly immunogenic (Teramato et al., 2000). While adeno-associated viruses are similar to 
adenoviruses but have lower immunogenicity and can integrate specifically into a site on 
chromosome 19 with no noticeable adverse effects but they have limited transgene capacity 
(up to 4.8kb) and require complicated process of vector production (Nayerossadat et al., 
2012). 
 
Table 1: Comparision of viral vectors for gene delivery. dsDNA = double stranded 
DNA; ssDNA = single stranded DNA.  
 
Viral vector Transgene  
capacity 




4kb - Broad cell trophism 
- Infect dividing and non-dividing cells 
-Prolonged and high transgene 
expression 
-Low immunogenicity and non-
pathogenic 
-Difficult to achieve high titres. 




10kb -Broad cell tropism 
-Infect dividing and non-dividing cells 
-Stable and high transgene expression 
 
-Possible insertional 
mutagenesis due to random 
integration into host genome. 
This could lead to oncogenicity. 
Hepes simplex 
virus (dsDNA) 
50kb -Infect dividing and non-dividing cells 
-High titres achieved 
-Natural tropism to neuronal cells 
-Possible toxicity 
-Risk of recombination 
-Transient transgene expression 
although prolonged in neurons 
Adenovirus 
(dsDNA) 
7-8kb - Broad cell trophism 
- Infect dividing and non-dividing cells 
-High transgene expression 
-High titres achieved 
 
-Capsid proteins trigger 
immune response to viral 
proteins. 
-Transient transgene expression 
 
As lentiviral-mediated gene delivery has been used as a method of gene delivery in this thesis, 




1.6.2.1 The lentiviral life cycle 
Lentiviruses are a subset of retroviruses which are naturally occurring single stranded RNA-
containing viruses. The life cycle of a retrovirus is typically divided into two stages as illustrated 
in Figure 5, infection and replication. The first phase involves the introduction of the viral 
genome into the cell, while replication entails the expression of structural and regulatory viral 
proteins that replicate the viral DNA and produce packaging proteins in order to produce 
lentiviral particles.   
In detail, the lentiviral life cycle involves entry into the host cells through a fusion step via 
specific cell surface protein receptors encoded by the viral env gene. Upon entry into the cell 
cytoplasm, the viral RNA is reverse-transcribed into double stranded DNA by the viral enzyme 
reverse transcriptase, encoded by the pol gene. The viral DNA is then translocated into the cell 
nucleus where it is integrated permanently and randomly into the host cell genome (Cepko, 
1988) due to the presence of long terminal repeats (LTRs). These are sequences that contain 
several repeats which flank functional genes and, in virus, are involved in the process of 
integration of viral DNA into cellular host DNA. As a result, all cells descended from an infected 
cell carry the viral genome. During cellular transcription and translation, the viral genomic RNA 
and viral structural proteins such as gag and env encoding for viral capsid and envelope 
proteins respectively, are produced and assembled to generate viral progeny. The unique 





Figure 5: The lentiviral life cycle (Dottori et al., 2011). 
Receptors on the lentivirus capsid can fuse with the host cell membrane receptors allowing the 
introduction of the viral genetic material into the cell cytoplasm. Here the viral single standed RNA is 
reverse transcribed to double stranded DNA by RNA polymerase. The viral genome is then integrated into 
the host cell genome where with the help of host cell transcription and translation machinery will 




1.6.2.2 Modification of lentiviral features for use in research 
A number of modifications are performed to convert natural viruses into useful tools for 
genetic modification for research and for biosafety. Alterations include the removal of viral 
genes responsible for virulence and pathogenesis, for instance, vif (induces G2 cell cycle 
arrest), vpr (alters cellular activation pathway), vpu and nef (both involved in the down 
regulation of the immune response) (Delenda, 2004). These ‘accessory genes’ are not essential 
for viral replication and are therefore absent.  
The entire lentiviral vector system is usually separated in three or four plasmids in the interest 
of improving bio safety: the packaging plasmid (may be split into 2 plasmids), the gene transfer 
plasmid and an envelope (env) plasmid. Hence, viral packaging can be achieved by using triple 
(2
nd
 generation) or quadruple (3
rd
 generation) co-transfection (Lever et al., 2004) to generate 
lentiviruses that express the desired foreign genetic element (Figure 6B). Further modifications 
include the removal of the env gene from the lentiviral genome and replaced with a foreign 
glycoprotein vesicular stomatitis virus glycoprotein (VSVG) (Figure 6A). The presence of this 
protein confers the virus particle with the ability to transduce a wide range of cell types 
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including primary cells, stem cells and early embryos (Naldini et al., 1996b; Lois et al., 2002; 
Pfeifer et al., 2002).  
The lentiviral gene transfer expression plasmid vector also contains some alterations of the 
viral genome such as the incorporation of a transcriptional cassette with a promoter or a post 
transcriptional regulatory element that enhances transgene expression, like the human 
hepatitis virus post transcriptional element (HPRE), or the heterologous polyadenylation 
enhancer elements, as those derived from simian virus 40 (SV40) (Durand & Cimarelli, 2011). 
Transfer plasmid vectors also contain altered LTRs to facilitate the integration of the transgene 
into the host cell genome Figure 6A. LTRs are essentially modified by removal of viral 
enhancers and other transcriptionally active sequences from the 3’LTR resulting in a self 
inactivating (SIN) LTR (Yu et al., 1986) which is thought to be safer than using native viral LTR. 
In addition, the lentiviral gene transfer plasmid vector contains several features that make it 
useful for its application in vitro and in vivo. For instance, it includes a strong promoter for 
gene expression and a fluorescent reporter gene, for example GFP (green fluorescent protein) 
or RFP (red fluorescent protein). As mentioned earlier, the viral gene transfer vector has been 
modified to contain a multiple cloning site for incorporation of foreign genetic materials e.g. a 
gene of interest or a short interfering RNA (siRNA). For gene overexpression, the open reading 
frame of the cDNA is amplified and cloned into the lentiviral expression gene transfer plasmid 
vector. In order to obtain sustained knockdown of a target gene, siRNA such as short hairpin 
RNA (shRNA) can be cloned into the gene transfer vector. On the whole, the resulting 
recombinant viral genome thus converts the infection process to an efficient transduction one, 
allowing for non-replicative entrance of a virus into the host cell followed by expression of the 
desired genetic information it carries in its genome. Accordingly, in the interest of biosafety, 






Figure 6: Genetic elements required for third generation lentiviral vector co-transfection 
system for lentiviral production taken from (Dottori et al., 2011).  
A) This system includes 4 plasmids for co-transfection: Recombinant gene transfer plasmid in which some 
genes from the wild type lentiviral genome have been deleted or modified; genes essential for viral 
production are encoded on different plasmids. VSVG (env) plasmid conferring a broad range of cell type 
tropism for infection; the Gag/pol encodes the capsid proteins and reverse transcriptase and Rev which 
contains the nuclear localisation sequence necessary for gene transportation into the nucleus. B) 
Lentiviral production using third generation lentiviral packaging system upon co-transfection of 








1.6.2.3 Advantages and applications of lentiviral mediated gene delivery 
The most widely used application of lentiviruses is to transduce desired genetic elements for 
investigating gene function. Owing to the envelope modification, lentiviruses are beneficial as 
they are able to transduce a wide range of cell types in vivo, including neurons, astrocytes, 
oligodendrocytes, primary hippocampal neurons  and adult neural stem cells depending on the 
type of promoter used (Janas et al., 2006; Hioki et al., 2007). Indeed, lentiviruses can infect 
both dividing and non-dividing cells, and is particularly useful in carrying out gene modification 
in neurons, which are generally difficult to transfect (Lo et al., 2001; Washbourne & McAllister, 
2002). Lentiviruses also offer an added advantage in that they have a moderately large insert 
capacity for transgenes (up to 10kb) (Cazzin & Ring, 2010) for investigating gene function by 
overexpression in a cell line or in vivo. Lentiviral mediated gene silencing has also been used to 
identify genes important in development (Gibson & Ma, 2011). Several reports have 
demonstrated that efficient transduction in mouse and monkey embryonic stem cells 
(Hamaguchi et al., 2000; Asano et al., 2002; Pfeifer et al., 2002). Moreover, it has been 
reported that transgene expression was not silenced throughout undifferentiated 
proliferation, as well as after differentiation in vivo and in vitro (Gropp & Reubinoff, 2006). 
Lentiviral-based vectors overexpressing speciﬁc transcription factors could direct the 
differentiation of hESCs toward a desired cell lineage or cell type including neuronal 
progenitors cells which could be useful for regenerative medicine. 
Of note, a beneficial feature of lentiviruses, especially for in vivo functional studies, is that 
normal cellular functions are not disrupted and no significant immune response is induced 
(Kordower et al., 2000b). Numerous studies have shown that lentiviral vector successfully 
target neuronal cells in the rodent brain (Naldini et al., 1996a; Naldini et al., 1996b; Blomer et 
al., 1997; Zufferey et al., 1997). The ability of the lentiviral genome to integrate permanently 
and stably in the host genome resulting in sustained gene modulation (Naldini et al., 1996a; 
Gascon et al., 2008) enables the study of behavioural consequences in vivo over extended time 
periods (Georgievska et al., 2004). Lentiviruses also offer localised delivery permitting study of 
gene manipulation in particular brain regions of interest associated with a given behavioural 
trait (Caceda et al., 2005; Lasek et al., 2007; Land et al., 2009; Ahmed et al., 2010; Johnson & 
Kenny, 2010; Lasek et al., 2010; Wang et al., 2010). Numerous studies have investigated the 
role of specific genes using lentiviral based genetic modification in animal models to 
investigate their contribution to the development of experimental models of neuropsychiatric 
conditions including anxiety-like disorders (Rubino et al., 2008; Eren-Kocak et al., 2011), 
addiction-like phenotypes (Boyer & Dreyer, 2007; Johnson & Kenny, 2010; Lasek et al., 2010) 
47 
 
and Parkinson’s Disease (Ahmed et al., 2010). For example, the growth factor GDNF (glial-
derived neurotrophic factor) has been shown to prevent neurodegeneration and promote 
regeneration in many animals models of Parkinson’s disease (Deierborg et al., 2008). 
Recombinant lentiviral vectors have been developed and used for GDNF gene delivery 
(Kordower et al., 2000a; Brizard et al., 2006) including in vivo gene delivery. Interestingly, 
intracerebral injection of lentiviral into lesioned rats and rhesus monkeys displayed 
improvements in locomotor function (Dowd et al., 2005).  Also, in the brain, intra-striatal 
lentiviral mediated gene delivery of GDNF demonstrated complete striatal dopamine 
innervation which resulted in improved motor function in a rat model of early Parkinson’s 
disease (Brizard et al., 2006). Despite its limitations, lentiviral vectors hold great promise for 
gene therapy for this disease and, lentiviral delivery of GDNF and other neurotrophins are 





1.7 Thesis Aims 
The overall aim of this study was to functionally characterise Dopamine D2 and D3 receptors 
(D2R and D3R respectively) using lentiviral mediated gene delivery technique as well as 
investigate the possible function of a gene with as yet  unknown function, Autism susceptibility 
candidate 2 (AUTS2). Specifically the aim of this thesis is sub-divided into the following: 
 
1) Establish lentiviral mediated gene delivery technique in vitro and in vivo by delineating 
the role of two well characterised genes D2R and D3R on locomotor behaviour. 
 
2) Elucidate the cellular localisation of AUTS2 and identify its protein interacting partners. 
 
3) Given its potential characterisation as a neurodevelopmental gene, investigate the 
consequence of manipulating AUTS2 expression on global gene expression in a newly 









Chapter 2  Materials and Methods 
 
This chapter details the generalised protocols used in the research reported in this thesis. 




• Solutions and buffers were prepared using ultrapure double distilled water (ddH2O) 
from an Elga Maxima water purification system, unless otherwise stated.  
• For tissue culture, all buffers and reagents including dH2O were tissue culture grade.  
• Molecular biology grade water and ethanol was obtained from Sigma, UK.  
• Restriction enzymes used throughout the chapters were purchased from New England 
Biolabs (NEB), UK.  




2.1 Tissue culture  
2.1.1 Materials 
2.1.1.1 Cell lines 
Four different cell lines were used in this thesis: 
i) Neuro2a – a clone established from a spontaneous neuroblastoma tumor of a strain of 
albino mouse (Klebe & Ruddle, 1969), was purchased from American Type Cell Collection 
(ATCC), USA. 
ii) HEK 293T – a highly transfectable cell line derived from human embryonic kidney, (ATCC, 
USA). An SV40 Large T-antigen is present which enables episomal replication of transfected 
plasmids containing the SV40 origin of replication.  
iii) 293FT – is a variant of the HEK 293T cell line, from Life Technologies, UK. 
iv) SPC-04 – Human foetal neural stem cells, are conditionally immortalized cell line, generated 
from 8 week old human fetal spinal cord as described in (Kubinova et al., 2010), a kind gift 
from Dr Graham Cocks and Prof. Jack Price (James Black Centre, King’s College London). The 
SPC-04 cell line was immortalized using a retroviral vector encoding for c-myc-ERTAM, that is 
c-myc fused to a mutant of the estrogen receptor sensitive to 4-OHT. Expression of this fusion 
protein enables cell immortalisation hence resulting in stable and continuous propagation 
while maintaining phenotypic and karyotypic stability, in the presence of 4-OHT. In the 
absence of 4-OHT, c-myc is not active and the cells cease to propagate.  
 
2.1.1.2 Media and supplements 
Table 2 contains details of the media and supplements for each cell line. Dulbecco’s Modified 
Eagles medium (DMEM) and Fetal Bovine Serum (FBS), 2mM L-Glutamine, 100U/ml Penicillin 
and 100µg/ml Streptomycin were purchased from Sigma, UK. All other reagents were 
purchased from Life Technologies, UK. Where FBS was required to be heat inactivated, this 




Table 2:  List of cell lines and details of the media required for their culture 
 
 
Table3: RMM+ media preparation for SPC-04 cell line.  
 
 
Cell line Media and supplements 
Neuro2a  DMEM containing 4.5g/L glucose and  2mM L-Glutamine supplemented 
with 10% heat inactivated FBS, 100U/ml Penicillin and 100µg/ml 
Streptomycin. 
HEK 293T 
HEK 293FT DMEM containing 10% FBS (non heat-inactivated) supplemented with 
0.1mM MEM-non-essential amino acids, 1mM sodium pyruvate, 6mM L-
glutamine and 500μg/ml Geneticin® . 
SPC-04 Refer to Table3 and section 2.1.1.3 for details. 
Components for RMM+ Final concentration Source 
DMEM:F12 (Ham)    - Life Technologies, UK 
Albumin serum, Human (HAS) 0.03% Baxter Healthcare Ltd., UK 
Human Apo-Transferrin  100µg/ml Sigma, UK 
Insulin, Human recombinant 5µg/ml Sigma, UK 
L-Glutamine   2mM Sigma, UK 
Progesterone 60ng/ml Sigma, UK 
Putrescine Dihydrochloride, Human 16.2µg/ml Sigma, UK 
Sodium Selenite 40ng/ml Sigma, UK 
4-hydroxy-tamoxifen 100nM Sigma, UK 
Human EGF 20ng/ml PeproTech EC Ltd, Germany 
Human bFGF  10ng/ml PeproTech EC Ltd, Germany 
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2.1.1.3 SPC-O4 media and reagents  
SPC-04 cell lines were maintained in reduced modified media (RMM) with growth factors and 
4-hydroxy-tamoxifen (4-OHT) denoted (RMM+). This media was filtered through a 0.2μM filter 
unit (Stericup; Millipore, UK) and was stored for no more than 4 weeks at 4°C. Suppliers for 
individual components and final concentrations required for RMM+ preparation are detailed in 
Table3: RMM+ media preparation for SPC-04 cell line. Stock solution preparations for 
individual components are given in Table 4.  
 
Table 4: Stock solutions prepared for some of the components in RMM+ 
 
Component  Stock solution preparation 
Albumin serum, Human 
(HAS) 
20% (w/v; no preparation required)  
Apo-Transferrin, Human 50mg/ml diluted in DMEM:F12 containing 1mM HEPES pH 7.4 
Human recombinant insulin  10mg/ml (w/v; no preparation required) 
L-Glutamine 200mM (no reparation required) 
Human Putrescine 
dihydrochloride 
8.1mg/ml dissolved in tissue culture grade water 
Sodium selenite  20µg/ml dissolved in DMEM:F12 
Progesterone  
 
1mg dissolved first in 100µl molecular biology grade ethanol 
and then diluted in DMEM: F12 to give 20µg/ml 
4-OHT 1mM dissolved in molecular biology grade ethanol 
EGF,Human 10µg/ml dissolved in DMEM:F12 containing 1mM HEPES and 
0.03% human albumin serum 
b-FGF, Human  
 
10µg/ml dissolved in DMEM:F12 containing 1mM HEPES and 
0.03% human albumin serum 
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2.1.1.4 RMM without growth factor and 4-OHT (RMM-) 
RMM without growth factors and 4-OHT denoted RMM- was used to induce and maintain 
differentiation in the SPC-04 cell line. This media contained all components in Table3, except 
for EGF, b-FGF and 4-OHT. 
 
2.1.1.5 Preparation of differentiation inducing agents 
Two stock solutions were prepared in order to induce differentiation in SPC-04 cells: DAPT (LY-
374973 N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) and ATRA (All-
trans retinoic acid). Both stock solutions of 10mM DAPT and 10mM ATRA were prepared in 
DMSO, aliquoted and stored at -80°C. 
 
2.1.1.6 Preparation of trypsin inhibitor solution (Trit) 
Trit consisted of DMEM:F12 containing 1% Human Albumin Serum, 0.55% soyabean trypsin 
inhibitor (v/w) and 0.025U/ml bensonase solution (Merck, UK). 
 
2.1.1.7 Growth surface for adherent cell lines 
All flasks, plates and other growth surfaces for 293T, 293FT and Neuro2a cell lines were 
purchased from BD Biosciences, UK.  
All flasks and 6-well plates used for SPC-04 cell culture or growth were Nunclon™ Δ Delta 






2.1.2.1 Maintenance of all cells lines 
Cell lines were maintained at 37°C with 5% CO2, humid incubator. All reagents were pre-
warmed before use. Cells were propagated until reaching approximately 80% confluency and 
were passaged as detailed in 2.1.2.2 for SPC-04 cell line and 2.1.2.4 for other cell lines. 
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2.1.2.2 Passaging SPC-04 
Appropriate size culture flasks were coated with a thin layer of 20μg/ml laminin (diluted in 
from a 1mg/ml stock in cold DMEM:F12) for three hours in a 37°C with 5% CO2, humid 
incubator. Just prior to plating cells, the excess laminin was aspirated off and the flask rinsed 
with DMEM:F12 to remove residual laminin. This was aspirated and replaced with RMM+ and 
returned to the incubator. Next, the culture flask to be passaged was first rinsed with HBSS 




; Life Technologies), followed by 
immediate addition of TrypZean (Lonza, UK) and returned to the incubator for approximately 2 
minutes. Upon confirmation of cell detachment under an inverted microscope, Trit was added 
to inactive the enzyme and the cell suspension was centrifuged at 900rpm for 5 minutes to 
give a pellet which was resuspended in a small volume of RMM+ for either freezing and/or 
plated for further propagation in a laminin coated flask at approximately 20,000 cells/cm
2
.  
For freezing, a 20% DMSO solution (diluted in RMM+ was added to an equal amount of cell 
suspension to give a final concentration of 10% DMSO. These were, frozen at 1°C/min in a 
freezing container (Mr. Frosty, Nalgene®) with isopropanol and stored at -80°C overnight 
and transferred to liquid nitrogen. 
 
2.1.2.3 Inducing differentiation of SPC-04 
For inducing differentiation, cells were seeded at 12,000 cells/cm
2
 in 6-well plates and allowed 
to grow over two days. Subsequently, cells were rinsed twice in RMM- to ensure removal of 
growth factors before RMM- containing a final concentration of 10μM DAPT and 100nM ATRA 
was added to the cells and incubated for 48 hours. This experimental stage is referred to as 
‘pre-differentiation’ hereafter. Following this, the medium is changed to RMM- only, every two 
days until the end of the experiment. For reference to the experimental stage, differentiation 
begins after pre-differentiation thus ‘3 days differentiation’ refers to 3 days after pre-
differentiation stage. Although it is challenging to quantify such level of differentiation, the 
above experimental stages were used for referencing and comparision purposes for the 
experiment. Of course this does not reflect or compare to the ‘level’ of differentiation in vivo. 
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2.1.2.4 Passaging other adherent cell lines 
293T, 293FT and Neuro2a cell lines were passaged at a 1:10 split ratio.  This process involved 
removing the culture medium and rinsing the adherent cells with 1x Dulbecco’s phosphate 
buffered saline (PBS) and incubating the adherent cells with a thin layer of 0.05% (1x) trypsin-
EDTA solution (Life Technologies, UK) at 37
o
C for 5 minutes; or until the cells detached from 
the flask. Complete medium was added to the detached cells and centrifuged at 1500rpm for 5 
minutes at RT. The cell pellet were resuspended in fresh complete medium, diluted accordingly 
and plated. Cells were maintained at 37°C with 5% CO2, humid incubator. 
For long term storage, cells were harvested by trypsinisation and spun down at 1500rpm for 5 
minutes. The resulting pellet was resuspended in freezing medium (10% dimethyl sulphoxide 
[DMSO], 90% appropriate culture medium) ensuring between 2 – 5 x10
6
 cells were frozen per 
ml and transferred to cryotubes. These were, frozen at 1°C/min in a freezing container (Mr. 
Frosty, Nalgene®) placed at -80
o
C overnight and transferred to liquid nitrogen storage. 
 
2.1.2.5 Cell counting 
For determining cell count, the trypsinisation protocol appropriate for each cell line was 
carried out for obtaining cells in suspension, and counted using a NucleoCounter NC-100 
(Chemometec, UK). Equal amounts of cell suspension, Reagent A (lysis buffer; Chemometec, 
UK) and Reagent B (stabilising buffer; Chemometec, UK) are mixed to give a minimum volume 
of 120μl. This mixture is then introduced into a Nucleocasette which contains an immobilized 
fluorescent dye propidium iodide (PI), in its interior. The PI intercalates with the DNA with 1 
dye molecule per 4-5 DNA base pairs. The nucleocassette is placed into the NeucleoCounter, 
the cellular DNA – PI stained mixture is automatically transferred to the measurement 
chamber. Green light excites the PI-DNA mix and the resulting red light emitted is registered 
and registered in the CCD camera for correlation into a cell count. Concentration was given in 
cells/ml. The dilution factor was multiplied with this figure to give final concentration of the 
cells in suspension obtained following trypsinisation. 
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2.2 Transfection  
2.2.1 Materials 
Unless otherwise stated, all reagents used in this section were purchased from Sigma, UK. 
Tissue Culture Grade dH2O was used to prepare reagents and buffer. These were filtered using 
a sterile 0.22μm pore filter (Sartorius Stedim).  
 
2.2.1.1 Hepes Buffered Saline (HBS), 2x  
281mM NaCl, 100mM HEPES, 1.5mM Na2HPO4, pH 7.12. Aliquoted and stored at -20°C. 
2.2.1.2 CaCl2, 2.5M 




2.2.2.1 Calcium phosphate transfection 
The day before transfection, cells were seeded as per Table 5 below, depending on size of 
plate or dish used. On the day of transfection, the medium was replaced with fresh culture 
medium and placed back in the incubator. Plasmid DNA and 2.5M CaCl2 as described in Table 5 
were added together and mixed. Then 2x Hepes Buffered Saline (HBS) pH 7.12 was slowly 
added in a dropwise manner whilst applying air pressure to generate a bubbling effect to mix 
the DNA/CaCl2/HBS solutions. This mix was then left at RT for 10 minutes to allow for the 
calcium DNA precipitates to form. Next, all of this mix was added to the medium and placed 
back in a humidified incubator at 37°C with 5% CO2. The following day, the medium was 
replaced with fresh culture medium. Cells were observed microscopically 48 hours after 
transfection to detect GFP expression. 72 hours after transfection, cells were either lysed for 
RNA and/or protein extraction (detailed in section 2.7 and 2.9 respectively) or trypsinized into 





Table 5: Details of reagents and cell for CaCl2 – mediated transfection.  
 
 10cm dish  6 well 
Number of cells plated 3x10
6




in 3ml culture medium 
Culture medium volume on 
the day of transfection  
5ml 1ml 
Plasmid DNA  20μg 3μg 
Total volume with dH2O 450μl 76.5μl 
2.5M CaCl2 50μl  8.5μg  
2x HBS pH7.4 500μl 85μl 




2.2.2.2 Determining transfection efficiency  
Transfection efficiency was determined approximately by dividing the number of 
GFP+ve cells over the total number of cells in the field of view at 20x magnification 
(atleast 100 cells /field). Three or four random areas of the plate/ well/slide were 
chosen to corroborate the results. 
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2.3 Lentiviral production, transduction and concentration 
2.3.1 Materials 
Unless otherwise stated, reagents used in this section were purchased from Sigma, UK. All 
tissue culture buffers and reagents were filtered using a sterile 0.22μm pore filter. The 
lentiviral plasmids used for lentiviral production have been described in further details in the 
specific data chapters. 
2.3.1.1 Polybrene, 1000x 
8mg/ml polybrene was prepared in Tissue Culture Grade H2O. 
2.3.1.2 Chloroquine, 100mM 
100mM chloroquine was prepared using Tissue Culture Grade H2O. 
 
 
2.3.2 Methods  
2.3.2.1 Lentiviral production 
Various transfection protocols were applied in this thesis and are described in detail in the 
relevant data chapters.  
2.3.2.2 Lentiviral Transduction 
This protocol has been previously optimised and used in the laboratory by Dr. Sylvane 
Desrivieres. 
Lentiviral transduction was carried out to 1) determine viral titres, 2) investigate knockdown 
efficiency of putative shRNAs in vitro and 3) verify the transcriptional gene induction efficiency 
of overexpression constructs. The following protocol is specific to the lentiviral transduction of 
293T cell line. The day before infection, cells were plated either at 1x10
5
 (for 24-well plates) 
and 5x10
5
 (for 6-well plates). On the day of infection, the lentiviral supernatants were added to 
the cells in a total volume of 1ml medium (for 24 well plates) and 3ml medium (for 6 well 
plates) with a final concentration of 0.4mg/ml Polybrene in order to facilitate the fusion of the 
virus particle to the cell membrane hence increasing the infection efficiency. The plates were 
centrifuged for 90 minutes at 2500rpm at RT and then placed for 2.5 hours at 37°C in a 5% C02 
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humid incubator after which the medium was replaced and incubated back for 72 hours. Prior 
to harvesting, cells were observed under a fluorescent microscope for the presence of GFP and 
estimation of transduction efficiency. The cells were lysed for RNA extractions (section 2.7.2.2 
below) and/or protein extraction (section 2.9.1 below). 
 
2.3.2.3 Concentration of lentivirus  
This protocol has been established in our laboratory previously. To concentrate the lentiviral 
particles, the filtered supernatants were ultracentrifuged at 75000xg (Beckman Coulter, UK; 
SW27 Rotor) at 4°C for 1.5 hours. The supernatant was removed leaving a small visible pellet 
containing viral particles to which cold PBS was added and left overnight at 4°C. The pellets 
were resusupended the following day and stored in aliquots at -80°C.  
 
2.3.2.4 Lentiviral quantification 
Virus titers were determined by transducing the 293T cell line (see 2.3.2.2 above) and 
measuring eGFP expression by FACS analysis. To estimate the concentration of functional 
transducing units/ ml, 293T cells were transduced with serial dilutions of an aliquot of each 













 dilutions and added to the cells with medium containing 1x polybrene (final 
concentration 0.4mg/ml). Cells were centrifuged for 90 minutes at 2500rpm at RT and then 
incubated for 2.5 hours at 37°C in a 5% C02 incubator after which the medium was replaced 
and incubated back. After 72 hours, cells were harvested and subjected to flow cytometric 
analysis.   
The transducing units (TU/ml) were calculated as shown in the equation below: 
TU/ml = (%GFP+ cells/100) x nb x dilution factor 
A dilution giving ~10-15% GFP+ cells were chosen which represents one virus integration site 
per cell and nb = number of cells plated x 2
number of days after plating 
. 
The standard titre obtained from using the transfection protocol in this thesis was 1 -3 
x10
9 
TU/ml. To ensure the same concentration of lentivirus was used for experiments, 





2.3.2.5 Infection of SPC-04 with lentivirus 
Transduction of the SPC-04 cell lines was carried out at the pre-differentiation stage in 6-well 
plates (9cm
2
). A higher density of cells was plated to account for apoptosis occurring as a result 
of differentiation and lentiviral infection. Thus, 20x10
3
 cells were plated 24 hours prior to 
adding RMM- medium containing 10μM DAPT and 100nM ATRA and a concentration of 
0.26x10
6  
TU/ml of lentivirus per well. The cells were incubated with this medium for 48 hours 
before replacing with RMM- medium. 
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2.4 Bacterial transformations and cultures 
2.4.1 Materials  
All reagents, solutions and chemically competent bacteria used in this section were purchased 
from Life Technologies, UK, unless otherwise stated. 
 
2.4.1.1 Ampicillin stock solution 
Ampicillin (Sigma,UK) was prepared at a stock solution of 100mg/ml in ddH2O and was 
aliquoted and stored at -80°C. 
 
2.4.1.2 Lennox L Broth base (LB)  
Lennox L Broth base (LB) was made by dissolving 20g of this powder in a litre ddH2O giving the 
following constituents per litre: 10g SELECT Peptone 140, 5g NaCl and 5g SELECT yeast extract, 
pH 7.0. The broth solution was autoclaved at 121°C for 15 minutes. Before use, ampicillin stock 
solution was added to the broth to give a final concentration of 100µg/ml and stored at 4°C.  
 
2.4.1.3 LB Agar  
LB-Agar was also purchased as a pre-mixed powder consisting of 1.2% (w/v) SELECT – agar in 
LB. A 3.2% (w/v) solution of LB-agar was prepared in ddH2O and autoclaved 121°C for 15 
minutes before use. Before cooling completely, ampicillin stock solution was added to give a 
final concentration of 100µg/ml. This was poured into 10cm diameter sterile petri dishes and 
allowed to solidify overnight. The plates were stored at 4°C for up to 8 weeks. 
 
2.4.1.4 Bacterial strains 
Transformations were carried out in chemically competent Escherichia coli (E. coli) host strains 
either TOPO® One Shot TOP10 or MAX Efficiency® Stbl2™ competent cells which are a 
derivative of the JM109 bacterial cells and are suitable for cloning unstable inserts such as 




2.4.2 Methods  
2.4.2.1 Transformation of E.coli with plasmid DNA 
Plasmid DNA (1-50ng) were transformed into 50µl chemically competent cells and incubated 
on ice for 30 minutes. This was followed by heat-shock at 42°C for 45 seconds and returned to 
ice for 2 minutes. 900µl of S.O.C medium was added and the cells were allowed to recover at 
30°C, shaking at 225rpm for 1.5 hours. The cells were then centrifuged for 5 minutes at 
2500rpm and resuspended in 300µl LB media. 100µl of the cell suspension was plated on LB-
agar plates containing ampicillin as described in 2.4.1 and incubated overnight at 30°C to 
isolate individual colonies. 
For TOPO® One Shot TOP10 competent cells, the above protocol was carried out except 
following heat shock, cells were allowed to recover at 37°C, shaking at 225rpm for 1 hour. And, 
upon plating on LB agar plates, were incubated at 37°C overnight to isolate individual colonies. 
 
Bacterial colonies growing on LB agar plates were individually isolated aseptically and grown as 
precultures by inoculating in 5ml of LB broth containing 100µg/ml ampicillin with gentle 
shaking at 225rpm overnight at 37°C for TOPO® One Shot TOP10 Chemically Competent E. Coli 





2.5 Quantification of DNA and RNA 
The concentration and purity of DNA were determined by UV spectrophotometry using a 
NanoDrop 1000 spectrophotometer (Fisher Scientific, UK). 1µl stock DNA was loaded onto the 
optical pedestal and the absorption at 260nm indicated the concentration of DNA in the 
sample after selecting the double-stranded DNA quantitation option. The same was done for 
RNA quantification, only the single-stranded RNA option was selected. The absorbance of 
samples were read at 260nm and 280nm (A260 and A280). DNA can be quantified at 260nm; a 
solution of DNA with an optical density (OD260) of 1.0 has a concentration of 50ng/µl (using a 
1mm path length). A260 / A280 absorbance ratio gives an indication of the purity of the sample, 
with pure DNA having a value of 1.8. If the ratio is lower, it may indicate the presence of 
protein, phenol or other contaminants that absorb at or near 280nm. 
 
 
2.6 DNA extraction and analysis 
All DNA extraction kits used in this section were purchased from QIAGEN, UK unless otherwise 
stated. All buffers and other reagents used here were obtained from Sigma, UK unless 
otherwise stated.  
 
2.6.1 Materials  
2.6.1.1 DNA Agarose gel 
DNA was separated by electrophoresis on a 0.8% - 2% (w/v) agarose gel made up in 1x TBE 
buffer, supplemented with 0.1μg/ml of ethidium bromide when sufficiently cooled. 
2.6.1.2 Gel loading buffer 





2.6.2.1 Mini- and Maxi- preps 
For minipreps, 3ml of bacterial culture was centrifuged at 2500 rpm for 5 minutes. Minipreps 
were carried out using the NucleoSpin Plasmid DNA Purification Kit (Machery-Nigel GmbH & 
Co. KG, Germany) according to the manufacterer’s instructions. Briefly, the pelleted cells were 
subjected to alkaline lysis and the DNA recovered by ion exchange chromatography by use of 
NucleoSpin® columns provided in the kit. Plasmid DNA was eluted in 60µl of Elution buffer 
(Buffer AE).  
Large scale plasmid DNA preparations, maxipreps, were generated using the Endofree® 
Plasmid Maxiprep Kit according to the manufacturer’s instructions. This yields high quality 
plasmid DNA without contaminating endotoxins from the E.Coli host. Endotoxin-free plasmid is 
required for mammalian cell transfection.  The maxiprep DNA concentration was measured 
using a nanospectrophotometer as described in 2.5. 
 
2.6.2.2 Agarose gel electrophoresis 
DNA was separated by electrophoresis on a 0.8% - 2% (w/v) agarose gel (see section 2.6.1.1). 
Samples were mixed with one-sixth volume of 6x gel-loading buffer (Thermo Scientific, UK) and 
loaded into the wells of the gel. The samples were electrophoresed in 1x TBE buffer at 80V-
120V for approximately 1-1.5 hours (depending on the gel percentage and appropriate 
fragment separation required). The bands were visualized using ultraviolet light and the 
estimated size of the DNA fragments made by comparison with a 1kb ladder (250-10000bp, 
Thermo Scientific, UK). 
 
2.6.2.3 DNA extraction from gels 
DNA bands of interest visualised in Ethidium bromide stained agarose gels were excised with a 
clean scalpel and DNA extracted using an ion-exchange chromatography column kit (QIAquick 
Gel Extraction Kit ; Qiagen, UK) according to the maufacturer’s instructions. The DNA was 
eluted in 40 µl of Elution Buffer EB). DNA concentration was measured using a 




2.6.2.4 DNA Sequencing  
DNA was either sequenced in-house or sent externally for sequencing. 
For external sequencing, a small amount of plasmid DNA was sent for Sanger sequencing at 
SourceBioscience along with the relevant primers.  
In-house DNA sequencing was performed using the Applied Biosystems sequencing kit (Life 
Technologies, UK). The reaction contained: 1x BigDye® sequencing buffer, 4μl BigDye® v3.1, 
0.5μl 10uM forward or reverse primer, 500ng DNA template made up to a final volume of 10μl 
with dH20. The PCR thermal cycling conditions are given in Table 6. Following this, the DNA was 
transferred to a clean microcentrifuge tube and precipitated by adding the following; 80ul 
ddH20, 1.25μl of 125mM EDTA  and 280ul of 95% (v/v) ethanol and was incubated for 15 
minutes at RT followed by centrifugation at 14,000xg for 30 minutes. The supernatant was 
removed and the remaining pellet washed with 250μl of 70% ethanol. The DNA pellet was air 
dried and 15μl formamide added before loading onto the ABI3700 DNA sequencer.  
In both cases, analysis of the results was carried out using Sequencing Analysis software v5.2 



















Step Time Temperature (°C) 
1 1 minute 96 
2 10 seconds 96 
3 5 seconds 50 
4 1 minute 15 
5 Go to step 2 – 15x 
6 10 seconds 96 
7 5 seconds 50 
8 1 minute 30 
9 Go to step 6 – 5x 
10 10 seconds 96 
11 5 seconds 50 
12 2 minutes 60 
13 Go to step 10 – 5x 
14 ∞ 4 
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2.7 RNA extraction and reverse transcription 
2.7.1 Materials  
DEPC-treated water and other reagents described in this section are obtained from Life 
Technologies UK, unless otherwise stated. RNase-free water was obtained from QIAGEN.  
2.7.1.1 Lysis buffer for RNA extraction 
Buffer RLT (Qiagen, UK) containing 1% ß-mercaptoethanol 
 
2.7.2 Methods 
2.7.2.1 Harvesting cells for RNA extraction 
The culture medium was aspirated and cells were washed in 1x PBS. Lysis buffer (2.7.1.1) was 
added to the cells (350μl for <5x10
6




). The cell lysate was collected 
using a sterile cell scraper and transferred to a 1.5ml eppendorf tube. The mixture was 
vortexed briefly to ensure thorough lysis. 
 
2.7.2.2 RNA extraction 
RNA extraction was performed using the RNeasy Mini Kit (Qiagen, UK) according to the 
manufacturer’s instructions. The cells were homogenised using the QIAshredder columns 
which was centrifuged at full speed for two minutes. On-column DNase-treatment was carried 
out using the RNase-Free DNase Set (Qiagen, UK) according to the manufacturer’s instructions. 
Total RNA was eluted in 30µl RNase-free water, and samples were quantified using a 
nanospectrophotometer as described in section 2.5. 
 
2.7.2.3 Reverse transcription and complementary DNA (cDNA) synthesis 
Reverse transcription was carried out using the SuperScript™ III first-strand cDNA synthesis kit 
from Life Technologies, UK. Briefly 2µg of RNA (extracted from either cells or tissue) was added 
to 1µl 50μM oligo dT and 1µl 10mM dNTP mix made up to 10µl with RNase-free water. The 
components were mixed and heated at 65°C for 5 minutes, then kept on ice for 2 minutes. To 
the mixture, 1µl 10x first strand RT buffer, 4µl 25mM MgCl2, 2µl 0.1M DTT, 1µl RNASE Out™ 
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and 1µl 200U/µl SuperScript III was added. The mixture was incubated at 50°C for 50 minutes 
and then 85°C for 5 minutes. Finally, to remove the RNA, 2U RNase H was added and 
incubated at 37°C for 20 minutes. 180µl of DEPC-treated water was added to give a total 
volume of 200µl at 10ng/µl cDNA. 
 
 
2.8 Real Time quantitative PCR 
Real-time quantitative PCR (qPCR) is an accurate method of simultaneous DNA quantification 
and amplification (Heid et al., 1996). The method exploits the 5' endonuclease activity of Taq 
DNA polymerase to cleave a fluorescently labelled oligonucleotide probe during PCR, thereby 
generating a detectable signal which is quantified after each round of amplification. Using 
sequence-verified positive controls, real-time PCR is often combined with reverse transcription 
PCR to quantify messenger RNA, enabling a researcher to measure relative and/or absolute 
gene expression at a particular time, or in a particular cell or tissue type. 
cDNA samples were amplified using an ABI Prism 7900HT sequence detection system in a final 
volume of 20µl containing 2x power SYBR green master mix, 4µl 10ng/µl cDNA and 0.07µM of 
each forward and reverse primer. PCR reactions were performed in triplicate under the 
following thermal cycler conditions: 95°C for 15 minutes followed by 95°C for 30 sec and 59°C 
for 30 sec for 40 cycles. The PCR reaction was evaluated by dissociation curve analysis to 




2.9   Protein Analysis  
2.9.1   Materials 
Reagents used in this section are purchased from Sigma, UK unless otherwise stated. 
 
2.9.1.1  Buffers and reagents for Immunocytochemistry and Immunohistochemistry 
Phosphate Buffer Saline (PBS) 
19% (v/v) 0.2M monobasic sodium phosphate was added to 0.2M dibasic sodium phosphate, 
followed by 1.8% (w/v) NaCl to give 0.2M PBS pH7.4.  
0.1M PBS pH7.4 was made by combining equal volumes of 0.2M PBS pH7.4 and ddH2O. 
Paraformaldehyde, 4% in 0.1M PBS pH7.4 
This solution was prepared under the fume hood. 8% paraformaldehyde powder was made in 
ddH2O and stirred for 5-10 minutes on a hot plate. 10N NaOH was added dropwise until 
solution became clear. Equal parts of 8% paraformaldehyde and 0.2M PBS were combined to 
give 4% paraformaldehyde in 0.1M PBS pH7.4 
PBS-Triton (PBST) 
PBST consisted of 0.1M PBS pH 7.4 with 0.25% (v/v) Triton-X-100.  
 
2.9.1.2  Buffers for SDS-PAGE, Western Blot and Co-Immunoprecipitation 
Radioimmunoprecipitation (RIPA) buffer 
RIPA buffer was used to lyse cells for cytoplasmic protein extraction with the following 
ingredients at final concentrations in Table 7. RIPA buffer was prepared without the protease 
and phosphatase inhibitors and stored at 4°C. These inhibitors were only added on the day of 




Table 7: Modified RIPA buffer ingredients. 
 
Components of RIPA buffer Final concentrations 
Tris HCl pH 7.4 50mM 
NaCl 150mM 
Nonidet P-40  1% (v/v) 
Sodium deoxycholate 0.5 (w/v) 
EDTA 1mM 
Phosphatase inhibitors Final concentrations 
Sodium fluoride 1mM 
Sodium vanadate 1mM 







SDS-PAGE running buffer (National Diagnostic Ltd, UK) 
SDS-PAGE buffer was purchased as a 10x concentrated solution containing 1% (w/v) SDS; 
0.25M Tris-HCl pH8.3; 1.92M glycine. This was diluted with ddH2O to give 1x SDS-PAGE running 
buffer. 
SDS-PAGE transfer buffer 
Transfer buffer contained 20% methanol in 1x SDS-PAGE running buffer. 
SDS-PAGE sample buffer, Laemmli 6x 
6x Laemmli sample buffer contained 40% glycerol (v/v); 50% 0.5M Tris pH 6.8 (v/v); 8% SDS 
(w/v); 0.004% bromophenol blue (w/v) and 2% β-mercaptoethanol. 
Stock acrylamide 




SDS-PAGE gel constituents 
Two different gels were required to carry out SDS-PAGE. Table 8 shows the amounts and 
volume of individual components required to make a stacking and a resolving gel. 
 
Table 8: Components for an SDS-PAGE gel 
Components  Stacking gel (4%) Resolving gel (10%) 
Acrylamide 11.5% (v/v) 33% (v/v) 
1.5M Tris-HCl pH8.8 - 42% (v/v) 
1M Tris pH6.8 6.25% (v/v) - 
10% sodium dodecyl sulphate (SDS) 1% (v/v) 1% (v/v) 
Tetramethylethylenediamine, (TEMED) 0.05% (v/v) 0.066% (v/v) 
10% Ammonium Persulphate (APS) 0.075% (v/v) 0.01% (v/v) 
  
 
Tris- Buffered Saline (TBS), 1 x 
TBS was prepared with 25mM Tris base, 150mM NaCl and 2mM KCL.  pH was adjusted to 7.4 
by addition of concentrated HCl. 
TBS containing Tween-20 (TBST) 
TBST was made by adding 0.05% (v/v) Tween-20. 
Blocking buffers  
TBST containing 5% (w/v) dried skimmed milk or TBST containing 5% (w/v) Bovine serum 
albumin (BSA). 
 
2.9.1.3 Primary and secondary antibodies 
Table 9 lists the primary and secondary antibodies used in the data chapters for carrying out 





Table 9: List of Primary and secondary antibodies used in this thesis.  
Details on host species and companies from which they were purchased are provided.  
GFP – Green fluorescent protein; GFAP – glial filbrillary acidic protein  
 
Primary antibody  Host species Source 
Anti-V5  Mouse monoclonal Life Technologies, UK 
Anti- AUTS2 Rabbit polyclonal Abcam, UK 
Anti – Actin  Rabbit monoclonal Cell Signaling, UK 
Anti-GFP rabbit polyclonal Abcam, UK 
Anti-GFAP mouse monoclonal Millipore, UK 
Anti-Neuronal nuclei (NeuN) mouse monoclonal Millipore, UK 
Secondary antibody Host species Source 
Alexa Fluor 594 anti-mouse Goat Life Technologies, UK 
Alexa Fluor 488 anti-rabbit Goat Life Technologies, UK 
Alexa Fluor 633 anti-mouse Goat Life Technologies, UK 
Odyssey anti-mouse 800CW  Goat LI-COR Biosciences, UK 









2.9.2    Methods 
2.9.2.1 Immunocytochemistry 
Immunostaining was performed on Neuro2a cells and 293T cells. A generalised protocol is 
described here. The specific antibodies and dilutions used are detailed in the relevant 
chapters.  
For the above cell lines, 14,000 cells were seeded into 1.2cm
2
 chamber slides (Nunc, UK) and 
incubated in a 37°C with 5% CO2, humid incubator for 2 days. For fixation, cells were rinsed in 
0.1M PBS pH 7.4 before adding 4% paraformaldehyde in 0.2M PBS pH 7.4. The cells were 
allowed to fix for 15 minutes at RT. The cells were then washed twice in ice cold PBS. 
Immediately, cells were permeabilised in PBST for 10 minutes and then removed. Next, 
blocking buffer containing goat serum and/or BSA in PBST with 0.3M glycine (see specific 
blocking buffer used in relevant chapters) was added and incubated for 30 minutes. The 
addition of glycine will bind free aldehyde groups that would otherwise bind primary and 
secondary antibodies which lead to high background. The primary antibody (diluted in the 
blocking buffer) was then added (see relevant chapters for dilutions used) and incubated at 
4°C overnight. The following day, the primary antibody was removed and washed 3 times for 5 
minutes in 0.1M PBS pH 7.4. The secondary antibody was added (diluted in blocking buffer) 
and incubated and protected from light at RT for 1 hour. The cells were washed thrice for 5 
minutes before mounting with Prolong Gold antifade reagent with DAPI (Life Technologies, UK) 
and then coverslipped. Images were taken using Leica TCS SP5 fluorescent microscopy (x10 
and x20 objectives). 
 
2.9.2.2  Immunohistochemistry 
Brain slices (40μm thick) were made from frozen tissue sections collected from a microtome. 
The brain slices were washed thrice in 0.2M PBS for 5 minutes and blocked (PBST containing 
1% BSA, and 1% normal goat serum) for 1 hour at RT. Primary antibodies in their appropriate 
blocking solutions (see relevant chapters) were added and incubated overnight at 4°C. The 
following day, the primary antibody was removed and the brain slices were washed in 0.2M 
PBS thrice for 5 minutes to remove any residual primary antibody. Sections were then 
incubated with the appropriate fluorescently conjugated secondary antibodies at RT for 1 
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hour. The secondary antibody was removed and the slices were washed in 0.2M PBS thrice to 
remove any residual secondary antibody. Sections were then mounted with Prolong Gold 
antifade reagent with DAPI (Life Technologies, UK) and coverslipped.  
 
2.9.2.3 Protein extraction 
The cytoplasmic protein extracts were prepared 72 hours post transfection from cell 
monolayer which was grown in 6 well plates. The cells were placed on ice, rinsed twice with ice 
cold PBS and then scraped into modified RIPA lysis buffer. Samples were transferred to a tube 
and placed on a shaker for 15 minutes at 4°C. Cell debris was then pelleted at 10000 rpm using 
a bench-top microfuge for 5 minutes at 4°C. The protein supernatant was transferred to a 
clean ependorph tube and quantified using DC™ protein assay (see section 2.9.2.4). 
 
2.9.2.4  Protein quantification 
Protein was quantified using the DC™ protein assay (Bio-RAD) according to the microplate 
assay protocol supplied by the manufacturers.  Six different concentrations of BSA (2mg/ml, 
1.5mg/ml, 1mg/ml, 0.5mg/ml, 0.25mg/ml, and 0.1mg/ml) were prepared in ddH2O, each at a 
total volume of 5μl, to serve as a protein standard.  In addition, various dilutions of each 
protein sample to be quantified were prepared (1:2, 1:5, and 1:10) in modified RIPA buffer, 
also at a total volume of 5μl.  In parallel, a ‘blank’ sample was prepared for both protein and 
BSA samples for normalization purposes.  Diluted protein, BSA, and blank solutions were 
added into wells of a fresh microtiter plate, and 25μl of reagent A’, consisting of 20μl reagent S 
for every ml of reagent A (Bio-RAD), was then added to each well.  Then, 200μl reagent B (Bio-
RAD) was added to each well and the microplate was incubated for ~15 minutes on a rocker at 
RT.  Absorbance were then read at a wavelength of 750nm using a SpectraMax® 384 
Microplate Spectrophotometer (Molecular Devices, UK). Standard curves were generated 
using absorbance readings for the various BSA dilutions. The protein concentrations of the 




2.9.2.5   SDS-PAGE and Western Blot 
i) SDS-page gel preparation 
Proteins were separated on one dimensional gels according to the method of Laemmli 
(Laemmli, 1970) using the Mini-PROTEAN® II Electrophoresis Cell gel system (Bio-Rad 
Laboratories). Section 2.9.1.2 details the materials used for gel preparation. A 10% resolving 
gel was prepared with TEMED and APS added last as they catalyse the polymerisation. 
Isopropanol was added to evenly align the gel. Following polymerisation of the resolving gel, 
the isopropanol was discarded and rinsed with ddH2O. A 4% (w/v) stacking gel was prepared 
and immediately poured above the resolving gel with the comb in place and allowed to 
polymerise. The resolving gels constituted three-quarter of the whole gel.  
 
ii) Sample preparation for loading and running 
30µg of protein samples were added to 5x protein sample loading (Laemmli) buffer. The 
protein and sample buffer mixture was heated at 95°C for 5 minutes before loading.  Known 
protein molecular weight markers – (Precision Plus Protein Standard, 10-250kD [Bio-Rad, UK]) 
were also run in parallel to the samples. The gels were run in 1x SDS-PAGE running buffer at 
150V for 1 hour approximately.   
 
iii) Semidry Transfer 
Separated proteins were transferred from an SDS –PAGE gel to a 0.45µm pore polyvinylidene 
(PVDF) membrane using a Trans-Blot® Semi Dry Transfer Cell™ (BioRad). As PVDF is highly 
hydrophobic, it was first soaked in methanol before use. The PVDF and extra thick blot filter 
paper sheets were pre-soaked in transfer buffer (detailed in section 2.9.1.2). The gel was 
placed onto a presoasked PVDF membrane (in methanol) and sandwiched between two sheets 
of extra thick filter paper (presoaked in transfer buffer) and electroblotted for 1 hour at 7V. 
Thus, the Trans Blot Semi Dry transfer unit was in the following order: cathode, extra thick 
filter blot paper, acrylamide gel, membrane, extra thick filter blot paper, and anode. Following 
transfer, the membrane was stained with 0.2% Ponceau S dye which is a ubiquitous stain for 
protein in 10% acetic acid at RT for 20 minutes for visualisation of the protein bands on the 
membrane. The resulting red staining was washed with 10% acetic acid before antibody 
incubations. The Ponceau S dye was then removed, and membranes were rinsed twice in 10% 
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acetic acid, followed by additional rinses in ddH2O to remove residual dye.  Following 
confirmation of successful transfer, membranes were covered and left at RT overnight to dry in 
preparation for antibody staining. 
 
iv) Antibody incubations 
PVDF membranes were immersed in methanol to reduce their hydrophobicity, and then rinsed 
in ddH2O.  Membranes were either blocked in a solution blocking buffer as detailed in section 
2.9.1.2.  Blocking solution used for positive control membranes to be exposed to β-actin 
antibodies consisted of 5% bovine BSA, as per the manufacturer’s recommendation. All 
membranes were incubated at RT in blocking solution for 1 hour on a rocker. 
Membranes were then rinsed briefly in TBST and primary antibodies were added at 
individually optimized concentrations in the relevant blocking solutions (see relavant chapters 
for details on blocking solutions and antibody dilutions used).  Membranes were incubated 
with primary antibodies overnight (~16 hours) at 4°C on a rocker, which was followed by three 
~10 minutes rinses in TBST. Membranes were then incubated with the relevant LI-COR IRDye 
secondary antibodies (usually 1:5000) depending on the host of the relevant primary antibody, 
in the appropriate blocking solutions for 1 hour at RT on a rocker.  This was followed by three 
rinses in TBST and then the membranes were scanned using the ODYSSEY® Infrared Imaging 
System (LI-COR Biosciences, UK).  Blots incubated with goat anti-Mouse 800CW infrared dye 
were scanned at 800nm fluorescence, and blots incubated with goat anti-Rabbit 680LT 
infrared dye were scanned at 700nm fluorescence.   
 
2.9.2.6  Co-Immunoprecipitation (Co-IP) 
Co-immunoprecipitation (co-IP) is a classical technique for discovering PPIs by enriching a 
whole cell lysate for a specific protein as well as ‘pull down’ any other proteins that are 
associated with it. Basically, the idea is to capture the target protein along with its interacting 
partner(s), by binding to an immobilised antibody specific to the target from a mixture of 
proteins present within the cell (Figure 7). In brief, the antibody intended to capture the target 
protein is bound to protein A or G (depending on its heavy chain) which is usually covalently 
attached to a bead or an immobilised matrix. This binding does not affect the antibody-antigen 
interaction. Upon addition of the protein lysate, the antibody forms a specific immune 
complex with its target protein and any binding partners, resulting in a precipitate. The matrix 
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is separated from the lysate and washed to remove any proteins that are not specifically 
bound to the captured immune complex. Finally, the immune complexes are released from the 
immobilised matrix (by boiling) so that the target protein and its binding partners are 
separated for detection by SDS-PAGE, western blot analysis and mass spectroscopy (Howell et 
al., 2006). In order to improve specificity, monoclonal rather than polyclonal antibodies are 
often recommended to prevent high background arising from precipitation of extraneous 
proteins. Tagged fusion proteins can circumvent this difficulty as the antibody targeting the tag 
is specific and does not cross-react with endogenous proteins. Furthermore, the use of affinity 
tags enables the identification of PPIs regardless of whether interacting partners bind directly 
or indirectly to the fusion protein; thereby potentially enabling the identification of PPIs 
involving multiple members of a given protein complex.  This could serve to provide more 
comprehensive information concerning the precise molecular mechanisms within which the 
fusion protein participates. Furthermore, epitope-tagged proteins can often be eluted by 
incubation with competing peptides, or other small molecules, instead of boiling, thus 
preserving the integrity of the proteins captured.  
Many PPIs are transient, and are characterised by small contact areas and less defined 
conformational changes upon binding of the interacting protein (Howell et al., 2006). An 
advantage of co-IP is its potential to identify transient or less tightly bound interactors with 
weak associations due to the more physiological conditions employed. However, this method 
is less suitable for low abundance proteins. A frequently encountered problem is that 
interference from the antibody in the gel analysis of the precipitated products. The antibody 
present in the immune complex, contains a heavy and light chain, which may co-migrate with 
any potential protein binding partners. Additionally, a high level of background is often 
observed due to protein non-specifically interacting with the immobilised matrix. To address 
this problem, a pre-clearing step is carried out in which, prior to incubation with the primary 
antibody, the lysates is incubated with just the immobilised matrix to reduce the background.
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Figure 7: Co-immunoprecipitation method 
 Protein of interest (red circles) with a fusion protein (black line), binding partner(s) (green circles) 






Recombinant fusion proteins consisting of a protein or part of it fused to a small epitope tag 
have been invaluable research tools in this regard. The specific epitope expression tag is 
coupled either at the amino- (N-) or carboxy- (C-) terminus of the protein of interest, without 
affecting protein function or solubility. Examples of small affinity tag protein include human 
influenza hemagglutinin most commonly referred to as HA  (Kolodziej & Young, 1991), c-myc 
(Munro & Pelham, 1986), FLAG™ (Hopp et al., 1988)  or V5 (Southern et al., 1991) tags and are 
recognised by specific monoclonal antibodies (Monti et al., 2005). Among other applications, 
recombinant fusion proteins have been useful for increasing the protein yield, enhancing 
protein solubility, facilitating protein detection and quantification, identifying protein 
modification and targeting to sub-cellular compartments and extracellular localisation (e.g. 
secretion). Additionally, the presence of small epitope tags enables easy detection and 
purification of the protein of interest and is commonly used for determining protein-protein 
interactions which can help elucidate gene function. 
 
In the case of AUTS2, a gene of unknown function, this thesis looks to investigate its protein 
binding partners by generating two expression plasmids cloned with AUTS2 in its native form 
and the other as V5-tagged AUTS2. Two different protocols were used depending on the 
antibody requirements for Co-IP as per the manufacturer’s guidelines. Protein-G or Protein-A 
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Sepharose® resin slurry was 50% slurry in lysis buffer were obtained from Life Technologies, 
UK. Approximately The whole cell lysate was extracted using RIPA buffer with a cocktail of 
protease and phosphatase inhibitors (section 2.9.1) and quantified (section 2.9.2.4). 500µg of 
protein was used for each Co-IP reaction. 
 
Anti-V5 antibody (Life Technologies, UK) 
In order to minimize non-specific binding of protein to the agarose beads, cell lysates were 
pre-cleared by incubating 50μl Protein-G Sepharose® resin slurry per 1ml of supernatant, 
rocked at 4°C for 1 hour and then centrifuged for 1 minute at 10,000xg at 4°C. The supernatant 
was transferred to a sterile microfuge tube and placed in ice. Following this, 2μg (unless 
otherwise stated) of primary antibody and 50μl Protein-G or -A Sepharose® resin slurry was 
added to the supernatant and rocked overnight at 4°C on a rocker to facilitate the formation of 
immunocomplexes. The following day the supernatant was discarded and the resin was 
washed with 500μl RIPA lysis buffer, followed by resuspension in modified RIPA buffer to a 
total volume of 50µl.   
 
Anti-AUTS2 antibody (Abcam, UK) 
Protein G sepharose beads (Life Technologies, UK) were prepared by washing them three 
times in an excess of 1x PBS, each time followed immediately by centrifugation (~20 seconds at 
10,000rpm) and removal of the supernatant. Agarose beads were then restored to a ~50% 
slurry in 1x PBS using a pipette tip with the end cut off to avoid disruption to the beads.   
Pre-clearing was done by adding 100µl of protein G agarose beads for every ml of cell lysate. 
The resultant solutions were incubated at 4°C for 10 minutes on a rocker, and this was 
followed by centrifugation at 4°C for 10 minutes at 10,000rpm. The supernatant was 
transferred to a fresh 1.5ml eppendorf tube to which 5µg of anti-AUTS2 primary antibody was 
added and mixed gently by pipetting up and down. Tubes were incubated overnight at 4°C on 
a rocker to facilitate the formation of immunocomplexes.     
The following day, immunocomplexes were captured by adding 50µl of washed (as described 
above) protein A agarose beads to each tube, followed by incubation at 4°C for 2 hours on a 
rocker. The agarose beads were then collected by centrifugation (~20 seconds at 10,000rpm) 
and the supernatant was discarded. The remaining beads/immunocomplexes were washed 
three times in an excess of modified RIPA buffer and then resuspended using modified RIPA 
buffer to a total volume of 50µl.   
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Finally, 10µl of 5x laemmli sample buffer containing 2% ß-mercaptoethanol was added to each 
coimmunoprecipitate, and samples were heated at 95°C for 5 minutes to denature the 
proteins ready for SDS-PAGE as per the above protocol in 2.9.2.5.  
From the Western Blot analysis, if a number of other bands appear apart from the expected 
band for AUTS2, indicating potential interating protein partners for AUTS2, the sample would 









Chapter 3   
 
Delineating the role of Dopamine D2 and D3 
receptors in vitro and in vivo using lentiviral-
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This chapter establishes lentiviral mediated gene delivery technique in vitro and in vivo using 
two extensively documented genes encoding for dopamine D2 and D3 receptors (D2R and D3R), 
for their role in various behavioural traits including motor processes. Thus to further explore 
the role of D2R and D3R, lentivirus-mediated gene knockdown and overexpression was used to 
specifically manipulate expression levels of these genes in the rat nucleus accumbens (NAcc), a 
brain area important for spontaneous and induced locomotor responses. Principle findings 
from this chapter will contribute to delineating the role of NAcc D2R and D3R in locomotor 
behaviour but also the established technique will serve to conduct further investigation into the 
functional characterisation of AUTS2 which is covered in the chapters following the current 
chapter. 
 
3.1.1 The current project and aims 
Given the limitations of using knockout mice and pharmacological agents for functional 
characterisation particularly in the interpretation of behavioural phenotypes, the current 
project applies lentiviral mediated gene delivery to address several issues with regard these 
techniques. As reviewed in Chapter 1, this technique not only enables the specific expression 
and silencing of any gene isoform in vivo but also allows investigation of gene function in 
specific brain regions on behaviour. Thus, the main aim of the present study was to establish 
this technique by distinguishing the individual role of D2R and D3R, two well characterised 
genes linked to the aetiology of several psychiatric traits and behaviours particularly locomotor 
behaviour. The alteration in D2R and D3R expression was thus assessed on novelty and light 
induced locomotor activity. For this purpose, lentiviruses were constructed which 
overexpressed either rat D2R or D3R. In addition, lentiviruses expressing siRNA specifically 
targeting rat D2R and D3R were also constructed. These viruses were tested in vitro and served 
for in vivo gene transfer, by means of stereotaxic injections into the rat NAcc, a brain area 
important for motor behaviour. Findings from this chapter will provide a validation of lentiviral 
mediated gene delivery in vitro and in vivo which can then be used to unravel the role of Auts2 





3.1.2 Dopamine receptors 
The effects of DA are mediated by five different receptors that have common structural 
characteristics. These dopamine receptors (DRs) belong to the G-protein-coupled receptor 
family. Member of this family contain a glycosylated extracellular N-terminus, a seven 
transmembrane domain forming the hydrophobic core of the receptors, three intracellular 
loops which differ in length among the different receptors and an intracellular C-terminal 
stretch (Figure 8).  Based on their structural and functional properties, the dopamine receptors 
are divided into two subgroups (Brown & Makman, 1972; Kebabian & Calne, 1979): ‘D1-like’ 
comprising D1R and D5R which are highly homologous (Dearry et al., 1990; Sunahara et al., 
1990) and ‘D2-like’ consisting of D2R, D3R and D4R (Bunzow et al., 1988; Sokoloff et al., 1990; 
Strange, 1993a). D1-like receptors are coupled to stimulatory Gα-proteins which enhance the 
activity of adenylyl cyclase and induces cAMP production and D2-like receptors inhibit the 
activity of adenylyl cyclase by coupling to inhibitory Gi- proteins (Neve et al., 2004) and thus 
reduces cAMP production. It is thought that many of the effects of D2–like receptors may be 





Figure 8: The dopamine receptor structure.  
The five dopamine receptors consist of a seven transmembrane domains and are coupled to G proteins 
(either stimulatory or inhibitory) which mediate various signalling pathways. This figure is taken from 





Both D2R and D3R belong to the D2-like receptor family. D2R is approximately 52% 
homologous to D3R sharing similarity in the transmembrane domains. D2R exists as two 
alternatively spliced isoforms: short (D2RS) and long (D2RL), which differ by 29 amino acids in 
the third intracellular loop (Monsma et al., 1989; Usiello et al., 2000). Since this loop is thought 
to play an important role in receptor coupling, the resulting splice variants may possess 
different functional roles (Missale et al., 1998). Both variants share the same distribution 
pattern although the short isoform is less abundantly expressed (Giros et al., 1989; Monsma et 
al., 1989). Although both isoforms inhibit adenyly cyclase, D2RS, has higher affinity than D2RL 
(Dal Toso et al., 1989; Montmayeur & Borrelli, 1991). It has been reported that protein kinase 
C (PKC) signalling modulates D2RS and D2RL  signalling with a selective inhibitory effect on the 
D2RS –mediated response (Liu et al., 1992). As of yet, there are no compounds that 
discriminate between the two variants. Some reports suggest that the D2RS functions as the 
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presynaptic receptor, whereas the D2RL is a postsynaptic receptor and D2RS is expressed to a 
greater extent in presynaptic receptors than in postsynaptic receptors (Lindgren et al., 2003; 
Jomphe et al., 2006). Further supporting the role of the D2RS isoform being a presynaptic 
receptor are studies from knockout mice of D2R (both short and long isoforms) and D2RL alone 
which suggest that D2RS mediates autoreceptor responses of dopaminergic neurons and D2RL 
is responsible for postsynaptic responses (Baik et al., 1995; Kelly et al., 1998; Usiello et al., 
2000).  
The rat D3R contains 446 amino acids compared to the human protein, which is made up of 
400 amino acids (Giros et al., 1989; Sokoloff et al., 1990). Splice variants also exists for D3R but 
only in mice (Fishburn et al., 1993). The isoform differ by 21 amino acids in the third 
intracellular loop. They have similar pharmacological profiles and have the same distribution 
profile in the brain with the long isoform being predominantly expressed. 
 
3.1.3 Distribution of D2R and D3R in the brain  
The expression profiles of D2R and D3R differ in the brain, which suggests they play distinct 
roles. D2R is broadly distributed in the brain and is highly expressed in the striatum, olfactory 
tubercle, and the core of the NAcc. D2R is also found in the prefrontal cortex, amygdala, 
substantia nigra pars compacta, ventral tragmental area where it is expressed by the 
dopaminergic neurons. Immunohistochemical analysis shows that D2R is present in the 
medium spiny neurons of the striatum where they are more concentrated in the spiny 
dendrites and spine heads (Missale et al., 1998).  
On the other hand, D3R has a distinctive pattern of localisation in the brain, expressed 
preferentially in the limbic brain regions displaying highest expression levels in the islands of 
Calleja (Diaz et al., 1995). It is also present at high levels in the NAcc, olfactory tubercles and 
the bed nucleus of the stria terminalis in the mesocorticolimbic system which influences motor 
function, cognition and motivation (Sokoloff et al., 1990; Bouthenet et al., 1991; Xu et al., 
1997). In the NAcc, D3R is mainly post-synaptically located (Diaz et al., 1995). Due to the 
preferential expression of D3R in these brain regions, D3R was suggested as a therapeutic 
target for the negative and cognitive symptoms of schizophrenia, drug addiction, and 
Parkinson’s disease (Joyce & Milian, 2005; Newman et al., 2005; Joyce & Millan, 2007). The 
distribution of D3R in the human brain, although not very well studied, is by and large similar 
to that observed in the rat, where increased levels of D3R mRNA is detected in the NAcc and 
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islands of Calleja and comparatively low levels observed in the anterior caudate and putamen 
(Landwehrmeyer et al., 1993). 
 
3.1.4 The neural circuitry of the ventral striatum and the nucleus accumbens  
The striatum and the NAcc are prominent structures of the basal ganglia that modulate 
different physiological functions such as motor behaviour, reward, motivation and learning 
(Mogenson et al., 1980; Nicola et al., 2000; Zahm, 2000). The intrastriatal circuitry consists of 
medium spiny GABAergic neurons that are the origin of two major striatal efferent pathways 
(called direct and indirect pathways), which connect the striatum to the other basal ganglia 
nuclei including the NAcc. These neurons transmit information carried by the DA fibres 
originating in the substantia nigra and by the cortical glutamatergic neurons (Nicola et al., 
2000). The interplay between DA and glutamate is what drives proper motor functions.  
 
The NAcc receives excitatory innervation from limbic structures such as the prefrontal cortex, 
hippocampus, and amygdala (Swanson & Cowan, 1975; Sesack & Pickel, 1990; Odonnell & 
Grace, 1995). Its main efferents innervate the pallidum, striatum, mediodorsal thalamus, 
prefrontal, including cingulate cortex and, as mentioned above, mesolimbic dopaminergic 
areas. The NAcc attains, thus, a central position between limbic as well as mesolimbic 
dopaminergic structures, basal ganglia, mediodorsal thalamus and prefrontal cortex. Together 
with the ventral striatum, the accumbens receives a strong input from the VTA and the dorsal 
tier of the substantia nigra (Groenewegen et al., 1999; Zahm, 2000). Degeneration of 
dopaminergic cells in the substantia nigra leads to loss of DA in the striatum, which is the 
underlying cause of Parkinson’s disease (Albin et al., 1989). Dysregulation of dopaminergic 
signaling in the striatum and NAcc can also lead to the development of several other common 
neuropsychiatric disorders, including Tourette’s syndrome, schizophrenia, and drug addiction 
(Nemeroff & Bissette, 1988; Koob & Nestler, 1997). 
The NAcc is subdivided into a central ‘core’ region, which is surrounded on its medial and 
ventral sides by a peripheral ‘shell’ (Herkenham et al., 1984; Zaborszky et al., 1985) (Figure 9). 
The (medial) shell region is predominantly innervated by the dopaminergic cells of the ventral 
tegmental area (A10 cell group) whereas the core region is predominantly innervated by the 
dopaminergic cells of the substantia nigra (A9 cell group) (Groenewegen et al., 1999). The core 
region contains a larger proportion of relatively small cells with high concentrations of D1- and 
D3-receptors (Heimer, 2000). Within the NAcc, information is transmitted from shell to core.  
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The NAcc has been demonstrated to play an important role in locomotor behaviours. This was 
demonstrated from observations that lesions in the accumbens cause a reduction in 
spontaneous and induced locomotion (Kelly & Iversen, 1976; Fink & Smith, 1980). 
Furthermore, injections of DA or DA agonists into the NAcc induce hyperlocomotion 
(Pijnenburg & van Rossum, 1973; Jackson et al., 1975). Similarly, strong locomotor activation is 
elicited by microinjection of cocaine, a potent blocker of presynaptic DA reuptake in the NAcc 
(Delfs et al., 1990). Accumbal dopamine is not only involved in mediating motor function but 




Figure 9: An anatomical localisation of the nucleus accumbens core and shell in a rat brain 
coronal section taken from (Heimer et al., 1997).  
The Nacc is sometimes referred to as a ventral extention to the striatum; CPu – caudate putamen, Se – 








3.1.5 D2R and D3R regulation of locomotor behaviour 
Injection of dopamine in the rat NAcc was shown to increase locomotor activity (Pijnenburg & 
van Rossum, 1973), suggesting a role for dopamine receptors in the control of this behaviour. 
Most of our current knowledge of D2R and D3R is obtained from studies using agonists, 
antagonists and  knockout mice (Beaulieu & Gainetdinov, 2011).  
For D3R, there is substantial literature on the effect of pharmacological ligands stimulating and 
inhibiting D3R on motor activity. Systemic administration of the D3R agonists, 7-Hydroxy-2-(di-
npropylamino) tetralin (7-OH-DPAT) and PD 128907, dose dependently decreased motor 
activity in mice (Gyertyan and Saghy 04;Millan et al 04). As seen in D3R knockout mice, 
numerous findings show that D3R antagonists enhance spontaneous locomotion in rodents 
(Waters et al 93a;Waters et al 93b;Klingpetersen et al 95;Sautel et al 95;Clifford and 
Waddington 98;Manzanedo et al 99;Carr et al 02;Gyertyan and Saghy 04;Millan et al 
04;Pritchard et al 07). It must be noted that low doses of the putative dopamine D3R 
antagonist, PNU 99194A, increased locomotor activity while higher doses suppressed 
locomotor activity (Gendreau et al 97). However, pharmacological approaches provide only an 
indication of the role of both D2R and D3R in locomotor function as results generated from 
these studies can be inconclusive since pharmacological agents vary in their affinities to and 
specificities for a given receptor (Heidbreder et al., 2005; Joyce & Milian, 2005). Further 
complications are raised by the recent recognition that D2R and D3R can heterodimerize, or 
even form functional complexes with D1R, which prevents straightforward interpretation of 
the actions of dopamine agonists and antagonists (Maggio & Millan, 2010). D2R agonists 
induce locomotor activity (Eilam et al., 1991; Hoffman & Wise, 1992; Ralph & Caine, 2005). 
While, lack of D2R attenuates spontaneous locomotion (Braun et al 97;Millan et al 04;Stuchlik 
et al 07;Huang et al 10). This is in line with knock out studies; the first study using D2R 
knockout mice reported a significant decrease in locomotor behaviour in the open field and no 
rearing behaviour (Baik et al., 1995), concordant with later studies (Kelly et al., 1998; Aoyama 
et al., 2000; Fowler et al., 2002). This phenotype is further exacerbated in mice mutant for 
both D2R and D3R (Jung et al., 1999). On the other hand, mice lacking the D3R only, exhibit 
hyper-locomotion (Accili et al., 1996; Xu et al., 1997). Although these findings indicate an 
important role of both these receptors in locomotor behaviour, results from the knockout 
studies are questionable due to genetic compensatory regulatory mechanisms, developmental 
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effects, and lack of regional specificity (Xu et al., 1997; Boulay et al., 1999a; Usiello et al., 2000; 
Wang et al., 2000; Barik & de Beaurepaire, 2005).  
 
This thesis also looks at the role of dopamine receptors in light- induced locomotor activity in 
rats. Sensory stimuli such as light and sound can induce locomotor behaviour in humans and 
animals which may indicate behaviour of exploration or fear. This sensorimotor processing or 
gating can be studied in rodent models. Presently, the most widely used model of 
sensorimotor gating is prepulse inhibition (PPI). This paradigm relies on the use of sound 
(prepulse), usually bursts of noise typically with the intensity of around 110dB (Hoffman & 
Ison, 1980) being more of an aversive stimulus generating a reflexive startle response in 
rodents (Geyer et al., 2001; Swerdlow et al., 2001). PPI is the attenuation of a startle response 
by a preceding non-startling sensory stimulus. Deficits in such behaviour has been seen in 
people under the influence of drugs, schizophrenia and Alzhiemer’s patients (Braff et al., 2001; 
Swerdlow et al., 2008). D2R and D3R have been investigated for their role in PPI (Swerdlow et 
al., 1990; Swerdlow et al., 1992; Wan et al., 1994; Varty & Higgins, 1998; Swerdlow et al., 
2001; Ralph-Williams et al., 2002; Zhang et al., 2006; Zhang et al., 2007; Swerdlow et al., 2009; 
Chang et al., 2010). Another stimulus used for sensorimotor gating is light. Light-induced 
locomotor activity is a paradigm for sensorimotor processing and provides a reliable method of 
generating a behavioural response to a visual stimulus in the rat (Pum et al., 2009b). It uses a 
low intensity range light (less than or equal to 440lx) which is not aversive and triggers 
exploratory behaviour observed by an increase in locomotor activity as this visual stimulation 
appears to be novel and provides some incentive salience for the animal. It has been 
previously shown that visual stimulation increases locomotor activity and rearing behaviour 
(Muller et al., 2007a; Pum et al., 2009a; Pum et al., 2009b). This basic behavioural process 
which may either lead to habituation of the stimulus response or the learning of associations 
of the stimulus with subsequent events. Importance of this behaviour has been shown in the 
investigation of the effect of cocaine on attention and responsiveness to sensory stimiuli in 
rodents which would be relevant for patients of drug abuse. Reports have also shown that on-
off visual stimulation works as a reinforcer in rodents (Roberts et al., 1958; Hughes, 2007; 
Olsen & Winder, 2009) as well as in primates (Blatter & Schultz, 2006). In light of the 
abovementioned findings, it is important to investigate the contribution of t both these 
receptors in the control of sensory stimuli induced response. As of yet, there are no studies 




3.2 Methods and Materials 
3.2.1 Materials 
3.2.1.1 Cloning plasmids LeGO - iG2 and LeGO-G 
cDNAs and short hairpin oligos were cloned into Lentiviral Gene Ontology (LeGO) vectors 
(Weber et al., 2008; Weber et al., 2010). These lentiviral expression vectors allow efficient 
transfer and expression in many different cell types including haematopoietic stem cells. 
Derived from the third generation lentiviral vectors LentiLox7.3, which do not encode any viral 
proteins but contain cis-active elements for packaging, reverse transcription, and integration, 
they are able to incorporate 9kb of foreign sequences LeGO –G (Figure 10) and LeGO – iG2 
(Figure 11) vectors contain an enhanced Green Fluorescent Protein (eGFP) marker while LeGO 



















Figure 10: LeGO-G and LeGO-C lentiviral vectors for gene silencing. 
This figure is taken from (Weber et al., 2008). The LeGO-G and LeGO-C vectors, contains a retroviral 
enhancer/promoter of spleen focus-forming virus (SFFV), which allows a broad and high expression 
pattern for expression of the reporter gene eGFP (enhamnced Green Flouresecent Protein) or Cherry, 
while the U6 promoter drives the expression of the shRNA cloned into the Multiple cloning site (MCS) 
using the HpaI and XhoI restriction sites. Other features include rev-responsive element (RRE); self-
inactivating-long-terminal repeat (SIN-LTR); Woodchuck hepatitis virus post-transcriptional regulatory 
element (wPRE) and central polypurine tract (cPPT). 







Figure 11: The lentiviral overexpression vector LeGO-iG2. 
This figure is taken from (Weber et al., 2008). The overexpression vector LeGO-iG2, contains an SFFV 
promotor, which allows a broad and high expression of the transgene in the MCS. Both D2R and D3R 
were cloned into the EcoRI and NotI site in the MCS. This is followed by an encephalomyocarditis virus 









3.2.2 Construction of D2R and D3R overexpression vectors 
3.2.2.1 PCR Amplification of D2R and D3R 
RNAs isolated from rat brain lysates (section 2.7) were reverse-transcribed using the 
SuperScript® III First-Strand Synthesis System (Life Technologies, UK) as described in section 
2.7. The cDNA for the D2R short isoform (D2RS) and D3R cDNAs (GenBank accession no. 
NM_012547 and NM_017140, respectively) were then amplified by PCR using the following 
forward and reverse primers (restriction sites are underlined): 
 
Table 10: Primers used to amplify D2R and D3R for cloning into the LeGO- IG2 vector.  




The forward primers contain an EcoRI restriction site (underlined) followed by the start codon 
and the 5’ rat cDNA-specific sequence; the reverse primers contain the 3’ rat cDNA-specific 
sequence, a stop codon and a NotI restriction site (underlined). The PCR reaction consisted of: 
40ng rat whole brain cDNA, 1x PCR buffer (Life Technologies, UK), 0.2mM dNTPs, 0.5μM 
forward primer, 0.5μM reverse primer, 7.5mM MgCl2, 1U Platinum Taq (Life Technologies, UK) 
and dH20 in a final volume of 50μl. The thermal cycling conditions are detailed in Table 11. 
 







Table 11: Thermal cycling conditions for touchdown PCR to amplify rat D2R and D3R. 
 
Step Time Temperature (°C) 
1 9 minute 95 
2 30 seconds 95 
3 30 seconds 56 
4 1 minute 30 seconds 72 
5 Go to step 2 -  40 times 
6 10 minutes 72 
7 ∞ 4 
 
 
3.2.2.2 Agarose gel electrophoresis 
The PCR reactions were run by electrophoresis on a 0.8% (w/v) agarose gel as detailed in section 
2.6.2.2, and the expected bands excised, gel-purified (as detailed in 2.6.2.3) and stored at -20°C 
until further use. 
 
3.2.2.3 Restriction enzyme digest 
The D2R and D3R PCR products were digested using the EcoRI and NotI restriction enzymes, which 
cleave DNA at the 5’ region of both sets of primers. A typical reaction contained 2 units of each 
enzyme /1μg DNA, 1x Buffer EcoRI, 1x BSA, made up to a final volume of 20μl with ddH20. The 
reaction mix was incubated at 37°C for 1 hour to allow complete digestion, followed by 20 minutes 
at 65°C to inactivate the restriction enzymes. Fragments were purified using the QIAquick PCR 
purification kit (QIAGEN, Crawley, UK) as detailed in section 2.6. 
The LeGO-iG2 lentiviral expression vector was also digested using the EcoRI and NotI restriction 
enzyme in the conditions described above. In addition, in order to prevent re-circularization of the 
plasmid after restriction enzyme digestion, the phosphate groups at the ends of the linear vector 
were removed. Thus digested vectors were dephosphorylated by the addition of 1U of Antarctic 
phosphatase/1μg DNA and 1x Antarctic phosphatase buffer to the restriction digest and samples 
incubated at 37°C for 30 minutes. Following this, the enzyme was heat-inactivated for 20 mins at 
65°C. Finally, to check for complete digestion of the plasmid, 200ng of the plasmid DNA was gel 
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electrophoresed (as detailed in section 2.6.2.2. Plasmid DNA was purified using the QIAquick PCR 
purification kit (QIAGEN, Crawley, UK). 
 
3.2.2.4 Ligation of the PCR products into the LeGO-iG2 lentiviral expression vector  
DNA ligation reactions were carried out using a 1:3 DNA molar ratio for the digested, 
dephosphorylated vector and digested insert DNA respectively. Typically, 50ng of vector and 150ng 
insert DNA was mixed with 1x T4 DNA ligase buffer and 1U T4 DNA ligase (NEB, UK) in a total 
reaction volume of 10μl. In parallel, control ligations were set up containing digested, 
dephosphorylated plasmid with no insert plus ligase and used as background to check for vector 
DNA restriction quality. The ligation reactions were incubated overnight at 16°C. 5μl of the ligation 
reaction was transformed into a 50μl aliquot of MAX EFFICIENCY® Stbl2™ cells (Life Technologies, 
UK as described in section 2.4. Colonies were picked and minipreps of the precultures were 
prepared in order to screen for positive clones; i.e. bacterial clones that contained the vector plus 
insert.  
 
3.2.2.5 Screening for positive clones 
In order to screen for positive bacterial clones, minprep DNA was digested with EcoRI and NotI. 
The restriction digest consisted of 1U of each enzyme in 1x Buffer EcoRI, 1x BSA and 16 μl of 
miniprep plasmid DNA. The reaction was incubated for 1 hour at 37°C and run on 0.8% w/v 
agarose gel.  A digest of the empty vector was also carried out and run alongside the miniprep 
digests for comparison.  The molecular weight of the D2R and D3R inserts were 1332 bp and 1341 
bp, respectively.  
 
3.2.2.6 DNA sequencing of positive clones 
DNA sequencing was performed using the Applied Biosystems sequencing kit. The reaction 
contained: 1x BigDye® sequencing buffer, 4μl BigDye® v3.1, 0.5μl 10uM forward or reverse 
primers (Table 12). 500ng DNA template made up to a final volume of 10μl with dH20. The PCR 
thermal cycling for the sequencing reaction is detailed in Table 13. Following the PCR reaction, the 
DNA was transferred to a clean microcentrifuge tube and precipitated by adding 80ul ddH20, 
1.25μl of 125mM EDTA and 280ul of 95% (v/v) ethanol. The DNA was precipitated for 15 minutes 
at RT and centrifuged at 14,000 x g for 30 minutes. The supernatant was discarded and the 
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remaining pellet washed with 250μl of 70% ethanol. The DNA pellet was air-dried and 15μl of 
formamide added before loading onto the ABI3700 DNA sequencer. Analysis of the results was 
carried out using Sequencing Analysis software v5.2 ©2004 (Applied Biosystems, UK). 
 
Table 12: Primers used to sequence D2R and D3R positive clones.  
Primers were designed at around 300bp within the sequence in order to cover the entire sequence length. 










Table 13: PCR thermal cycling for the DNA sequencing reaction. 
 
Step Time Temperature (°C) 
1 1 minute 96 
2 10 seconds 96 
3 5 seconds 50 
4 1 minute 15 
5 Go to step 2 – 15x 
6 10 seconds 96 
7 5 seconds 50 
8 1 minute 30 
9 Go to step 6 – 5x 
10 10 seconds 96 
11 5 seconds 50 
12 2 minutes 60 
13 Go to step 10 – 5x 
14 ∞ 4 
 
Primer Sequence 5’ > 3’ 






3.2.3 Construction of D2R and D3R shRNA recombinant lentiviruses 
3.2.3.1 D2R and D3R shRNA design  
The small interfering RNA sequences, targeting the coding domain of the Drd2 (both isoforms) 
and Drd3 transcripts were designed using the siRNA Retriever software 
(http://cancan.cshl.edu/RNAi_central/).  The sense target sequence is shown in Table 14. 
For D3R, two shRNAs were designed since a combination of the two gave a higher knock down 
efficiency than either used on its own. The target sequences for D3R listed have been used 
previously (Bahi et al., 2005) with highly efficient silencing of the receptor in vitro and in vivo. 
The oligos were ordered with the addition of a 5’phosphate and PAGE purified. 
 







These sequences were used to synthesize complementary oligonucleotides for vector-based 
small hairpin RNA (shRNA) expression using the following design:  
For D2R: Sense oligo: 5’ TG - (28 nt, sense oligo) CAAGCTTC (28 nt, antisense oligo) TTTTTTC. 
Antisense oligo: complement of sense with additional nucleotides at 5’ end to generate XhoI 
overhang (Brummelkamp et al., 2002). 
For D3R: Sense oligo: 5’ T - (18 nt, sense oligo) – (TTCAAGAGA) – (18 nt, antisense oligo) – 
TTTTTTC. Antisense oligo: complement of sense with additional nucleotides at 5’ end to 
generate XhoI overhang.  
 
3.2.3.2 Annealing shRNA oligos 
The sense and antisense oligos, (60pmoles of each) were annealed in buffer containing 100mM 
potassium acetate, 30mM HEPES-KOH pH 7.4 and 2mM magnesium acetate, by incubation at 
94°C for 4 minutes, 70°C for 10 minutes followed by a temperature decrease of 0.1°C/minute 
until to 4°C.  
 
Gene Sense target sequence 5’ > 3’ 
D2R ATCCACTGAACCTGTCCTGGTACGATGAC 
D3R (1) TGGTGAGCCTGGCTGTGG 
D3R (2) TGGAGTCTGGAATTTCAG 
98 
 
3.2.3.3 Restriction enzyme digest of LeGO-G and LeGO-C plasmids 
LeGO-G and LeGO-C plasmids described in section 3.2.1.1 (Weber et al., 2008), were digested 
using the HpaI and XhoI restriction enzymes. A typical reaction contained 2U of each enzyme 
/1μg DNA, 1x Buffer EcoRI, 1x BSA made up to a final volume of 20μl with dH20. The reaction 
mix was incubated at 37°C for 1 hour to allow complete digestion, followed by 20 minutes at 
65°C to inactivate the restriction enzymes. To prevent re-circularisation of the vector, a 
dephosphorylation step was carried with 1 unit of Antarctic phosphatase/1μg DNA and 1x 
Antarctic phosphatase buffer and incubated at 37°C for 30 minutes followed by enzyme 
inactivation for 5 mins at 65°C. Finally, to check for complete digestion of the plasmid, 200ng 
of the plasmid DNA was gel electrophoresed. Plasmid DNA was purified using the QIAquick PCR 
purification kit (QIAGEN, Crawley, UK). 
 
3.2.3.4 Ligation of annealed shRNA into the LeGO-G plasmid vector 
DNA ligation reactions were carried out using a 1:1 DNA molar ratio for the digested, 
dephosphorylated vector and annealed oligos. Typically, 30fmoles of vector and 30fmoles of 
annealed oligos was mixed with 1x T4 DNA ligase buffer and 1U T4 DNA ligase (NEB, UK) in a 
total reaction volume of 10μl. In parallel, control ligations were set up containing digested, 
dephosphorylated plasmid with no insert plus ligase and used as background to check for 
vector DNA restriction quality. The ligation reactions were incubated overnight at 16°C. 5μl of 
the ligation reaction was transformed into a 50μl aliquot of MAX EFFICIENCY® Stbl2™ cells (Life 
Technologies, UK), as described in section 2.4. Individual colonies were picked and grown for 
precultures and subsequently minipreps were carried out for plasmid DNA extraction.  
 
3.2.3.5 Screening for positive clones 
miniprep DNA digestion was carried out using XhoI and XbaI to screen for the presence of an 
insert. The reaction consisted of 1x Buffer 4, 1x BSA, 1 unit of each enzyme and 18μl of 
miniprep DNA. Both enzyme restriction sites were present in the multiple cloning site of the 
vector and positives were analysed in comparison to empty vector. The expected sizes were as 
follows: For empty vector: 449bp + 7kb; for vector + insert: 509bp + 6.9kb. Due to this very 




3.2.3.6 DNA sequencing of ligated LeGO-G vector 
Cloned inserts were sequenced to verify the integrity of each construct following the 
sequencing protocol described in 2.6.2.4, using the following primer which recognises the U6 
promotor sequence in the vector: CGCACAGACT TGTGGGAGAA GCTCG 
 
3.2.4 Production and titration of lentiviruses 
Lentiviruses were prepared by co-transfection (calcium phosphate co-precipitation) of one of 
the gene transfer plasmids (carrying either D2R or D3R cDNAs, or shRNAs against D2R or D3R 
or the empty plasmids) together with the packaging plasmids into HEK-293T cells, as described 
previously (Jankiewicz et al., 2006; Vafaizadeh et al., 2010). This protocol was previously 
developed and optimised in the lab. The transfection was carried out according to the 
following protocol: The day before transfection, 5x10
6
 cells were plated in complete medium 
in 10cm dishes to obtain 80% confluency. The following day, three hours prior to transfection, 
the medium was replaced with 5ml fresh culture medium. For each dish to be transfected, the 
reaction mix was prepared in a final volume of 500μl with 10μg gene transfer plasmid; 5μg 
pRSV-Rev; 10μg pMDLG/pRRE; 3.5μg pMD2.G (plasmids obtained from Open Biosystems, 
Thermo Scientific, UK) with 50μl 2.5mM CaCl2.  500μl of 2x Hepes Buffer Saline (HBS) pH7.12 
was slowly added in a dropwise manner whilst applying air pressure to generate a bubbling 
effect to mix the DNA/CaCl2/HBS solutions. This was left at RT for 30 minutes. Immediately 
prior to the transfection, 1μl of 100mM chloroquine was added to the 5ml culture medium 
followed by 1ml of the calcium phosphate precipitated DNA and left overnight at 37°C with 5% 
CO2 humid incubator. The following day, the medium was replaced with 10ml complete 
medium. Lentiviruses-containing supernatants were collected 48 and 72 hours after 
transfection, pooled, filtered through 0.22μm pore nitrocellulose and stroed at -80°C. For 
lentiviral concentration, viral supernatants were ultracentrifuged as detailed in section 2.3.2.3. 








3.2.5 Transduction of 293T cells with lentiviruses either expressing or 
silencing D2R and D3R 
In vitro expression analysis was carried out to assess the effectiveness of the lentivirus 
constructs.  In order to a) quantify the expression level of D2R and D3R; b) investigate knock 
down efficiency of shRNAs; c) test specificity of shRNAs, HEK293T cells were infected with 
lentiviral supernatants as follows:   
 
For Drd3 expression: 1) empty vector; 2) D3R only; 3) D3R + shD3R; 4) D3R + shD2R 
For Drd2 expression: 1) empty vector; 2) D2R only; 3) D2R + shD2R; 4) D2R + shD3R 
 
The day before the infection, 1x10
5
 HEK293T cells were plated per well in six-well plates. On 
the day of infection, the lentiviral supernatants were added to the cells in a total volume of 
3ml medium with a final concentration of 0.04mg/ml Polybrene (Sigma, UK). The plates were 
centrifuged for 90 minutes at 2500rpm at RT and then incubated for 2.5 hours at 37°C in a 5% 
C02 incubator after which the medium was replaced and incubated back for 72 hours. The cells 
were lysed for RNA extractions using the QIAGEN RNeasy Mini Kit (QIAGEN, UK), followed by 
cDNA synthesis (as described before in 2.7.2.3).  
 
3.2.6 Quantification of D2R and D3R transcripts levels 
cDNAs were amplified by quantitative PCR, with β−actin as an internal control. The primers are 
listed Table 15. qPCR was carried out as in section 2.8. 
 
Table 15: qPCR primers for rat D2R, D3R and human β−ACTIN 
 









3.2.7 Stereotaxic surgery and lentivirus injection  
The stereotaxtic surgeries in the rat NAcc and lentiviral injections were carried out by Alanna 
Easton and Dr Christian Müller. 
Rats were anesthetized using 0.2 ml/100g (intra - peritoneally) of a mixture of Ketamine 
(100mg/ml), Medetomidine (1mg/ml) and sterile water (analgesic treatment: 5 mg/kg Rimadyl, 
subcutaneously). They were then placed in a Kopf stereotaxic frame and an incision in the 
scalp was made. The skin was retracted to expose the skull. Animals were bilaterally injected 
with 2 μl concentrated lentiviral stock (1.1-1.2 × 10
9
 TU/ml) into the NAcc (coordinates vs. 
bregma/skull surface: AP +1.8, ML ± 2.2, DV -7.4; (Paxinos & Watson, 2007)) via an injection 
cannula by using a microinfusion pump (flow-rate: 0.2 μl/min). Animals received a D2R- (n=7) 
or D3R over-expressing lentivirus (n=7) or an empty vector control injection (n=8) or 
lentiviruses expressing shRNAs targeting either D2R (n=12), or D3R (n=10) or the 
corresponding empty vector (n=8). Following the injection, the cannula was left in place for 5 
min to allow for diffusion of the lentivirus particles, and then retracted in steps of 0.5 mm/ 
5min for 1 mm before being finally removed. The holes in the skull were closed with dental 
cement and the wound was sutured and disinfected. Animals were allowed to recover for one 
week and were handled daily. There were no losses of animals due to e.g. animal health or 
injection misplacement. Animals were tested 2 weeks or 2 months after injection (see Project 
timeline in 3.2.8). Since the expression of cellular markers as well as the behavioural results 
was similar between animals with various test latencies, data were collapsed for analysis. 
 
 
3.2.8 Behavioural testing 
The animal handling, behavioural testing and analysis was carried out by Alanna Easton and Dr. 
Christian Müller. 
 
3.2.8.1 Open field 
In the open field test, locomotor activity and anxiety-related behaviour were measured on day 
1 of testing. On day 2 habituation learning was assessed. Testing was carried out in an open-
field (40 x 40 x 39 cm) of a light-beam fitted TruScan system (Coulbourn Instruments, 
Allentown, USA). Each animal was tested in the open field for 20 min on 2 consecutive days. 
For open field testing the animal was placed into the middle of the open field, facing away 
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from the experimenter (Figure 12). Locomotor activity was measured as distance moved and 
rearing, as the number of times the animal lifted both forepaws from the ground, in blocks of 5 
min (Figure 13). To measure anxiety-related behaviour in the open field (Prut & Belzung, 2003; 
Pum et al., 2009a), the arena was virtually subdivided in a 30 x 30 cm centre and a periphery. 
Centre entries were measured as the number of times the animal entered the centre. Centre 
time was the time that the animal spent in the centre. Habituation learning was assessed by 
comparing locomotor activity and rearing from day 1 and day 2 (Thiel et al., 1999) (see 
timeline of project below). 
 
 
Figure 12: Open field paradigm 
 A commonly used test to measure general locomotor activity, anxiety and rearing behaviour in rodents 






Figure 13: Rearing behaviour in rats 
The rat on the left is disolaying rearing behaviour which is when the animal stands in its hind legs lifting 





















1. Generation of lentiviral plasmids for overexpressing and knocking down D2R and D3R 
and lentiviral production. Testing shRNA for knock down efficieny in vitro. Large scale 
lentiviral production. 
2. Stereotaxic injections in rats. 
3. 2 weeks or 4 weeks post injection: Behavioural testing for novelty-induced locomotion 
‘Day 1’ 
4. Behavioural testing for novelty-induced locomotion ‘Day 2’. On this day, light-induced 
locomotor behaviour was measured (refer to the next section for more details), 
5. Animal culling and brain extraction and fixation 
6. Brain slicing and Immunostaining   
 
6 1 2 4 3 5 
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3.2.8.2 Light-induced activity 
Light-induced locomotor activity is a paradigm for sensorimotor processing and provides a 
reliable method of generating a behavioural response to a visual stimulus in the rat (Pum et al., 
2009b). It uses a low intensity range light (less than or equal to 440 lux) which is not aversive 
and triggers exploratory behaviour observed by an increase in locomotor activity as this visual 
stimulation appears to be novel and provides some incentive salience for the animal. 
After animals were habituated to the open field with an illumination of 32 lux on day 2 of the 
testing for 20 min, light-induced activity was assessed (see Timeline of project above). During a 
subsequent 20 min test interval, 10 light stimuli (constant white light) with 30 sec duration 
each were presented, distributed randomly over the 20-min period. The light was a constant 
white light of 420 lux. Locomotor activity and rearing were measured automatically by the 
TruScan light beam system. 
 
3.2.9 Extraction of rat brains and fixation 
The brains were removed, fixed and sliced by Alanna Easton.  
After behavioural testing, (i.e. either 2 or 4 weeks post lentiviral injection), animals were 
deeply anesthetized with 0.5 ml Nembutal (containing 0.6 mg/ml Pentobarbital; Sanofi, 
France) and transcardially perfused with 0.5% sodium nitrite (in 0.1 M phosphate buffered 
saline pH7.4, PBS) for 3-5 minutes, and 4% paraformaldehyde (in 0.1M PBS) solution for 15 
min. Brains were removed and stored overnight in 4% paraformaldehyde solution, moved for 
15 min to a 10% sucrose (in 0.1M PBS) solution and finally stored in a 30% sucrose + 0.05% 
NaN3 (in 0.1M PBS) solution for atleast 24 hours.  
 
3.2.10  Histological analysis 
Immunohistochemical staining was performed as per section 2.9.2.2, with primary and 
secondary antibody dilutions as shown in Table 16. Images were taken using Leica TCS SP5 





Table 16: Primary and secondary antibodies used in histological analysis of rat brains 
 






Anti-GFP 1: 1000 Alexa Fluor 488 1:1000 
Anti- NeuN 1:1000 Alexa Fluor 633 1:1000 
Anti-GFAP 1:1000 Alexa Fluor 633 1:1000 
 
3.2.11  Statistics 
Quantification of D2R and D3R expression in HEK293T cells: Data were expressed as mean ± 
SEM and normalised to the values obtained from cells infected with Lenti-D2R and Lenti-D3R. 
To verify a between treatment difference, a one-way ANOVA with factor treatment was used. 
To test for treatment differences, pre-planned comparisons were conducted using the 
independent sample t-test.  
 
Behavioural analysis: data were expressed as mean ± SEM. To assess the effects of gene 
overexpression or knockdown on behaviour, two-way ANOVAs with the factors treatment and 
time were used. To test for group differences at single time points, pre-planned comparisons 






3.3.1 Generation of lentiviruses altering expression of D2R and D3R 
For in vitro experiments, Human Embryonic Kidney, (HEK) 293T cell line were used, which does 
not endogenously express D2R and D3R. In order to test the knockdown efficiency of the 
shRNAs in vitro, this cell line was co-infected with the overexpression and knockdown 
constructs. Thus to distinguish the lentivirus efficiency during transduction in vitro, LeGO- iG2 
was used to overexpress our gene of interest (green) and LeGO – C (mCherry; red) was used to 
clone the shRNA . In parallel, the same shRNAs were cloned in LeGO – G (GFP; green) which 
would be used for in vivo experiments. Since the lentiviruses overexpressing and silencing D2R 
and D3R would be injected separately into the animals, this was simply a preference as GFP 
fluorescence is generally easily observable than mCherry (for example when determining the 
level of lentiviral spread in the rat brain slices; see next section).  The lentiviruses of the same 
titre were used (1.1 x 10
9
 TU/ml) for all experiments.  
 
  As shown in Figure 14, infection of cells with lentiviruses with D2Rs or D3R cDNAs led to high 
expression of the corresponding transcripts. Co-infection with lentiviruses expressing a 
selective shRNA led to drastic reduction of the targeted receptor, with no effect on the 
expression of the other, related receptor. There was significant effect between groups on D2R 
(F4,10= 824.43, p<0.001) and D3R expression (F4,10=1006.05, p<0.001). Post- hoc analysis 
showed significant knockdown of D2R by D2R-shRNA (p<0.001) and D3R by D3R-shRNA 
(p<0.001). No significant differences in D2R expression were found when comparing cells 
expressing D2R alone and cells expressing D2R + D3R-shRNA (p=0.102; Figure 14A). Similarly, 
no difference in D3R expression was observed when comparing cells expressing D3R alone and 
cells expressing D3R + D2R-shRNA (p>0.05; Figure 14B). These results demonstrate the 
efficiency and specificity of the D2R- and D3R targeting lentiviral constructs. 
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Figure 14: Effects of D2R- and D3R-targeting lentiviral constructs on D2R (A) and D3R (B) 
expression in vitro.  
HEK293T cells were infected with lentiviruses carrying an empty vector, D2RS encoding vector (D2R) or 
D3R-encoding vector (D3R), alone or in combination with lentiviruses encoding shRNAs targeting D2R 
(D2R-shRNA) or D3R (D3R-shRNA), as indicated. Quantification of mRNA levels was performed by real-
time quantitative PCR (mean + S.E.M from 3 independent experiments), ***p<0.001, ANOVA followed by 






3.3.2 Stereotaxic lentivirus injections and immunohistochemical analysis 
To investigate the function of D2R and D3R in the NAcc, lentiviruses were bilaterally injected in 
the brain of rats and the injection sites confirmed by Immunohistochemical analysis. Staining 
of brain sections for the lentivirus-associated GFP marker demonstrated proper targeting of 
the NAcc (Figure 15, A). Co-localisation of GFP with the neuronal marker NeuN (Figure 15, B), 
but not with the glial marker fibrillary acidic protein (GFAP) (Figure 15, C), indicated that NAcc 
neurons were primary targets of the lentiviruses. This having been verified, the consequences 
of interfering with D2R and D3R expression with lentiviruses on behaviours were investigated 




Figure 15:  Immunohistochemical analysis of lentiviral-mediated gene delivery in the NAcc  
A) Graphical representation of the NAcc areas in which lentiviral constructs were expressed Grey areas in 
both hemispheres represent cumulative immunochemistry staining for GFP from brains of all injected 
animals. ac – anterior commissure B) High levels of neuronal infection in the NAcc (bar=100μm): Green 
staining is green fluorescent protein (GFP) marker from virus. Red staining shows neuronal nuclei (NeuN). 
The white arrowheads in the magnified image (bar=25μm) shows GFP-positive and NeuN-positive 
neurons in the NAcc. C) Infection of glial cells in the NAcc was not detected, at x20 magnification (bar = 
100μm). Green staining is GFP from virus. Red staining shows the astrocyte marker, glial fibrillary acidic 
protein (GFAP). The x100 magnified image (bar = 25μm) shows no co-localisation between the GFP-
positive cells and glial cells. This image and other used for analysis presented here are taken from rats 4 
weeks after lentiviral injections.  
 
 
                        
 




3.3.3 Reduction of novelty-induced locomotor activity by either NAcc D2R or 
D3R knockdown 
The effect of NAcc D2R and D3R manipulation was investigated on locomotor behaviour in rats 
as well as rearing behaviour (standing on hind legs usually to survey the environment for 
possible threats or novelty). Both these behaviours were measured using the open field 
paradigm as described in the methods sections above.  
 
Rats injected with lentiviruses overexpressing D2R or D3R in the NAcc displayed no effect on 
locomotor activity on either test day 1 (when the environment is novel) or day 2 (when 
habituation of the environment has occured ) (Figure 16) compared to empty vector controls. 
The figure shows that there was an effect of time on both days (day 1: F3,57=71.89, p<0.0001; 
day 2: F3,57=51.38, p<0.0001), i.e. over the course of the session on each day, locomotor 
activity decreased  which indicated a within-trial habituation, however there was no  effect of 
neither treatment nor interaction between the three groups (p>0.05). Similarly, 
overexpression of D2R or D3R in the NAcc had no effect on rearing behaviour. There was also a 
within-trial habituation of rearing behaviour on both test days (day 1: F3,57=18.74, p<0.0001; 
day 2: F3,57=13.04, p<0.0001), but no effect of treatment nor interaction (p>0.05) between 
groups.  
  
Knockdown of either D2R or D3R in the NAcc significantly reduced spontaneous locomotor 
activity on day 1, but not on day 2 (Figure 16). There was an effect of treatment on day 1 (F2,30= 
5.65, p=0.008), an effect of time (F3,90= 130.35, p<0.0001), and a treatment x time interaction 
(F6,90= 2.62, p=0.022). The D2R knockdown group showed a significant reduction in locomotor 
activity on day 1 (when the open field arena represented a novel environment) in all four test 
intervals (p=0.01; p=0.001; p=0.021; p=0.024). The D3R knockdown group showed a significant 
reduction in locomotor activity on day 1 in the last three test intervals (p=0.005; p=0.011; 
p=0.008) and a tendency in the first one (p=0.07). These effects were not observed on day 2 
anymore indicating that this effect only occurs in a novel environment. While there was still an 
effect of time (F3,90= 48.74, p<0.0001) for each group, where there a decrease of locomotor 
behaviour over time as expected. There was no significant effect of treatment or interaction 




The knockdown of D2R and D3R in the NAcc had no significant effect on rearing behaviour on 
day 1 or 2. There was a within-trial habituation of rearing behaviour on both test days (day 1: 
F3,66= 51.89, p<0.0001; day 2: F3,90= 22.17, p<0.0001), but no effect of treatment or interaction 
(p>0.05) between any of the groups.  
 
As changes in locomotor activity in the activity arena may reflect anxiety (Prut & Belzung, 
2003), a possible contribution of anxiety to the behavioural changes observed above was 
investigated, using the elevated plus maze test. Neither D2 nor D3 receptor over-experssion 
had an effect on time spent in open arms or entries to it (p>0.05). However, number of entries, 
but not time spent in the closed arms was significantly increased in D3 over-expressing animals 
(p<0.0047) suggesting at least a small anxiogenic effect in this paradigm (Figure 17). The knock 
down of D3 receptors in the Nac increased tendentially the time spent in the closed arms of 
the maze (p<0.074), thus, suggesting a small anxigenic effect. Neither time nor entries to the 
open arms were changed, nor was the number of closed arm entries (p>0.05).  Indeed due to 
technical issues, we could not prove that D2R and D3R were indeed overexpressed or knocked 




Figure 16: The effects of NAcc D2R and D3R overexpression and knockdown on locomotor 
activity and rearing behaviour.  
Testing was carried out on day 1 (novel environment) and day 2 (familiar environment), (mean ± SEM), 
**p < 0.05, *p < 0.01, ANOVA followed by t-tests vs. empty vector (EV) control. Overexpression of D2R 
and D3R showed no differences in neither locomotor nor rearing behaviours on both days. D2R and D3R 
knockdown in the NAcc led to decreased locomotion and a tendency for decreased rearing on day 1 but 





Figure 17: Effect of nucleus accumbens D2R and D3R over-expression and knock down on 
anxiety-related behaviour in the elevated-plus-maze test.  
Increased open arms entries and time spent indicate less anxiety and vice versa. Neither D2R nor D3R 
silencing and over-experssion had an effect on time spent in open arms or entries to it. With the 
exception of D3R overexpression where the , number of entries, but not time spent in the closed arms 
was significantly increased. Mean + S.E.M, **p<0.005, ANOVA followed by t-tests vs. empty vector (EV) 












3.3.4 Light-induced activity is controlled by NAcc D2R and D3R 
As D2R and D3R knockdown demonstrated a decrease in novely-induced locomotor behaviour, 
it would be interesting to see how manipulation of these genes would have an effect on light 
induced locomotor behaviour. In a well habituated environment, the presentation of a new 
unconditioned stimulus, such as a bright light, can induce exploratory activity measured as an 
increase in locomotion and/or rearing (Muller et al., 2007a; Pum et al., 2008). It has been 
previously shown that light-induced exploratory activity is highly stable during repeated testing 
(Pum et al., 2009b). Thus, the current chapter aimed at investigating the possible involvement 
of D2R and D3R in light-induced exploratory activity.  
 
 In this paradigm, once the animal was habituated to its environment (in this case the open 
field box), a non-aversive light stimulus was presented. Locomotor and rearing behaviour was 
measure for 10 minutes at 5-minute interval. Not surprisingly, as seen in Figure 18, the 
presentation of a light stimulus resulted in an increase in locomotor activity and rearing 
behaviour in control animals injected with empty vectors, but there was also an increase in 
light-induced activity in the animals injected with D2R- and D3R- expressing lentiviruses only in 
the first 5 mins of presenting the light stimulus (time: F2,45= 16.91, p < 0.0001 in the  ﬁrst 5-min 
interval vs. baseline (before presentation of the light stimulus) ; for empty vector, p= 0.001; 
D2R, p = 0.026; and D3R, p = 0.011However, compared to the empty vector controls light-
induced locomotion was signiﬁcantly lower in animals injected with D2R-expressing 
lentiviruses (p < 0.027; Figure 18,A). While, injection of D3R-expressing lentiviruses had no 
signiﬁcant effect (p > 0.05) on locomotion. Rearing activity was also increased in all groups; 
(time: F2,45= 22.54, p < 0.0001 in the ﬁrst 5 min interval compared to baseline. Empty vector, p 
= 0.001; D2R, p = 0.0031; D3R, p < 0.0001). When comparing with the empty vector control, 
the light-induced increase in rearing behaviour was not affected by D2R or D3R receptor 
overexpression (p > 0.05; Figure 18,B). 
 
In the case of knockdown, as expected the presentation of a bright light stimulus resulted in an 
increase in locomotor activity in control animals injected with empty as well as DA-receptor-
shRNA expressing lentiviruses (time: F2,81 p < 0.0001, ﬁrst 5 min interval vs. baseline; Figure 19, 
A). Light-induced activity was altered in rats injected with D2R- or D3R-shRNA-expressing 
lentiviruses (Figure 19,A) as there was a signiﬁcant effect on locomotion (F2,27=23.42, p< 
0.0001). Group comparisons revealed that the injection of lentiviruses expressing D2R-shRNA 
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in the NAcc signiﬁcantly increased light-induced locomotion (p = 0.002) compared to control. 
This is supported by attenuation of this behaviour for D2R overexpression described above. 
Contrary to the behaviour seen for D2R, the knockdown of D3R in the NAcc reduced light-
induced locomotion (p = 0.002) compared to empty vector control. 
 
The presentation of the light stimulus had a significant effect on rearing behaviour  (F2,27= 3.47, 
p = 0.045) in all thee groups compared to baseline (time: F2,81= 23.21, p < 0.0001, ﬁrst 5 min 
interval vs. baseline; empty vector, p = 0.0019; D2R, p < 0.0001; D3R, p = 0.0065). However, 
there were no significant effect of neither D2R nor D3R knock down on light-induced rearing 
compared to the empty vector controls although D3R knockdown resulted in a tendency for 
diminished rearing behaviour (p = 0.056; Figure 19,B).  






Figure 18: The effect of nucleus accumbens D2R and D3R overepression on light-induced 
locomotor activity (mean + S.E.M.). 
Left figures show the time course of the light-induced activation (hatched bar – time of light- stimulation 
;BI - baseline. Bar graphs (right panels) show genotype differences when activity was collapsed over 10 
minutes of stimulation) *p>0.05, ** p>0.01, ANOVA followed by t-tests vs. Empty vector (EV) control.  
A) The left panel shows that locomotor activity upon introduction of a light stimulus was increased in all 
three groups including EV. However, this behaviour was signiﬁcantly reduced in animals injected with 
D2R-expressing lentiviruses vs. EV (p< 0.027) while, D3R-expressing lentiviruses had no signiﬁcant effect 
(p>0.05; right panel). B) Rearing activity was also increased in all three groups after the light stimulus 
was introduced (left figure). Although, the light-induced increase in rearing behaviour was not 
significantly different by D2R or D3R receptor overexpression (p> 0.05) compared to EV. 
 
 
                                     





Figure 19: The effect of nucleus accumbens D2R and D3R knock down on light-induced 
locomotor activity (mean + S.E.M.).  
Left figures show the time course of the light-induced activation (hatched bar – time of light- stimulation; 
BI - baseline. Bar graphs show genotype differences when activity was collapsed over 10 minutes of 
stimulation) *p>0.05, ** p>0.01, ANOVA followed by t-tests vs. Empty vector (EV) control.  
Left panels show that upon introduction of a light stimulus, overall locomotor (A) and rearing behaviours 
(B) were increased in all three groups including EV controls. A) Light induced locomotor behaviour was 
signiﬁcantly increased in animals injected with D2R-expressing lentiviruses vs. EV (p=0.002) and, in 
contrast, reduced for D3R overexpression (p=0.002). B) Light-induced increase in rearing behaviour was 
not significantly affected by D2R or D3R receptor overexpression (p > 0.05) compared to EV. 
 
                               





3.4  Discussion 
3.4.1 Summary of results 
The results presented here aimed at investigating the specific contributions of D2R and D3R, 
expressed in the NAcc, in novelty- and light- induced locomotor activity. Lentiviral-mediated gene 
overexpression and targeted gene knockdown were used to specifically and locally manipulate 
expression of these genes. In vitro transduction in HEK-293T cells of these lentiviral vectors 
showed significant overexpression as well as efficient and specific knock down of these receptors. 
Bilateral stereotaxtic lentiviral injections were performed in the NAcc of rats and subsequently 
novelty and light induced locomotor activity were investigated. It was found that NAcc D2R and 
D3R share a similar function in spontaneous locomotor activity in a new environment though no 
contribution of these receptors to locomotor activity in a familiar environment was found. 
However, there was a difference in their role in visual stimulation-induced locomotor activity. 
NAcc D2R seems to limit light-induced activity, as silencing NAcc D2R potentiated this behaviour. 
On the other hand, NAcc D3R slightly reduced light-induced activity. In order to corroborate this 
data, in vivo validation of DA-receptor overexpression and knock down is required. 
Immunohistochemical staining of the brain sections from the different groups demonstrated that 
the injections were indeed localised in the NAcc and that the lentiviruses targeted specifically 
neuronal cells in this region.  
 
 
3.4.2 Novelty - induced locomotor activity 
The functional role of D2R and D3R in novelty-induced (spontaneous) locomotor activity has been 
extensively studied in receptor knockout mice and using pharmacological ligands. Because of the 
limitations associated with these methods, lentiviral - mediated gene delivery approach was 
applied, which enables specific spatio-temporal gene manipulation. The data presented here 
demonstrates that knockdown of NAcc D2R (both isoforms) resulted in a significant decrease in 
locomotor activity on day 1 of testing (representing a novel environment), but not on day 2, when 
habituation has occurred. Mice lacking D2R have been reported to display decreased locomotor 
activity (Baik et al., 1995; Aoyama et al., 2000; Fowler et al., 2002), which is in agreement with the 
data presented here. Also consistent with our findings are studies using D2R antagonists, 
suggesting that decrease in D2R function has an inhibitory effect on spontaneous locomotion. For 
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example, chronic blockade of D2R using metoclopramide, a selective D2R antagonist led to a 
decrease in sponataneous locomotion in rats (Braun et al., 1997).  Other studies have also 
obtained similar findings using different D2R antagonists (Millan et al., 2004; Huang et al., 2010a). 
Administration of a D2R antagonist, sulpiride, resulted in a dose-dependent decrease in locomotor 
behaviour whereas quipirole, a D2R agonist dose-dependently increased locomotor behaviour 
(Stuchlik et al., 2007). NAcc-specific D2R stimulation has been shown to increase locomotor 
activity in rats (Gong et al., 1999). These studies, together with our findings, demonstrate that D2R 
has an inhibitory effect on spontaneous locomotor activity. 
 
The data from this study also indicate that silencing of D3R in the NAcc resulted in decreased 
locomotion. This hypoactivity was generally less pronounced than that obtained by D2R 
knockdown and was only significant after the initial 5 minutes on the first day of testing. The 
behavioural consequences of D3R silencing presented here are in contrast to earlier reports. 
Previously, antisense oligonucleotides targeted against D3R (Ekman et al., 1998) has found to 
increase locomotor activity while the idea that D3R plays an inhibitory role in locomotion is also 
supported by another study  (Menalled et al., 1999). Pharmacological studies report attenuating 
effects of the D3R preferential agonists, 7-Hydroxy-2-(di-n-propylamino) tetralin (7-OH-DPAT) and 
PD 128907 on locomotor activity in rodents (Gyertyan & Saghy, 2004; Millan et al., 2004). 
Furthermore, these D3R agonists, when infused directly into the NAcc also led to a decrease in 
locomotor function (Ouagazzal & Creese, 2000; Millan et al., 2004). On the other hand the 
hyperlocomotor effects of D3R antagonists are reported by a wide range of studies (Waters et al., 
1993a; Waters et al., 1993b; Klingpetersen et al., 1995; Sautel et al., 1995; Clifford & Waddington, 
1998; Manzanedo et al., 1999; Carr et al., 2002; Gyertyan & Saghy, 2004; Millan et al., 2004; 
Pritchard et al., 2007). As highlighted in these reports, a possible account for the contradictory 
results may be due to the lack of selectivity of these ligands (Burris et al., 1995; McNamara et al., 
2006). Further support for this reasoning comes from the observation that three different D3R 
agonists decreased locomotor activity in wild type and D3R knockout mice to similar levels (Boulay 
et al., 1999b).  
 
Studies using D3R knockout mice reveal contrasting findings as D3R deficient mice were reported 
to display levels of spontaneous locomotor activity that are either at (Karasinska et al., 2005; 
Chourbaji et al., 2008), below (Boulay et al., 1999b) or above (Accili et al., 1996; Xu et al., 1997) the 
level of wild type mice. Adaptive mechanisms occurring in the knockout mice (Jung et al., 1999) 
may account the inconsistencies in the above results. For example, in the D3R knockout mice were 
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found to express increased dopamine transporter mRNA, have increased dopamine reuptake and 
decreased tyrosine hydroxylase in the striatum compared to wild type (Le Foll et al., 2005). 
Moreover, rodent species have varied genetic backgrounds which hinder the interpretation of 
pharmacological treatments (Ralph & Caine, 2005), and may account for the above discrepancies.  
For instance, C57BL/6J mice display higher novelty-induced locomotion than DBA/2 mice which 
may be, due to C57BL/6J mice having lower D3R mRNA expression (McNamara et al., 2006).  
 
Interestingly, the reduced locomotor phenotype of D2R-/- mice has been found to be further 
exacerbated by deletion of D3R (Jung et al., 1999), suggesting that D2R and D3R share a similar 
function in regulating spontaneous locomotion. The data presented in this study confirm and 
expand this hypothesis, showing that such shared functions occur in the NAcc. Further supporting 
our findings, is the recent discovery that D2R and D3R interact physically and functionally with one 
another (Scarselli et al., 2001), forming D2R/D3R heterodimers that are preferentially activated by 
the anti-parkinsonian agents, S32504, pramipexole and ropinirole (Maggio et al., 2003) 
 
Although knockdown of NAcc D2R and D3R resulted in obvious phenotypes, enhancing expression 
of these receptors in the NAcc had little effect on novelty-induced behaviour. Previously, 
transgenic mice over-expressing D2R and GFP, display hyperlocomotor phenotype in a novel 
environment (Kramer et al. 2011). And, D2R stimulation increases locomotor activity (Ralph & 
Caine, 2005; Stuchlik et al., 2007), also when specifically occurring in the NAcc (Gong et al., 1999). 
One possible explanation for the lack of effect of the D2R and D3R overexpression seen in this data 
might be that both receptors are well expressed in the NAcc, already at saturating levels and may 
have been internalised for example. Alternatively, the exogenous receptors might have not 
efficiently integrated into functional networks in vivo.Carrying out a radioligand binding assay 
would allow to verify if there are increased functional receptors on the membrane surface. 
Although even if this is the case, in order to see a effect, perhaps additional dopamine may be 
required to bind to the increased receptors on the membrane surface.  It should also be noted that 
while the shRNA used to knockdown D2R targeted both D2RS and D2RL isoforms, only  the effects 
of D2RS overexpression was investigated. Distinct roles for the two D2R isoforms were suggested in 
selective knockout approaches (Usiello et al., 2000; Wang et al., 2000). Mice expressing D2RS but 
not D2RL display reduced levels of spontaneous locomotion (Wang et al., 2000; Hranilovica et al., 
2008), implicating that D2RS may play an inhibitory role in controlling locomotion and/or D2RL has 
a stimulatory role. In fact, D2RL deficient mice which still express functional D2RS, at the same level 
of D2R in wild type mice suggest that there is a compensatory increase in D2RS expression in the 
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mutants. It would be worthwhile to perform stereotaxic injections of NAcc D2RL expression as well 
as knockdown to delineate the effect of both isoforms on locomotor behaviour.  
 
 
3.4.3 Light-induced activity 
Light-induced activity provides a reliable method of generating a behavioural response to a novel 
discrete visual stimulus in rats in a familiar environment (Muller et al., 2007a; Pum et al., 2009b). 
Previously the method of on-off light stimulation has been found to induce an increase of 
horizontal locomotion and rearing behaviour in a stimulus-intensity dependent manner (Pum et 
al., 2008). Within the low intensity range used in this study (<440 lux), the light stimulus is not 
aversive but triggers exploratory behaviour (Pum et al., 2009b) and appears to be a novel stimulus 
with some incentive salience for the animal. This interpretation is in line with a number of studies 
showing that the on- and off-set of low intensity visual stimulation works as a reinforcer in rodents 
(Roberts et al., 1958; Hughes, 2007; Olsen & Winder, 2009) as well as in primates (Blatter & 
Schultz, 2006).  
Our results suggest that D2R and D3R in the NAcc have opposite roles in the processing of visual 
stimuli, with D2R inhibiting locomotor activity induced by a visual stimulus and D3R promoting this 
behaviour. The observed effects may result from the activation of DA neurons in the ventral 
tegmental area (Horvitz et al., 1997). Indeed, it has been proposed that DA neurons transmit 
additional nonreward signals in response to surprising, novel, salient and even aversive 
experiences (Bromberg-Martin et al., 2010). Our results support and extend this notion, showing 
that activation of D2R and D3R in the NAcc has distinct effects on light-induced locomotor 
response. Other evidence for a role of the D2R in processing of visual stimuli is provided by (Doi et 
al., 2006)), showed that D2R-/- mice had reduced light-induced hypoactivity, compared to their 
wild type counterparts. However, their experiment is not directly comparable to the data 
presented in this chapter, as they investigated the light-induced suppression of locomotor activity 
elicited by changes in light-dark cycles. 
 
There is an interesting similarity between the light-induced exploratory activity experiments 
presented in this study and prepulse inhibition (PPI) of the acoustic startle response— an 
operational model of sensorimotor gating. PPI, observed as a reduction in the startle response 
following a weak stimulus or ‘prepulse’ preceding the startling stimulus, is disrupted by altered DA 
levels in the NAcc (Swerdlow et al., 1990) and involvement for both D2R and D3R in PPI have been 
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well documented (Swerdlow et al., 1992; Wan & Swerdlow, 1993; Swerdlow et al., 1998; De Bruin 
et al., 2001; Swerdlow et al., 2009). Although not directly comparable, our results indicate 
contributions of both receptors in light-induced activity, which also reflects interaction between a 
sensory stimulus (in that case visual) and motor processing. 
 
 
3.4.4 Further consideration, limitations and conclusion  
The differences in locomotor activity observed in our experiments could have been explained by 
differences in anxiety levels between groups. To test this, the elevated plus-maze test (Walf & 
Frye, 2007) was used. No anxiety related measures were significantly affected in this test. Our 
results are not surprising despite a number of studies implicating (though often with contrasting 
results) D2R and D3R in anxiety-like behaviours (Steiner et al., 1997; Drago et al., 1998; Black et al., 
2002; de Oliveira et al., 2006; Micale et al., 2009). The amygdala, rather than the NAcc, is thought 
to modulate fear and anxiety through mechanisms possibly involving D2-like receptors (de la Mora 
et al., 2010). 
 
One consideration to take note of is the fact that, unlike the overexpression construct LeGO-iG2, 
the knockdown plasmids LeGO-G and LeGO-C, have separate promoters for the cloned insert and 
the reporter gene. This raises the question of the shRNA essentially being expressed when we only 
assessed for GFP expression. Therefore, in order to further improve the study design, in vivo 
validation of both overexpression and knockdown constructs are required. Although an a 
behavioural effect is seen, it will be useful to quantify the expression of both D2R and D3R in vivo 
either at mRNA or protein level in order to validate gene silencing and overexpression. Attempts 
have been made to achieve this using in situ hybridisation without any success as even 
endogenous D2R and D3R mRNA was not detected. In this case, the RNA probes were not used 
previously so further optimisation would be required in the probe design so that they hybridise 
efficienctly. Also, it is thought that the RNA may have degraded in the process. Furthermore, 
immunostaining using a number of D2R and D3R targeting antibodies which failed to detect any 
protein expression in the brain slices. Several concentrations of the primary and secondary 
antibodies were tested which did not work. Another technique that could be used is careful 
isolation of the NAcc tissue for qPCR analysis of mRNA levels of both genes as well as for protein 




A further consideration regarding the spread of the lentiviral particles in the nucleus accumbens 
needs to be considered. Although the spread of lentiviral particles has been subjectively 
investigated by determining the spread by immunostaining for GFP. It would be useful to quantify 
the extent of spread of the lentivirus from the injection site. From my observations, the injection 
sites and lentiviral spread were generally consistent in each rat. For larger brain regions such as the 
striatum, some publications perform more than one stereotaxic injections to ensure that the 
whole region is covered. Nonetheless, quantifying the coverage of the lentiviral particles is 
important especially because some genes may have a subtle effect on behaviour and in order to 
see an effect, most neurons will need to be infection. Another consideration is the fact that only 
neurons have been infected despite the fact that the CMV promoter is non-specific in terms of 
driving transgene expression in different cell types although it has been shown to have variable 
expression in different human and rodent cell lines (Qin et al., 2010). For this project, it is 
important to verify that the GFP expression is exclusively seen in neurons and not glia. Thus, in 
addition to GFAP, another glial-specific marker S100b, could have been used for 
immunohistochemical analysis to confirm that the transgenes are not expressed.  
 
In conclusion, this study demonstrates that lentivirus-mediated gene delivery can provide 
important insights into the brain region-specific functionality of individual genes in behaviour. 
Using viral mediated gene delivery, long term and localised neuronal overexpression of, or 
selective knock down of, D2R and D3R in the NAcc were obtained. Our results suggest that while 
NAcc D2R and D3R are both required for novelty-induced locomotor activity, they are less 
important once an environment became familiar. Importantly, based on our knock down results, 
this data demonstrate opposite roles of NAcc D2R and D3R in locomotor activity elicited by a 
novel, discrete light stimulus in a familiar environment. Data from this chapter will contribute to 
understanding the differential functional roles of D2R and D3R in mediating behavioural responses. 
Furthermore, our results also demonstrate that this technique can be applied to study the 





















Chapter 4   




4.1 Chapter Aims 
 
As discussed in the general introduction chapter, despite its apparent implications in a number 
of neuropsychiatric disorders, the cellular and molecular function of AUTS2 is largely unknown. 
The aim of this chapter is to: 
1) Investigate its sub-cellular localisation, and 
2) Gain insight into its biological function by identifying its interacting protein partners.  
In order to achieve this, a plasmid expression vector overexpressing AUTS2 either in its native 
form or as a fusion protein containing a V5 tag was designed. 293T cells were transiently 
transfected with these constructs and western blot was carried out to a) test a commercially 
available antibody targeting AUTS2; b) detect successful expression of AUTS2 at the protein 
level. Immunocytochemistry was also performed to determine the cellular localisation of 
AUTS2 in cells transfected with the overexpression constructs. In addition, attempts to identify 




AUTS2 was initially identified as an autism susceptibility candidate gene in a pair of 
monozygotic twins (MZ) with autism who had identical balanced chromosomal translocation at 
t(7;20) (q11.2; p11.2) which disrupted the AUTS2 gene (Sultana et al., 2002). Other studies 
have also identified disruptions in AUTS2 in patients with different severities of autism and/or 
mental retardation (MR) (Sultana et al., 2002; Richler et al., 2006; Kalscheuer et al., 2007; 
Huang et al., 2010b). As reviewed in Chapter 1, recent genetic findings implicate its 
involvement in a number of psychiatric disorders such as ADHD (Elia et al., 2010), 
schizoaffective disorder (Hamshere et al., 2009), epilepsy (Komoike et al., 2010; Mefford et al., 
2010) and more recently, alcohol addiction (Schumann et al., 2011; Zuo et al., 2012).  
Notably, comparison of the Neanderthal genome to that of modern day human revealed that 
AUTS2 was one of many genes positively selected early in human development which, the 
authors suggest, may be due to its potential contribution in cognitive processes (Green et al., 
2010). Moreover, it has been cited that the amino acid sequence of the nuclear localisation 
sequence is highly conserved in human, mouse and chicken  (Bedogni et al., 2010b) providing 
further evidence for its biological importance as a possible nuclear protein.  
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4.2.1  AUTS2 – molecular function 
The human Autism Susceptibility Candidate 2, AUTS2, gene spans 1.2 Mb of genomic DNA and 
is located on Chromosome 7 (q11.22- q11.23); it is also referred to as KIAA0442. There are 
three validated transcript variants of this gene obtained as a result of alternative splicing which 
are translated into fairly large proteins as illustrated in Figure 20 and Table 17. 
 
 
Figure 20: The different isoforms of human AUTS2 on Genome Browser (Human Feb 2009 
(GRCh37/hg19) Assembly).  






Table 17: Details of the three different isoforms of human AUTS2.  






ORF Size (bp) NCBI  mRNA ID 
 
NCBI Protein ID  
(molecular weight  in 
Daltons) 
UCSC 
(1) Long  3780bp NM_015570.2 NP_056385.1 
(138,982) 
uc003tvw.3 
(2) Medium  3708bp NM_001127231.1 NP_001120703.1 
(136,416) 
uc003tvx.3 






AUTS2 mRNA expression in the human brain tissue is present at high levels in the adult frontal 
cortex, caudate putamen and amygdala (Schumann et al., 2011). However, its expression 
pattern is not brain specific. The human AUTS2 mRNA is also strongly expressed in skeletal 
muscle and kidney with lower levels in the placenta, lung, and leukocytes (Sultana et al., 2002) 
as well as in the liver (Hevner et al., 2001; Schumann et al., 2011). Analysis of porcine tissue 
mRNA showed high expression in muscle and brain and to a lesser extent ovary (Sato et al., 
2011). 
However, the molecular and cellular role of AUTS2 is largely unknown. The detection of highly 
conserved nuclear localisation sequences at the N-terminal of the AUTS2  sequence suggest it 
may be a nuclear protein (Bedogni et al., 2010b). Indeed, immunocytochemical staining of 
293T cells overexpressing AUTS2 showed that this protein was specifically localised to the 
nucleus. In the same study, immunohistochemical staining of mouse brain sections show that 
it is present specifically in neuronal nuclei (Bedogni et al., 2010b). Nonetheless, its specific role 





4.3 Methods and Materials 
4.3.1.1 Construction of human AUTS2 overexpression vectors 
Two plasmid expression vectors were constructed that encoded AUTS2 either in its native form 
or as a fusion protein with the V5 tag at the C-terminal. The pLenti7.3/ V5 – TOPO® vector 
backbone is shown in Figure 21. 
 
Figure 21: The pLenti7.3/ V5 – TOPO vector.  
This lentiviral expression plasmid contains a CMV promoter, a EmGFP reporter gene, an ampicillin 
resistance gene. A V5 epitope is present in the multiple cloning site which can result in a tagged protein 





Primer design for AUTS2 amplification 
Primers were designed to amplify the 3708bp (medium) isoform of human AUTS2. The forward 
primer incorporated the KOZAK consensus ([G/A]NNATGG) sequence – the optimal sequence 
required for translation initiation. Two reverse primers were designed to obtain either the 
AUTS2 protein sequence in frame with the V5 epitope tag resulting in a fusion protein (AUTS2 
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+ V5 or V5-tagged AUTS2) or the native AUTS2 protein.  Table 18 shows the primer sequence 
used for amplification. To obtain the native form of AUTS2, a stop codon was included in the 
reverse primer. While to obtain V5-tagged AUTS2 protein, the stop codon was removed and 
the underlined nucleotides were added to keep in frame with the V5 epitope.  
 
 
Table 18: Primers used to amplify the medium isoform of human AUTS2 (3708bp) open-
reading frame (ORF) for cloning into pLenti7.3/V5 TOPO® TA vector.  
In order to generate two forms of AUTS2 protein products (i.e. native and V5-tagged AUTS2), two 
different reverse primers were used. Both primers have a similar sequence except for the primer resulting 
in the fusion protein has the stop codon removed and replaced with two cytosines to keep the AUTS2 
sequence in frame with the V5 sequence. 
 
Primer  Sequence 5’ > 3’ 
Forward primer ACCATGGATGGCCCGACGCGG 
Reverse primer (native AUTS2) TCGGGCCTCGATATCCTT 
Reverse primer (AUTS2 + V5) CCTCGGGCCTCGATATCCTTCAGCG 
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PCR Amplification of human AUTS2 
After several trials, the optimal PCR reaction for AUTS2 amplification contained a final 
concentration of 1x High Fidelity Phusion® buffer (Thermo Scientific, UK), 200µM of each dNTP 
(Life Technologies, UK), 0.5µM forward primer, 0.5µM reverse primer (either native or V5), 1U 
High Fidelity Phusion® DNA Polymerase (Thermo Scientific, UK), 3% DMSO, 10ng template DNA 
and dH20 to a final volume of 50µl. The addition of DMSO inhibits the formation of secondary 
structures in the template DNA. The cycling conditions are shown in Table 19. The PCR reaction 
was run by electrophoresis on a 0.8% (w/v) agarose gel as detailed in 2.4.2 and the fragment 
band corresponding to the expected size of AUTS2 (approximately 3.7kb in length) was 
isolated, gel-purified (as detailed in section 2.6.2.3) and stored at -20°C until further use. 
 
 
Table 19: PCR thermal cycling conditions used for amplifying human AUTS2 
 
Step Time Temperature (°C) 
1 -  Initial denaturation  30 seconds  98 
2 - denaturation 10 seconds 98 
3 - annealing 30 seconds 68 
4 - extension 2 minutes  72 
5 -  number of cycles        Go to step 2 -  35 times 
6 – final extension 10 minutes 72 
 
 
Addition of 3’ A-Overhangs Post-Amplification 
High Fidelity Phusion® DNA Polymerase lack the terminal transferase activity which adds the 
3’A overhangs required for the ligation process. Therefore, following PCR amplification and 
fragment band purification, 3’A overhangs were added to the purified PCR product in a 
reaction containing a final concentration of 1x Taq buffer with magnesium, 1ng/µl PCR 
product, 1mM dATP (Life Technologies, UK) and 5U Taq Polymerase (Roche, Hertfordshire, UK) 
in a total volume of 10µl. The mix was heated at 72°C for 20 minutes and the ligation reaction 
below was carried out immediately.  
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Ligation of AUTS2 into pLenti7.3/V5 TOPO expression vector 
To perform the ligation, pLenti 7.3/V5 TOPO® TA cloning kit® (Life Technologies, UK) was used. 
The TOPO® cloning reaction consisted of: 1µl of the above PCR product with the 3’ A overhang, 
1µl salt solution, 1µl pLenti-TOPO® vector in a final volume of 6µl. In parallel, a control reaction 
was set up with no insert DNA to assess the re-ligation efficiency of the linearised vector. This 
mixture was incubated at RT for 20 minutes and then placed on ice. 3µl of this reaction was 
transformed into One Shot® Stbl2™ Competent E.coli. 
 
Verification of correct DNA inserts  
Following transformation, colony isolation and plasmid purification by minipreps; an enzyme 
digest was carried out to look for the presence of the insert in the vector and its orientation 
with respect to the vector. Therefore, additional digests were performed using restriction 
enzymes that would cleave once in the Multiple Cloning Site of the vector and also once in the 
AUTS2 ORF at either the 5’ or 3’ end, not mid sequence. The BamHI enzyme met this criterion 
and thus was used to determine the orientation of the AUTS2 ORF. A couple of miniprep DNA 
that contained AUTS2 cDNA in the correct orientation were sent for sequencing to verify the 
sequence integrity of the insert using the primers listed in Table 20. Following correct 
sequence verification, maxipreps (section 2.6.2.1) were carried out for virus production.  The 
above enzyme digest was repeated to confirm the presence of the insert before use.  
 
Table 20: Primers used for sequencing of the human AUTS2 open-reading frame (ORF) cloned 
into pLenti 7.3/V5 TOPO® TA vector 
 
Primer Orientation Sequence 5’ > 3’ 
AUTS2 seq1 Forward CACCAAAATCAACGGGACTT 
AUTS2 seq2 Forward CGGGAAAGGCTCAGTGATAG  
AUTS2 seq3 Forward ATATGTTTGCCCCTCCCACT  
AUTS2 seq4 Forward GTGCTGCACACCCAACTG  





4.3.1.2 Production of lentiviruses overexpressing AUTS2 
The ViraPower™ Lentiviral Support Kit and Lipofectamine™ 2000 (Life Technologies, UK) was 
used for transfection according to the manufacturer’s instructions for producing lentiviruses. 
The lentiviral packaging cell line was 293FT. 
Briefly, the day before transfection, 5.5 x 10
6
 293FT cells were plated (trypsinisation and cell 
count was done as per section 2.1.2.4 and 2.1.2.5) in 10cm sterile tissue culture dishes in a 
total volume of 10ml medium without antibiotics. On the day of transfection the culture 
medium was removed and replaced with 5ml Opti-MEM® I medium containing serum but no 
antibiotics. For each transfection sample, 9μg  of the ViraPower™ Packaging Mix (Life 
Technologies, UK) and 3μg of the pLenti expression plasmid DNA) was added to 1.5ml Opti-
MEM® I Medium without serum and mixed gently. Three plasmids were transfected: empty 
pLenti vector, pLenti + native AUTS2 and pLenti + V5-tagged AUTS2 . Separately, for each 
transfection reaction, 36μl of Lipofectamine™ 2000 was added to 1.5ml Opti-MEM® without 
serum and antibiotics and mixed gently. This mixture was incubated at RT for 5 minutes. The 
diluted Lipofectamine™ 2000 was subsequently added to the diluted plasmid DNA and viral 
packaging mix. This mixture was then incubated for 20 minutes at RT for the DNA-
Lipofectamine™ 2000 complexes to form. Following incubation, the DNA-Lipofectamine™ 2000 
complexes were added drop wise to each plate and mixed. The cells were then placed back in 
a humidified incubator at 37°C with 5% CO2.  The following day, the medium containing the 
DNA-Lipofectamine™ 2000 complexes was removed and replaced with 10ml complete culture 
medium without antibiotics and placed back in a humidified incubator at 37°C with 5% CO2. 
The virus containing supernatants were harvested 24 and 48 hours later. These were 
centrifuged at 3000rpm for 15 minutes at RT to pellet the cell debris. Following centrifugation, 
the supernatants were filtered through 0.22μm pore nitrocellulose, aliquoted and stored at -
80°C until use. Finally RNA and protein cell lysates were extracted (see sections 2.7 and 2.9). 
 
4.3.1.3 Transduction of 293T cells with lentiviruses expressing AUTS2 
293T cells were infected with lentiviruses overexpressing either native or V5-tagged AUTS2 as 
well as the empty vector as detailed in section 2.3.2.2. Lysates were collected for RNA and 
protein extraction as detailed in sections 2.7 and 2.9 respectively. However, only 
approximately 2% transduction efficiency was achieved using this protocol. Having optimised 
the protocol several times, by increasing viral particles, longer incubation times with particles, 
there was no improvement in infection efficiency. This may have been to low titre obtained 
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during transfection since the transfection efficiency observed based on the number of GFP 
positive cells was high (~80%-90%) 48 hours post transfection. 
 
4.3.1.4 Transient transfection of 293T cells with plasmid DNA 
As mentioned above, the lentiviruses produced using the above protocol was inefficient in 
transducing 293T cells. Transient plasmid DNA transfection was carried out in 293T cells. This 
was performed in 6 well plates as per 2.2.2.1. Transfection was done for the below constructs 
and carried out in triplicates for RNA extraction, protein extraction and for immunostaining: 1) 
no plasmid DNA - only transfection mix; 2) empty vector; 3) overexpression - native AUTS2; 4) 
overexpression - AUTS2 + V5.  
 
4.3.1.5 qPCR and analysis 
The primers used to amplify exogenous AUTS2 mRNA were designed to detect the medium 
isoform (3708bp) acknowledged by both RefSeq and the UCSC genome browser. Human ACTIN 
was used as the housekeeping gene against which expression values for AUTS2 were 
normalized to produce ΔCt values (ΔCt = CtAUTS2 – CtACTIN). Ct was defined as the fractional cycle 
number at which the amount of amplified target reached a fixed threshold. The ΔCt value for 
each condition was subtracted from the ΔCt of the control condition i.e. cells transduced with 
empty vector. The changes in mRNA expression relative to this control was obtained by raising 
2 to the negative power of the calculated difference i.e., for AUTS2 overexpression: 2
−(Δct AUTS2-
overexpression −ΔCt empty vector)
. The primers sequences are given in Table 21. 
 
Table 21: Primers used to amplify the AUTS2 and β -ACTIN for qPCR 
 
Primer  Sequence 5’ > 3’ 
AUTS2 medium isoform (forward) GCCATTGTCAGCCTACAACA 
AUTS2 medium isoform (reverse) GTGGTGGGAGATGTGAGGTG 
β-ACTIN  (forward) GCTCGTCGTCGACAACGGCTC 




4.3.1.6 Western Blot 
Protein extraction and western blot was carried out as described in 2.9, using the antibodies 
and dilutions shown in Table 22. 
 
Table 22: Primary and secondary antibodies, dilutions and blocking buffer used for western 
blot.   




4.3.1.7  Immunocytochemistry 
Immunocytochemistry was carried out as described in section 2.9.2.1. The blocking buffer used 
was 10% goat serum in PBST containing 0.3M glycine. Primary and secondary antibodies and 
their dilutions are shown in the table below. 
 
Table 23: Dilutions of primary and secondary antibodies used for immunoytochemistry.   
Source and host species of antibodies are detailed in section 2.9.1.3. 
 
 
4.3.1.8 Co-Immunoprecipitation (Co-IP) 
Co-IP of AUTS2 using the anti-AUTS2 and anti-V5 antibody was carried out as detailed in 
section 2.9.2.6. 
Blocking buffer Primary antibody Dilution  Secondary antibody Dilution 
 TBST+ 5% milk  Anti-V5   1: 5000   Odyssey anti-mouse 800CW   1:10000 
 TBST+ 5% milk  Anti- AUTS2  1:1000   Odyssey anti-rabbit 680  1:5000 
 TBST+ 5% BSA  Anti –ACTIN   1:1000   Odyssey anti-rabbit 680  1:5000 
Primary antibody  Dilution  Secondary antibody Dilution 
Anti-V5  1: 200  Alexa Fluor 594  1:500 




4.3.2.1 Subcellular localisation of AUTS2 
Overexpression of AUTS2 and assessment of a commercially available anti-AUTS2 
primary antibody  
In order to determine its sub-cellular localisation, two lentiviral expression plasmids were 
generated that encoded either human AUTS2 in its native form or as V5-tagged AUTS2. 293T 
cells were transiently transfected by calcium phosphate co-precipitation with these plasmids 
and empty vector; a transfection efficiency of approximately 75% was achieved. As seen 
fromFigure 22, qPCR analysis show that AUTS2 mRNA expression is induced approximately 
320-fold and almost 500-fold in 293T cells transduced with the lentiviral plasmid vector 
overexpressing native AUTS2 and V5-tagged AUTS2 respectively compared to expression with 
the empty vector. In parallel, in order to eliminate the fact that the induction of AUTS2 mRNA 
expression was due to amplification of plasmid DNA contaminants in total RNA samples, as 
opposed to the corresponding cDNA, a reverse transcription reaction was set-up in parallel 
whereby the reverse transcriptase enzyme was not included, preventing cDNA synthesis. Thus 
any signal obtained from the amplification reaction would reflect only plasmid DNA 
contamination. Very low levels of expression were detected in this control reaction – Ct values 
for ‘AUTS2 native’ and ‘AUTS2 + V5’ were 31.2 and 29.4 respectively compared to their 
respective Ct values with the reverse transcriptase enzyme added (14.6 and 13.9 respectively), 
indicating that some contaminating plasmid was present in the cDNA samples, however, this 





Figure 22: AUTS2 mRNA expression in 293T cells transfected with either empty vector or 
vector overexpressing AUTS2.  
Values are analysed relative to empty vector control, and taking into account expression level 
attributable to contaminating plasmid DNA in the cDNA sample. AUTS2 mRNA expression is induced 
significantly in cells transfected with plasmid overexpressing either native AUTS2 or V5-tagged AUTS2 
compared to empty vector. This data is representative of one experiment of two that were conducted; as 

















Having verified that AUTS2 is induced at the mRNA level, establishing that it is also expressed 
at the protein level was required. This was done using two antibodies (anti- V5 and anti-
AUTS2) for Western Blot analysis on protein extracts of 293T transfected with plasmids 
overexpressing human AUTS2 either in its native form or as a V5-tagged fusion protein, empty 
vector and no plasmid vector. Equal loading of the protein extracts was demonstrated in the 
control blots for which the anti-ACTIN antibody was used (Figure 23A). Using the anti-V5 
antibody, which has been successfully used previously (Berghs et al., 2001; Malagelada et al., 
2006; Irobi et al., 2011; Ramonet et al., 2012), revealed a band of a relatively higher than 
expected size of ~200kDa (Figure 23B) compared to the expected size of ~130kDa for human 
AUTS2, which was only present in the extracts overexpressing V5-tagged AUTS2 but not in 
other extracts, as expected. This demonstrated that V5-tagged AUTS2 over-expression is 
achieved successfully at the protein level and the higher than expected band size could be 
explained by another protein still bound to AUTS2. Another possible reason is that this could 
be another uncharacterised isoform of AUTS2 which is of a higher molecular weight. 
Also, a commercially available antibody targeting AUTS2 from Abcam, UK, which has not been 
previously tested, was assessed here. The abovementioned antibody was predicted to 
recognise human AUTS2 according to the manufacturers’ guidelines and was thus required to 
be tested prior to application in protein methods used subsequently in this thesis, such 
immunocytochemistry and immunoprecipitation. The AUTS2 antibody was tested by Western 
blot on protein extracts from 293T cell lines transfected with the same constructs as above. 
Figure 23C, shows that using this antibody, AUTS2 was indeed overexpressed at the protein 
level as a band of approximately 200kDa was present in the wells containing protein extracts 
from cells overexpressing native AUTS2 and V5-tagged AUTS2 but not in the empty vector or 
no plasmid extracts indicating three things: 1) that this anti- AUTS2 does indeed recognise 
human AUTS2 protein; 2) AUTS2 is successfully overexpressed at the protein level in its native 
form  3) that endogenous AUTS2 is not present at detectable levels in this cell line using this 
antibody. It must be noted that although overexpressed, the band detecting AUTS2 using both 
antibodies is faint despite loading a large amount of protein extract (30µg protein extracts) as 
shown by a very thick band for the control, ACTIN (Figure 23A). Owing to the higher than 
expected band size, in order to verify that the band corresponds to AUTS2 and/or another 





Figure 23: Western blot to determine the level of exogenous AUTS2 expression in 293T cell 
line transiently transfected with plasmids overexpressing AUTS2.  
A) β-Actin control (molecular weight ~45kDa) is detected in all extracts. B) The anti-V5 antibody detects a 
specific band (indicated by arrow) of ~200kDa only in cells transfected with plasmid overexpressing V5 
tagged Auts2 (AUTS2+V5). C) A band of the same size (indicated by arrow) was also detected by the anti- 
AUTS2 antibody (Abcam, UK) in cells overexpressing both native AUTS2 and V5-tagged AUTS2. Expected 







AUTS2 is expressed in mouse whole brain extracts and Neuro2a cell line 
Western blots were carried out on a mouse neuroblastoma cell line, Neuro2a, and mouse 
whole brain to verify if this antibody recognises the mouse AUTS2 protein. The antibody 
epitope target sequence is present in mouse AUTS2 protein. Figure 24 shows a relatively 
intense band of an expected size of ~140kDa detected in the well containing mouse brain 
lysates. However, a band of a higher than expected size (~150kDa) was identified in the mouse 
Neuro2a lysates (Figure 24); This could indicate a different isoform of mouse AUTS2 which may 
be exclusively expressed in the Neuro2a cell line. Alternatively it could indicate that there may 
be another small protein still attached AUTS2 and thus appearing at a higher than expected 
size.  In order to identify if the band indeed corresponds to AUTS2 and/or another protein, 
mass spectrometry for example liquid chromatography tandem mass spectrometry 
(LC/MS/MS) could be performed.  
Another observation is that there is considerably more protein in the mouse brain lysate than 
in the cell line, this could be explained by the fact that there is higher expression of this protein 
in the brain than the cell line.  
140 
 
Figure 24: SDS-PAGE analysis to determine the level of AUTS2 protein expression in whole 
mouse brain lysate and Neuro2a (mouse neuroblastoma) cell line.  
The anti-β-Actin antibody successfully detected β-Actin in both lysates with a molecular weight of ~45 
kDa as expected. The AUTS2 antibody (Abcam) also detected a clear specific band in both cells although 
they were slightly different sizes: ~150 kDa in the mouse Neuro2a cell lysate and an expected size of 




AUTS2 is localised in the nucleus  
Having ascertained that the plasmid expression vector successfully induces AUTS2 expression 
at the protein level and the antibody specifically recognises both human and mouse AUTS2, 
immunocytochemistry was performed to determine cellular localisation of AUTS2 in 293T and 
Neuro2a cell lines using either  the anti-V5 and anti- AUTS2 antibodies.  
293T cell line was first transfected with plasmid V5-tagged AUTS2 and as seen in Figure 25, 
although higher transfection efficiency (approximately 70%) was achieved, a lower number of 
GFP+ve cells are seen due to the cells being re-seeded onto specialised culture chamber slides 
for immunostaining.  Nonetheless, in this way, staining from non-transfected cells can be 
compared to that of transfected cells in the same field of view.  Deducable from the results, 
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firstly is co-localisation of the Green Florescent Protein marker (expression from the plasmid n 
vector), with the V5 antibody staining, shows that AUTS2 was overexpressed in these cells 
(Figure 25 a-c). In addition, co-localisation of V5 and DAPI (a nuclear counter stain) shows that 
AUTS2 is localised within the nucleus of 293T cell line (Figure 25c-e). Endogenous AUTS2 in the 





Figure 25: Nuclear sub-cellular localisation of AUTS2. 
a-e) 293T cell line were transfected with the plasmid vector overexpressing V5-tagged AUTS2 as shown 
by the GFP flourescence from the lentiviral vector (green) and anti-V5 antibody staining (red). Merged 
images of GFP and V5 are colocalised as indicated by arrows. Merged images of V5 and DAPI staining 

































c) GFP + V5 
e) DAPI + V5 
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Figure 26 : Nuclear sub-cellular localisation of AUTS2. 
a-c) The anti-AUTS2 was used to determine subcellular localisation of endogenous AUTS2 in Neuro2a 
mouse cell line. Positive endogenous AUTS2 staining is shown in green. Merged images (teal colour) of 
DAPI staining (blue) and anti-AUTS2 antibody staining (green) indicate that AUTS2 is localised in the 
nucleus (indicated by arrows). Images are taken at 40x magnification. Bar represents 50 µm. 
 
      
  
 
e) DAPI + V5 
a) DAPI  
b) AUTS2 
c) DAPI  + AUTS2 
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4.3.2.2 Potential interacting partners of AUTS2 
Co-Immunoprecipitation (Co-IP) of AUTS2 
In order to find out its protein- protein interactions, co-IP of AUTS2 was performed with the 
aim to ‘pull out’ any interacting partners that would point out to its role in the nucleus. The 
anti-V5 and anti-AUTS2 antibody were assessed for their suitability for immunoprecipitation. 
Despite several attempts to optimise this protocol, the anti-AUTS2 antibody failed to 
specifically immunoprecipitate AUTS2 and its interacting partners in mouse brain lysate. As 
seen from Figure 27, A a very faint band of the expected size of AUTS2 was recognised by this 
antibody along with a substantial amount of non-specific binding.  A smear of bands similar to 
the well with mouse brain lysate were present in the control (no primary antibody). Attempts 
to reduce this background by washing in PBS to have a more stringent condition led to no band 
detection at all.  
 
On the other hand, using 293T cells overexpressing AUTS2 in the human 293T cell line, the 
anti-V5 antibody did not pull out V5-tagged AUTS2 as no band was detected corresponding to 
its expected size (Figure 27,B). Two other bands were visible which were equivalent to the size 
of the heavy and light chain for this antibody. The lack of immunoprecipiated AUTS2 could be 
explained by the need for a higher transfection efficiency; in this experiment a transfection 
efficiency of approximately 60% was achieved. Also as AUTS2 may be localised in the nucleus 
as shown above, nuclear protein extracts would enrich AUTS2 which may enable to ‘pull out’ 






Figure 27: Western blot to assess the efficacy of the A) anti-AUTS2 antibody and B) anti-V5 
antibody for immunoprecipitation (IP) of AUTS2 protein.  
A) 500 µg mouse whole brain lysate was used to purify AUTS2 protein by IP using the anti-AUTS2 
antibody. A Western blot was performed to ascertain whether AUTS2 had been purified successfully. The 
anti-AUTS2 antibody is not effective for purification of AUTS2 in mouse brain lysate as a substantial 
amount of background is detected despite a faint band comparable to that detected in the non-purified 
lysate is visible (indicated by arrows). B) 100µg 293T cell lysate overexpressing V5-tagged AUTS2 was 
purified using the anti-V5 antibody. A band comparable to that detected in non-immunoprecipitated 
sample (indicated by arrow) was not detected. Instead the bands that were detected are those 
corresponding to the light and heavy chain of the anti-V5 antibody. ‘No antibody’ represents the 








A              Mouse brain lysate B        293T human cell line 
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4.3.2.3  Summary and discussion 
 
The purpose of this chapter was to determine the sub-cellular localisation of AUTS2 and 
identify its potential interacting protein partners in order to gain some insight into its function.  
In order to ascertain its sub-cellular localisation, firstly, two lentiviral expression plasmids were 
generated; one which encoded human AUTS2 in its native form and another that 
overexpressed a small epitope tag, V5, C-terminally fused to AUTS2 (denoted V5-tagged 
AUTS2). 293T cells were transiently transfected with these plasmids and, in parallel, with an 
empty vector as control. RNA and protein extracts were obtained so as to 1) verify the 
induction efficiency of the plasmid overexpression constructs at the mRNA and protein level 
and 2) evaluate the specificity of a commercially available anti-AUTS2 antibody.  
 
Quantitative PCR analysis demonstrated a high AUTS2 mRNA induction. Its expression was also 
induced at the protein level, evident from a Western blot analysis of 293T cells transfected 
with V5-tagged AUTS2 using the anti-V5 antibody. Additionally, the anti-AUTS2 antibody was 
assessed for its target specificity in the same Western blot analysis that also contained lysates 
overexpressing AUTS2 in its native form, which successfully demonstrated that it recognises 
AUTS2. However, in the abovementioned blots, a higher than expected molecular weight band 
was detected by both antibodies. This may be due to post-translational modifications such as 
phosphorylation, myristoylation and glycosylation; putative sites for these modifications have 
been reported previously (Sultana et al., 2002). Additional reference to Uniprot indicated that 
AUTS2 is a phosphoprotein (uniprot code: Q8WXX7). Ultimately, data from the above findings 
demonstrate that anti-AUTS2 and anti-V5 antibodies specifically recognise their target protein. 
 
Secondly, to determine the subcellular localisation of AUTS2, fluorescent immunostaining was 
performed in 293T cells overexpressing the V5-tagged form of this protein. Co-localisation of 
this protein (stained for by the anti-V5 antibody) with the counter-stain DAPI confirmed that 
AUTS2 is a nuclear protein. This finding may explain the faint band obtained in the 
abovementioned SDS-PAGE analysis for both antibodies. Nuclear rather than whole cell 
protein extracts may enrich the amount of AUTS2 protein obtained in order to see the high 
levels of expression. A consideration here is the fact that a human cell line that endogenously 
expresses AUTS2 would be appropriate to use. Although, to consolidate the above findings, 
SDS-PAGE analysis of extracts from a mouse neuroblastoma cell line Neuro2a was performed 
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to detect endogenous AUTS2 expression at the protein level using the anti-AUTS2 antibody 
assessed above. As with the results above, a higher than expected molecular weight size was 
detected, potentially indicating post translational modifications. To determine its sub-cellular 
localisation, immunostaining in Neuro2a showed co-localisation of endogenous AUTS2 within 
the nucleus (DAPI counterstain) confirming that AUTS2 is a nuclear protein in this cell line. 
Together, these results are in agreement with a previous report which demonstrated its 
localisation in neuronal nuclei in the mouse brain (Bedogni et al., 2010b).  
 
Next, having determined its cellular localisation, it was necessary to find out what exact role it 
played in the nucleus. Co-immunoprecipitation (Co-IP) was attempted using the validated anti- 
AUTS2 and anti-V5 antibodies with the aim of investigating its function by identifying its 
interacting protein partners. Co-IP was performed to pull-down the AUTS2 protein from 
cultured cells transiently overexpressing the native form of AUTS2 or V5-tagged AUTS2 along 
with other proteins either bound to it directly or as part of a protein complex. Initial 
assessment intended to determine suitability of the anti-AUTS2 antibody for 
immunoprecipitation using mouse brain lysate showed that it may have captured a small 
amount of AUTS2 but a high degree of background was detected in all samples including 
control (no primary antibody included in the lysate). Despite several protocol optimisations, 
such as longer pre-clearing time and using increased protein lysates, the above results either 
persisted or no band was visible at all indicating that this antibody is not be suitable for 
immunoprecipitation. Trial with the anti-V5 antibody for ‘pulling out’ AUTS2 and its associated 
proteins, lead to no visible band. A possible explanation for the lack of success in this 
technique may be that AUTS2 expression is not at an adequate level for pulling out. As the 
previous immunostaining data suggest that it is a nuclear protein, this may be ameliorated by 
enriching its purification by performing nuclear protein extracts as opposed to whole cell 
extracts, carried out here. Two other commercially available antibodies have previously been 
tested in our group, which were also found to be unsuitable for immunoprecipitation.   
 
In order to gain some indication of proteins that interact with AUTS2, references to several 
publically available databases containing information on protein structure, function and 
interactions or those that can predict this, were interrogated with one database showing 
interactions of AUTS2 between a number of putative proteins, many of which are involved in 
neurobiological and neurodevelopmental processes. Various bioinformatic resources that 
provide annotation for known and predicted PPIs were interrogated to ascertain whether 
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there is currently any evidence of AUTS2 interacting protein partners.  STRING 9.0 software 
revealed a number of predicted PPIs (Figure 28), though these data are based on findings from 
text mining; there is no actual experimental evidence of any physical interaction between any 
of these proteins and AUTS2. Nonetheless it is interesting to note that some of these supposed 
interacting proteins play a role in developmental neural circuitry as described in Table 24. The 
remaining bioinformatic resources had no record of PPIs involving AUTS2. Nonetheless as 
demonstrated recently, tandem affinity purification (TAP) of 293TREx cells stably expressing 
Polycomb group ring fingers PCGF3 and PCGF5, recovered AUTS2, FBRS and FBRSL (Gao et al., 
2012). These highly conserved proteins are part of a chromatin modifying multi-component 
complex called PRC1-like complex involved in the regulation of embryonic development 
through transcriptional repression of as yet unknown genes. As TAP enables the identification 
of stable PPIs, it is possible that AUTS2 may be part of or interacts with this complex in order 





Figure 28: In silico analysis of potential protein-protein interactions (PPIs) involving human 
AUTS2 protein.  
Output from STRING 9.0 software illustrating putative PPIs based on evidence from text-mining. The 
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A transcriptional regulator 
involved in brain 
development. 
Tbr1 is thought to  regulate 








Regulates the exocytosis of 
vesicles from neurons and 
neuroendocrine cells. 
Both AUTS2 and CADPS2 have 
been strongly associated with 
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human evolution (Green et 
al., 2010). 
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been strongly associated with 
autism and were both 
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al., 2010). 
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in children with Autism 
spectrum disorders 





A possible approach that could be used to find out about PPIs of AUTS2 is the yeast-two hybrid 
system. Very briefly, this would involve cloning AUTS2 into a bait vector which also contains 
another gene encoding a DNA-binding domain from a transcription factor (e.g. Lex A), thus 
generating a Bait-DNA-binding domain fusion protein. On another plasmid vector, a putative 
interacting protein (e.g. PCGF5) designated the term ‘prey’ is cloned in frame to an activation 
domain of the Gal14 yeast transcription factor. If the two proteins (bait and prey) physically 
interact, this would bring the DNA-binding domain of one vector and the activation domain in 
the other vector in close proximity to restore a functional transcription factor. Thus the 
reporter gene (e.g. LacZ) is transcribed resulting in the blue coloration of the yeast cells which 
would otherwise not occur. This can be repeated for any number of prey proteins and would 
verify previous findings as mentioned above and determine novel interacting partner proteins.  
 
In conclusion, this sub-chapter has successfully constructed plasmid overexpressing AUTS2 in 
its native form as well as V5-tagged AUTS2. These constructs were used to validate a 
commercially available anti-AUTS2 antibody which successfully detected its target. Previously, 
other commercially available antibodies assessed in our lab, failed to detect AUTS2. This 
chapter has thus identified an antibody that specifically targeted AUTS2. Using the validated 
antibody and overexpression constructs, it was demonstrated that AUTS2 was localised in the 
nucleus in two cell lines from different species (human and mouse). Although co-
immunoprecipitation failed to reveal its interacting protein partners and the above in silico 
analyses have served to provide clues concerning the potential functioning of AUTS2 protein, 
in vitro research is clearly needed to try to verify and extend upon these findings. Given its 
association to a number of neuropsychiatric disorders, the next chapter aims to investigate its 









Chapter 5   
 
Lentiviral mediated gene silencing of AUTS2 in 





5.1 Project Aims 
Given that AUTS2 is a neurodevelopmental gene implicated in a number of neuropsychiatric 
disorders, this chapter aims to expand our understanding of its function in brain development 
using a human neural stem cell line to model neurodevelopment in vitro. Figure 29 illustrates a 
brief outline of the intended plan for this part of the thesis. 
More specifically, the aims of this chapter are to: 
1) Ascertain the role of AUTS2 in neurogenesis and neural differentiation, key process for 
neurodevelopment. 
2)  Investigate changes in gene expression patterns of other genes in response to AUTS2 





Figure 29:  A brief overview of the methods used to investigate the functional role of AUTS2 
using human foetal neural stem cell line, SPC-04.  
Adapted from (Jakel et al., 2004). The overall research plan is to transduce SPC-04 in order to silence 
AUTS2 expression and assess for changes in cellular features such as cell survival, cell proliferation, and 
differentiation at the undifferentiated stage as well as various stages of differentiation. As analysed by 
RT-PCR, AUTS2 expression is high and consistently maintained at this level in various stages of 
differentiation in this cell line (unpublished data). In addition, a global gene expression profile will be 
carried out using microarrays to look at differential gene expression of those involved in 






5.2  Introduction 
 
5.2.1 Neural stem cells (NSCs) as an in vitro model to study 
neurodevelopment 
In addition to animal studies, the use of neural stem cells has contributed substantially to 
research in the molecular mechanisms underlying neurodevelopment and how genetic as well 
as ‘environmental’ alterations can impact this process. With the view that most psychiatric and 
neurodegenerative disorders may be due to aberrant processes taking place during 
development, currently a major focus of research is directed towards studies using stem cell 
lines.  
Stem cells are undifferentiated cells that have the ability to self renew through cell division and 
have the potential to differentiate into multiple cell types also known as multipotency. Stem 
cells can be derived from embryonic, foetal as well as adult tissues. Human embryonic stem 
cells are derived from the inner cell mass (group of cells that will develop into the embryo) of 
the embryonic blastocyst which can be induced to differentiate into any cell type. In culture, 
these cells form embryoid bodies (aggregates of differentiated and undifferentiated cells) 
which in turn can differentiate into the three primordial germ layers: ectoderm, mesoderm 
and endoderm. Under specific conditions, the embryoid bodies can be induced to differentiate 
into mature neurons and glia through an intermediate differentiation stage involving neural 
precursors (Reubinoff et al., 2001). The latter can give rise to neurally derived cells. Neural 
development can be divided into three main stages: neural induction, neural specification, and 
neural maturation. Each of the stages in the developing embryo can be modelled in vitro in 
hESCs. They provide a useful tool in studying the various differentiation stages in neural 
development and understanding the mechanisms involved in brain development (Vaccarino et 
al., 2011). NSCs can also be isolated directly from the foetal brain between 8 and 20 weeks’ 
gestation (Carpenter et al., 1999; Vescovi et al., 1999) and can be expanded into large numbers 
in culture. The generation of specific cell types from these cells and their fates during 
development is regulated by factors that affect cell division, differentiation and apoptosis. 
Adult human neural stem cells can also be obtained and are increasingly being used in 
research as there are no ethical concerns relating to their use. However, they are difficult to 




In mammalian development, neural stem cells (NSCs) appear during the period of neural 
induction, which occur after the differentiation of the germ layer from the epiblast. They have 
the ability to self-renew as well as generate all the different neural cell types (Carpenter et al., 
1999; Vescovi et al., 1999). Fibroblast growth factor-2 (FGF2) and epidermal growth factor 
(EGF) along with insulin like growth factor enable the proliferative self renewal of NSCs 
(Arsenijevic et al., 2001). To identify progenitor cells, most commonly, nestin, an intermediate 
filament, Mushashi, an RNA-binding protein, as well as Sox2, a transcription factor essential for 
maintaining pluripotency used as a markers for undifferentiated cells. While in the absence of 
mitogens, these cells can differentiate into neurons and glia (Svendsen et al., 1998). 
Temporally, in utero, neurogenesis precedes gliogenesis (Shimazaki, 2003). Neurons and glial 
cells can be identified by their morphology and expression of cell-specific markers such as, for 
neurons, MAP2 (microtubule-associated protein 2) and βIII-tubulin (microtubule protein 
exclusively found in neurons) and glial cell specific markers like GFAP (glial fibrillary acidic 
protein) and S100b (glial-specific calcium binding protein B. 
 
Brain development entails differentiation of specialised cell types and their organisation in 
precise special anatomy. As such, research into neurodevelopment and the underlying 
mechanisms involved will provide insight into the biological bases for neurodevelopmental and 
psychiatric disease. Genetic modification of stem cells is important for the study of gene 
function in early human development. Although gene transfer using transfection and 
electroporation methods have been employed (Eiges et al., 2001; Furuya et al., 2003; Zwaka & 
Thomson, 2003; Urbach et al., 2004; Vallier et al., 2004); they have either resulted in 
inefficient transfer (Eiges et al., 2001; Zwaka & Thomson, 2003), or cytotoxicity (Furuya et al., 
2003; Zwaka & Thomson, 2003) or produce transient gene expression (Lakshmipathy et al., 
2004; Lorenz et al., 2004). Increasingly, the use of viruses in genetic modulation of particularly 
neurodevelopmental genes in rodent and human stem cells has proven useful. Stable 
transduction of human stem cells using lentiviral vectors has been widely reported (Gropp et 
al., 2003; Ma et al., 2003; Kosaka et al., 2004; Ben-Dor et al., 2006; Clements et al., 2006). 
Foetal neural stem cells (NSCs) have been shown to be successfully transduced with the viruses 
as vectors for gene transfer (Fu et al., 2008). An example of its use, is lentiviral-mediated 
overexpression of the mutant HD in human NSCs derived from the striatum to investigate its 
effect on neural cell death upon differentiation and maturation (Tabrizi et al., unpublished 
data). Silencing of DISC-1 in neural progenitor cells showed reduced neural migration 
supporting its vital role in neurodevelopment (Kobayashi et al., 2010). There is a plethora of 
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such proof of principle findings in the literature demonstrating that neural stem cells are 
indeed a good model for studying neurodevelopment. As with all models there are 
disadvantages, being an in vitro model system, it lacks the entire contents of the brain 
functional system. Also, the cells in culture may be in a state of ‘stress’ due to handling and 
repeat passaging which may effect cellular and molecular mechanisms. Furthermore, the brain 
is constantly learning, experiencing different emotion, thoughts and feeling which cannot be 
modelled in vitro. Nonetheless it is important to obtain some indications and ideas on how 
neurodevelopmental processes occur to further our understanding of brain function.  
 
 
5.3 Methods and Materials 
5.3.1 Lentiviral constructs for AUTS2 silencing  
Lentiviruses were produced for the below plasmid constructs, all of which were obtained from 
Open Biosystems®, Thermo Scientific, UK. The pGIPZ lentiviral plasmid contains a CMV 
promoter, a puromycin resistance gene and TurboGFP marker among other common lentiviral 
features (Figure 30, A).  The sense sequences for the siRNA (micro-RNA adapted shRNA, Figure 
30,B) used are given below: 
 
1) pGIPZ + non-silencing siRNA; sense sequence: ATCTCGCTTGGGCGAGAGTAAG 
2) pGIPZ + siRNA_ AUTS2 # 1; AUTS2 target sequence: CTAAAGCTGTGTTCCCATA  





Figure 30: Features of A) pGIPZ lentiviral vector and B) siRNA design. 
A) A commercially available plasmid (pGIPZ) cloned with the siRNA was obtained from Open Biosystems, 
UK. The CMV promoter is responsible for the expression of the reporter gene, turboGFP. This is followed 
by an encephalomyocarditis virus internal ribosome entry site (IRES), to facilitate the expression of the 
mammalian selection puromycin resistance gene and the siRNA. Other features include,  cPPT: central 
polypurine tract to help translocation into the nucleus of non-dividing cells; WRE: Woodchuck response 
element to enhance the stability and translation of transcripts; SIN-LTR (Self Inactivating Long Terminal 
Repeats); pUC Ori to maintain high copy replication and maintancence of plasmid in E.Coli. and ampicillin 













5.3.2 Lentiviral production and ultracentrifugation 
Open Biosystems® TransLenti Viral Packaging System (Thermo Scientific, UK) was used for 
transfection and production of lentiviral particles according to the manufacturer’s instructions. 
Briefly, the day before transfection, 5.5x 10
6
 293T cells were plated per 10cm dish in complete 
medium. For each transfection, 9μg transfer vector and 28.5μg packaging mix was diluted in 
1ml serum free medium and separately, 187.5μl of Arrest-In was diluted in 1ml of serum free 
medium. The diluted DNA and the diluted Arrest-in reagent were combined and incubated at 
RT for 20 minutes before adding 3ml complete medium. Following this step, the growth 
medium was aspirated from the cells and the transfection complexes mix. The cells were 
placed back at 37°C in 5% CO2 humidified incubator. Five hours later, the transfection mixture 
was replaced with 12ml culture medium and replaced in the incubator. Lentivirus-containing 
supernatants were harvested 48h and 72h following transfection. These were centrifuged at 
3000 rpm for 20 minutes at 4°C to pellet cell debris, filtered in a 0.22μm pore nitrocellulose, 
aliquoted and stored at -80°C until use. The supernatant were ultracentrifuged as described in 
2.3.2.3. General titres obtained using this protocol  ranged from 1.0-1.2 x10
9
 TU/ml.  
 
5.3.3 Lentiviral transduction of 293T and SPC-04 cell lines 
293T cells were transduced as described in 2.4. Successfully transduced cells were selected by 
addition of complete medium with 10µg/ml puromycin 48h after transduction.  
SPC-04 cell culture and lentiviral transduction is comprehensively explained in sections 2.2 and 
2.4. Puromycin was not used for positively transduced selection as the SPC-04 cell line is 
sensitive to this antibiotic nonetheless high transduction efficiency is achieved using the 
protocol described in 2.4. Transduction/ transfection efficiency was determined as described in 
Chapter 2, section 2.2.2.2. 
 
5.3.4 qPCR analysis 
RNA extraction and reverse transcription were carried out as per details in section 2.8. 
Quantitative RT-PCR was performed as in section 2.9. Human Actin was used as the 
housekeeping gene for qPCR analysis of cDNA produced from 293T RNA extracts while the 
control gene used for analysis of SPC-04 cDNA was RPL18, a gene that encodes one of the L18E 
family of ribosomal proteins that comprise the 60S subunit; its expression was found to be 
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relatively consistent at the different stages of neural stem cell differentiation. The primer 
sequences for human, ACTIN, AUTS2 and RPL18 are as follows: 
 
Table 25: qPCR primers used to amplify AUTS2, ACTIN and the control gene RPL18 in SPC-04.  
The AUTS2 primer amplified the medium and long isoform.  
 
Primer  Sequence 5’ > 3’ 
Human ACTIN  (forward) GCTCGTCGTCGACAACGGCTC 
Human  ACTIN  (reverse) CAAACATGATCTGGGTCATCTTCTC 
Human AUTS2  (forward) ACCCCATCCGGGACCCCTTG 
Human  AUTS2  (reverse) GGAGCCGCGTGTGCTCGTAG 
Human RPL18  (forward) GAGAGGTGTACCGGCATTTC 
Human RPL18  (reverse) CTCTGGCACGCTCGAACT 
 
The primers used to amplify exogenous AUTS2 mRNA were designed to amplify the long 
(transcript variant 1) and medium (transcript variant 2) isoforms acknowledged by both RefSeq 
and the UCSC genome browser as the shRNA targeted these isoforms. For data analysis, 
expression values for AUTS2 were initially normalized against the internal control mRNA 
expression value to give ΔCt values (ΔCt = Cttarget – Ctcontrol). Ct was defined as the fractional 
cycle number at which the amount of amplified target reached a fixed threshold. The ΔCt value 
for each condition was subtracted from the ΔCt of the control condition i.e. cells transduced 
with non-silencing siRNA. The changes in mRNA expression relative to this control was 
obtained by raising 2 to the negative power of the calculated difference i.e. for siRNA_AUTS2 
(2
−(Δct siRNA AUTS2 infected cells−ΔCt non−silecning infected cells)
). 
 
5.3.5 Microscopy and imaging 
Images were taken with the Lieca fluorescence microscope DM2500 with images taken at 10x 




5.3.6 RNA quantification, labelling and Microarrays 
The RNA quantification, labelling, hybridisation, washing and scanning steps were carried out 
by Eric Nasser, Biomedical Research Centre (BRC) genomics facility, King’s College London. 
Total RNA was quantified using the Qubit® RNA assay kit (Life Technologies, UK) on a Qubit®2.0 
fluorometer according to the manufacturer’s instructions. RNA integrity was checked using the 
Agilent RNA 6000 Nano Kit on an Agilent 2100 Bioanalyzer. Total RNA was labelled 
(biotinylation) using TargetAmp™-Nano Labeling Kit for Illumina® Expression BeadChip® 
(Cambio, Cambridge, UK) according to the manufacturer’s instruction, with RNA quantification 
using the Qubit®  RNA assay kit  on a Qubit®2.0 fluorometer as previously mentioned. Gene 
expression profiling was performed using the HumanHT -12 v4.0 expression BeadChip Kit 
(Illumina Inc, CA, USA) which contains more than 47,000 probes derived from the National 
Centre for Biotechnology Information Reference Sequence (NCBI). Arrays were read on an 
Illumina Bead array confocal scanner. Each sample was done in triplicates (n=3). 
 
5.3.7 Statistics 
qPCR quantification of AUTS2 expression: Data were expressed as mean ± SEM and 
normalised to the values obtained from cells infected with non-silencing siRNA expressing 
lentiviruses. To verify a between treatment difference, a one-way ANOVA with factor 
treatment was performed. To test for treatment differences, pre-planned comparisons were 
conducted using the independent sample t-test.  
Microarrays: Analysis was performed by Dr Venu Pullabhatla, NIHR GSTFT/KCL Comprehensive 
Biomedical Research Centre, using GenomeStudio Data Analysis Software with the following 
parameters: 1) Background subtraction; 2) Quantile normalization; 3) t-test model for 
identifying differentially expressed probes and genes; 4) Benjamini and Hochberg error 
correction for multiple testing (FDR). 
For identifying differentially expressed genes, a Differential Score of +/- 13, is the equivalent of 









5.4.1 Silencing of AUTS2 in 293T cell line 
Two commercially available lentiviral plasmids encoding AUTS2-targeting siRNA were tested 
for efficient knock down in the 293T cell line which endogenously express all three isoforms of 
AUTS2. As 293T cells expressed AUTS2 at a similar level to SPC-04 (Figure 31), this cell line was 
used to screen for siRNA that efficiently knockdown AUTS2 as it easy to culture and less costly 
to maintain. Although a human neuroblastoma cell line SHSY5Y, was available in our lab, which 
would be well –suited for this prupose, its, AUTS2 expression level was low in this cell line 
compared to 293T cell line (Figure 31); hence the latter was used for the experiment.  
 
293T cell line was transduced with lentiviruses containing these constructs alongside a control 
i.e. lentiviruses encoding non-silencing siRNA. As shown inFigure 32, cells transduced with 
lentiviruses expressing siRNA_AUTS2 # 1 efficiently silences this gene down to approximately 
30%. There was significant effect between groups on AUTS2 expression (F4,10 = 31.64, p<0.001). 
Post-hoc analysis showed significant knockdown of AUTS2 by this siRNA (p<0.001). Data is 
shown for the expression of the long and medium isoform, as this siRNA targeted these 
specifically. On the other hand, siRNA_AUTS2 # 2 had no significant effect on AUTS2 expression 
(p=0.186). Data is shown for the medium and long isoform although this siRNA targeted all 
three isoforms. Analysis of the expression of all three isoforms showed similar results as that 




Figure 31: RT-qPCR to confirm endogenous AUTS2 mRNA expression in three human 
cell lines.  
Lower delta Ct values (CttAUTS2 – CtACTIN) indicate higher levels of expression and vice versa. These findings 
indicate that AUTS2 mRNA is endogenously expressed in the three cell lines examined, with the highest 





Figure 32: Effects of the AUTS2-targeting lentiviral constructs on AUTS2 expression in vitro.  
HEK293T cells were infected with lentiviruses carrying a vector either encoding a sequence that does not 
target any mammalian sequence (denoted non-silencing siRNA) or encoding siRNAs targeting AUTS2. 
Quantification of mRNA levels was performed by real-time qPCR (mean ± S.E.M of 3 independent 













































5.4.2 SPC-04 cell line differentiation upon lentiviral mediated silencing of 
AUTS2 
SPC-04 have the ability to generate a high number of neurons as described in (Jeffries et al., 
2012), where undifferentiated cells (Figure 33, A) after 7 days differentiation, acquire a more 
elongated morphology (Figure 33, B). This change is more pronounced after 14 days 
differentiation.  
Having ascertained that siRNA#1 efficiently knocked down AUTS2 in the 293T cell line, SPC-04 
were transduced at the undifferentiated state after which lysates for RNA extraction were 
collected 48hours later. In addition, this cell line was also transduced during differentiation 
(i.e. addition of the lentiviral particles along with the differentiation-inducing agents). Lysates 
for RNA extraction were collected 7 days after the removel of the lentivirus and 
differentiation-inducing media (denoted 7 days differentiation). Refer to section 2.1.2.3 for 
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more protocol details on the various differentiation stages. A transduction efficiency of 85-90% 
was achieved in both these experiments. 
Before harvesting the cells for qPCR and microarray analysis, the morphological features of the 
cell line were compared between cells infected with lentiviruses containing non-silencing 
siRNA and siRNA targeting AUTS2 at the undifferentiated stage and after 7 days differentiation. 
Results indicated that there were no visible differences in morphology of the undifferentiated 
and differentiated cells between the two groups (Figure 33, C-D).  The same applied to cells 
transduced during differentiation; there were no morphological differences between the two 




Figure 33: Representative images of SPC-O4 morphology before and after differentiation.  
A) undifferentiated B) after 7 days differentiation C) Undifferentiated transduced with non-silencing 
siRNA D) undifferentiated AUTS2 siRNA E) after 7 days differentiation non-silencing siRNA F) after 7 days 
differentiation AUTS2 siRNA. Bar represents 200µm. GFP is the reporter gene expressed from the same 









5.4.3 Silencing of AUTS2 in undifferentiated and differentiated SPC-04 cell 
line  
 
Having verified that siRNA_AUTS2 #1 efficiently knocked down its target, the human foetal 
neural stem cell line SPC-04 was transduced with this siRNA. As controls, cells were infected 
with lentiviruses encoding non-silencing siRNA and non-infected cells were included. 
Microarrays were performed in triplicates for 2 experiments: Experiment 1: cells transduced at 
the undifferentiated stage. Experiment 2: cells transduced during differentiation; lentiviruses 
were introduced during the addition of the differentiation inducing agents. Cells were 
harvested at various stages of differentiation i.e. pre-differentiation (after 48 hours incubation 
with medium containing differentiation agents and lentiviruses), 3 days after this stage 
denoted 3 days differentiation, 7 days differentiation and 14 days differentiation. Samples for 
14 days differentiation were not included in the microarray due to low RNA yield and quality 
during RNA extraction. Disappointingly, microarray results showed no differential expression 
of any genes between any of the groups analysed including no knockdown of AUTS2 detected 
(Table 26). No gene was identified with a Differential Score of greater than +13 or less than -13 
in any of the comparisons performed indicating that no differentially expressed genes were 
identified. A Differential score of +/- 13 is equivalent to a p value < or = 0.05. The transfection 
efficiency was observed to be approximately 80% so lack of knockdown of AUTS2 could not be 
attributed to lack of transduction. The entire dataset is not shown; however, Table 26 shows 
the microarray analysis for selected genes involved in neurodevelopmental processes for 
comparison between non-silencing and siRNA_AUTS2 at 7 days differentiation. Noticeably, the 
standard deviation between arrays is larger than the mean which is one reason why no 
significant differential gene expression is observed in the entire dataset. 
 
qPCR were also performed to confirm the above finding. 
Experiment 1: Figure 34A, shows that cells transduced with lentiviruses expressing 
siRNA_AUTS2 # 1 did not silence the gene in this cell line. There was no significant effect 
between groups on AUTS2 expression (F4,10 = 3.28, p=0.109). 
 
Experiment 2: Alongside the above experiment, the same siRNA was used to knockdown 
AUTS2 expression during the differentiation process. Results show no significant differences in 
AUTS2 expression between non-silencing siRNA and AUTS2-targeting siRNA in any of the 
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stages of differentiation (Figure 34,B). Data is representative of one experiment. An 
observation that is worth noting is that the presence of lentiviral particles seems to reduce 
AUTS2 expression regardless of the insert (non-silencing siRNA and AUTS2-targeting siRNA) in 
all the stages of differentiation. This reduction is similar in both groups demonstrating that 





Table 26: Microarray analysis of selected genes involved in neurodevelopment for 7 days SPC-04 
differentiation for non-silencing vs siRNA_AUTS2.  
No significant changes in global gene expression profiles were seen between any groups. No knock down of 
AUTS2 was detected after 7 days differentiation. Other genes involved in various cellular processes for 
neurodevelopment are listed below. A Differential Score of +/- 13, is the equivalent of a P value < or = 0.05 
where +/- indicates directionality of the differential expression (up or down regulation).  















AUTS2 4572.7 702.874 4419.1 548.882 -0.001 7 Autism susceptibility candidate 2  
CEND1 190.6 10.218 275.4 13.092 0.001 11 Cell cycle exit and neuronal 
differentiation 1 
PAFAH1B1 5492.4 1123.935 5928.8 993.808 0.001 17 Platelet-activating factor 
acetylhydrolase, isoform Ib 
GFAP 12466.7 5542.773 13813.4 8048.107 0.001 17 Glial fibrillary acidic protein 
TSC1 813.7 200.529 861.2 240.879 0.001 9 Tuberous sclerosis 1 
RUFY3 1094.4 324.047 1239.6 556.044 0 4 RUN and FYVE domain containing 
3  
NRXN2 24.5 21.579 16.9 10.554 0 11 Neurexin 2 (NRXN2) 
NPTX1 32.2 25.929 13.6 21.275 0   PREDICTED: neuronal pentraxin I 
SYNGR1 68.3 29.367 87.6 49.353 0 22 Synaptogyrin 1 transcript variant 
1b, mRNA. 
CDK5R1 1164.2 381.941 1111 226.356 0 17 Cyclin-dependent kinase 5, 
regulatory subunit 1 (p35)  
NRCAM 6514.2 2446 6290.4 1685.686 0 7 Homo sapiens neuronal cell 
adhesion molecule 
GAD1 773.7 72.459 742.1 235.402 0 2 Glutamate decarboxylase 1 (brain, 
67kDa), transcript variant GAD25 
ARHGEF7 1029.8 59.575 966.2 14.098 0 13 Rho guanine nucleotide exchange 
factor (GEF) 7, transcript variant 1, 
mRNA. 
COPG2IT1 109.2 53.492 71 11.019 0 7 COPG2 imprinted transcript 1 
(non-protein coding)  
NES 35.9 25.157 19.2 11,247 0 1  Nestin (NES) 
MSI1 89.7 80.787 101.6 60.875 0 12 MSI1 musashi RNA-binding 
protein 1  
 
SOX1 65.6 39.934 47.6 23.981 0 13 SOX1 SRY (sex determining region 
Y)-box 1  
 
BASP1 1208.4 1840.204 594.5 705.352 -0.001 5 Brain abundant, membrane 
attached signal protein 1  
INA 3411.4 1140.874 2296.4 641.606 -0.001 10 Internexin neuronal intermediate 
filament protein, alpha (INA) 
SYN1 58.8 49.832 44.5 18.083 -0.001 X Homo sapiens synapsin I  
STMN2 690.1 1179.64 135.5 205.947 -0.001 8 Stathmin-like 2  
ERC2 133.5 46.334 95 30.84 -0.001 3 ELKS/RAB6-interacting/CAST 
family member 2  
S100B 17.5 14.944 15.4 12.584 -0.001 21 S100 calcium binding protein, 
beta (neural) (S100B) 
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Figure 34:  Effect of the AUTS2-targeting lentiviral construct on AUTS2 expression in 
undifferentiated SPC-04 cell line and upon inducing differentiation.  
A) Undifferentiated SPC-04 cell line was infected with lentiviruses carrying a vector either encoding a 
sequence that does not target any mammalian sequence (denoted non-silencing siRNA) or encoding a 
siRNA that previously knocked down AUTS2 expression in 293T cells. Quantification of mRNA levels was 
performed by real-time qPCR (mean + S.E.M from 3 independent experiments). There was no significant 
difference between groups p=0.109. B) The cell line was infected with the abovementioned lentiviruses 
upon inducing differentiation. Note: error bars are not present as fold expression is calculated from one 



















































































5.5 Summary and Discussion 
 
The results presented above aimed at delving further into the neurodevelopmental role of 
AUTS2 using human foetal neural stem cell line SPC-04, to model neural stem cell 
differentiation. The idea was to silence AUTS2 expression in a neural stem cell line 
(undifferentiated and differentiated) and investigate its effect on neural stem cell 
differentiation, proliferation and cell survival. Additionally, another goal was to identify 
differential gene expression upon AUTS2 silencing which would enable the identification of 
gene networks that interact together with this gene.  
A couple of commercially available AUTS2-targeting microRNA-adapted shRNAs (siRNAs) were 
tested for their silencing efficiency initially in 293T, a cell line that endogenously expressed this 
gene at relatively high levels; its expression was found to be similar to that of the house 
keeping gene ACTIN. As explained earlier, this cell line is easy and less costly to maintain and 
was thus used to test knockdown efficiency of the siRNAs. qPCR analysis of these cells 
transduced with one of the siRNA (targeting specifically the medium and long isoforms of 
AUTS2) showed a 70% overall knockdown efficiency (based on three independent 
experiments). 
Thus, this siRNAi was then used to transduce a newly established human foetal neural stem 
cell line, SPC-04. At the time of writing this thesis. there were no publications on genes that 
could be knocked down in this cell line. However a PhD student within our group did 
successfully knock down another gene, Myt1l, in this cell line (unpublished data).  
 
Together, the expression of the medium and long isoforms of AUTS2 in SPC-04 is slightly lower 
than that in the 293T cell line; however the expression level is adequate to detect a 
knockdown. This cell line was transduced at two stages in triplicates: undifferentiated 
(experiment 1) and upon inducing differentiation i.e. during the addition of differentiation-
inducing factors and removal of growth factors (experiment 2). RNA extracts were collected for 
the following stages of the differentiation process: 1) undifferentiated (only experiment 1); 2) 
pre-differentiation (upon removal of differentiation-inducing agents; lentiviruses were also 
removed at this stage); 3) three days differentiation and 4) seven days differentiation for non-
infected, non-silencing and AUTS2-siRNA. Approx 85-90% transduction efficiency was seen at 
each of these stages. 
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There were no distinctive visible differences in morphology or cellular features such as cell 
appearance, apoptosis, and cell proliferation between cells infected with lentiviruses 
containing non-silencing siRNA and siRNA targeting AUTS2 transduced at both stages 
(undifferentiated and during differentiation). So quantitative analysis assessing these features 
was not performed.  
 
Microarray analysis was also performed on extracts from both experiments. A surprising 
finding however, was that despite the visible change in morphology after inducing 
differentiation where the cells looked elongated, there were no differentially expressed genes 
detected in the microarray experiments between any of the stages of differentiation tested. It 
is expected that progenitor cells that undergo differentiation, will have stopped proliferating 
thus it would be expected that genes responsible for this cellular event would be down 
regulated. Also, as cells differentiate into more specialised cell types, markers of 
undifferentiated phenotype such as Sox1, Nestin and Mushahi will decrease while neuronal-, 
glial- and oligodendrocytic- specific markers will start to increase. The microarray probes were 
present for these markers but showed no significant changes in the expression of these genes. 
It is difficult to speculate on the likely cause of this considering that sample preparation for 
microarray was performed by an external facility. However, it is worthy to mention that 
working with the SPC-04 cell line had been a challenging task as there were difficulties in 
inducing differentiation. Furthermore, the biological replicates did not ‘behave’ similarly i.e. 
despite treating all replicates similarly, some replicates yielded dying or dead cells. Thus, for 
the above experiments, six biological replicates were carried out in order to ensure that cell 
lystes were obtainable upon completion of the experiment. In light of these points raised, it 
may be that a possible discrepancy for microarray result could be due to two reasons: 1) the 
stochastic nature of this cell line in which cells randomly ‘behave’, would obviously result in 
inconsistencies across the triplicates. 2) In terms of differentiation, the triplicates may contain 
different proportions of neurons, astrocytes and oligodendrocytes. In fact, a mixture of cell 
types is thought to be a major source of biological variation in microarray experiments 
(Imbeaud & Auffray, 2005). Additionally, it has been shown that even if ‘genetically identical 
cells’ are cultured under ‘identical’ conditions, there is considerable disparity in gene 
expression profiles between them (Blake et al., 2003). Early passage cells were used for the 




In retrospect, since this cell line had not been studied previously and is not yet available 
commercially, it would have been advisable to investigate the characteristics of this cell line 
before conducting such an experiment. For example, carry out initial immunostaining analysis 
to look at number of each cell type in order to evaluate its consistencies in differentiation. 
One reason why there was no significant differential gene expression detected in the data set, 
is because the there were large standard deviation between arrays which could arise from 
either an abnormal biological sample, RNA preparation or poor hybridisation. Removal of 
potential outliers from the data set during analysis would decrease the standard deviations 
and possible increase the chances of finding significant changes in gene expression.   
 
An equally disappointing finding from the microarray data and subsequent qPCR analysis was 
that there was no significant difference in AUTS2 expression between those infected with non-
silencing siRNA and with siRNA targeting AUTS2 neither in undifferentiated nor differentiated 
SPC-04. The microarray contained one probe for AUTS2 which detected the long and medium 
isoform.  Likewise, amplification of the same isoforms was detected by primers for qPCR. The 
lack of AUTS2 knockdown in the SPC-04 is surprising as this siRNA clearly knocked down the 
medium and long isoforms in the 293T cell line. One possible explanation for the discrepancy 
between the two cell lines could be that perhaps the intrinsic silencing mechanisms may differ. 
While in 293T cells, the siRNA silencing mechanism may involve the degradation of RNA, it is 
possible that in the SPC-04 cell line the mRNA may be prevented from being translated. In 
order to corroborate this idea, protein lysates from the above experiments are required to 
carry out Western Blot using the anti-AUTS2 antibody that was previously used in Chapter 4. 
Due to time constraints to finish writing this thesis, this was not performed. Protein lysates 
were not collected for the above experiments so the whole experiment would need to be 
repeated. Nonetheless, an alternative cell line, preferably of neuronal origin could have been 
used to test for knockdown efficiency of AUTS2. The human neuroblastoma cell line SH-SY5Y 
was available in the laboratory but it expressed AUTS2 only at low levels. In hindsight we 
should have tested the siRNA in the SPC-04 cell line itself before performing microarray 
analysis. Ultimately, it is important to verify that AUTS2 is silenced at the protein level. Thus, 
the antibody characterised in the previous chapter could be used to corroborate this in the 
293T as well as the SPC-04 cell lines. 
 
In terms of future studies, further research is required to determine the role of AUTS2 in 
neurodevelopment. Ideally, more siRNAs will require to be tested in this specific cell line 
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before experimentation. In the Chapter 3.4, shRNA oligos were manually designed according 
to Hannon’s design strategy (Paddison et al., 2004). Although it is a more time consuming 
process to produce these shRNA constructs, were demonstrated to efficiently silence their 
targets in vitro. Furthermore, the antibody characterised in the previous chapter would 
confirm the knock down of AUTS2 at the protein levels which is ultimately what we want. 
As the SPC-04 cell line is not a commercially available cell line, perhaps more optimisation is 
required prior to its application to research experiments. Alternatively other neural stem cell 
lines could be used; for example human embryonic stem cells lines have been efficiently used 
as an in vitro model of neurodevelopment in order to study gene function (Shin et al., 2006; 
Kirkeby et al., 2012; Tirotta et al., 2012).  
 
In conclusion, neural stem cells are good models for neurodevelopment especially for their 
ability to manipulate gene expression at various stages of differentiation in order to investigate 
gene function. Although, the SPC-04 cell line used in this chapter was used without success to 
ascertain the neurodevelopmental role of AUTS2 in vitro, further work is required to achieve 



























6.1 Summary and discussion of data chapters 
The general aim of the work reported in this thesis was to investigate the functional role of 
three genes involved in neuropsychiatric disorders, dopamine receptors D2 and D3 as well as 
AUTS2 using lentiviral mediated gene delivery as a primary method of gene transfer.  
 
The first data chapter aimed to establish the above technique in vitro and in vivo using two 
dopamine receptor genes encoding for dopamine D2 and D3 receptors (D2R and D3R), for 
which their roles in locomotor activity has been well characterised in the literature. Lentiviral-
mediated gene knockdown and overexpression constructs for these genes were developed to 
specifically manipulate expression levels of these genes in the rat NAcc, a brain area important 
for spontaneous and induced locomotor responses. The findings from this chapter first showed 
that the lentiviruses generated indeed overexpressed and silenced D2R and D3R in vitro. 
Furthermore, the results demonstrated that NAcc D2R and D3R share a similar function in 
spontaneous locomotor activity in a novel environment though no contribution of these 
receptors to locomotor activity in a familiar environment was observed. However, there was a 
difference in their role in visual stimulation-induced locomotor activity. While NAcc D2R seems 
to limit light-induced activity, as silencing NAcc D2R potentiated this behaviour. On the other 
hand, NAcc D3R slightly reduced light-induced activity. Immunohistochemical staining of the 
brain sections from the different groups demonstrated that the injections were indeed 
localised in the NAcc and that the lentiviruses targeted specifically neuronal cells in this region. 
In order to completely validate this technique, in vivo confirmation of overexpression and 
knockdown of both D2R and D3R, either at the RNA or protein level, is required. 
 
The next chapter specifically aimed at determining the sub-cellular localisation of AUTS2 and 
its interacting protein partners. Thus, to achieve this assessment of a commercially available 
anti-AUTS2 antibody was carried out to verify its target specificity. This was done by creating a 
lentiviral plasmid overexpressing AUTS2 either in its native form or as a fusion protein to give 
V5-tagged AUTS2. Using anti-AUTS2 and anti-V5 antibodies, western blot analysis of 293T 
lysates transfected with the above constructs revealed that AUTS2 was indeed overexpressed 
at the protein level. Immunocytochemical analysis using the anti-AUTS2 antibody, on Neuro2a, 
a mouse neuroblastoma cell line showed that this protein was endogenously localised in the 
nucleus. This finding was confirmed by immunocytochemical analysis using the anti-V5 
antibody on lysates overexpressing V5-tagged AUTS2 in the 293T cell line. These findings 
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confirm a previous report by Bedogni et al. (2009) in which immunostaining was performed on 
mouse brain slices using a different anti-AUTS2 antibody. Interestingly, in this paper, AUTS2 
was specifically localised in neuronal nuclei. Data from this chapter has not only confirmed 
AUTS2 as a nuclear protein but also has validated a commercially available antibody that can 
be used for Western Blot and immunostaining for future studies.  
 
Next, having verified that the overexpression vector constructs and antibodies worked, both 
antibodies were used to co-immunoprecipitate AUTS2 in order to ‘pull out’ its potential 
binding/interacting protein partners. However, these antibodies were found to be unsuitable 
for co-IP despite a number of optimisations of the technique. In order to obtain some 
indication of its function, in silico analysis for AUTS2 had limited information on its potential 
interacting protein partners with little data from experimental evidence. However, the recent 
finding that AUTS2 and AUTS2-related proteins were recovered through tandem affinity 
purification of PCGF proteins (Gao et al., 2012), which are involved in suppression of gene 
expression by modification of histone protein during embryonic development, suggest that it 
may be part of a protein complex and is important early in development. As discussed earlier, 
the yeast two-hybrid system would enable the identification of other protein interacting 
partners and confirm its association with PCGF proteins. Clearly further investigation is 
required to verify and extend upon the above findings.  
 
Given its implications in a broad range of psychiatric disorders and its characterisation as a 
neurodevelopmental gene (Sultana et al., 2002; Richler et al., 2006; Bakkaloglu et al., 2008; 
Hamshere et al., 2009; Elia et al., 2010; Komoike et al., 2010; Mefford et al., 2010; Schumann 
et al., 2011), very little is known about the functional role of AUTS2 in neurodevelopment. 
Chapter 5 attempts to investigate this using lentiviral-mediated gene silencing of AUTS2 in 
human neural stem cell line, SPC-04. For this purpose, a couple of commercially available 
lentiviral plasmids containing microRNA-adapted shRNA (siRNA) (Boden et al., 2004; Siolas et 
al., 2005) targeting AUTS2 were obtained. Their target silencing efficiency was assessed in the 
293T, human embryonic kidney cell line which are easy to culture, less costly to maintain and 
endogenous AUTS2 expression was detected at relatively high levels. qPCR analysis of RNA 
extracts from cells transduced with one of the siRNAs showed a 70% overall knockdown 
efficiency (based on three independent experiments). This siRNA was then used to transduce 
the newly established human foetal neural stem cell line, SPC-04 at two stages of 
differentiation: undifferentiated and during differentiation. At the morphological level, there 
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were no visible differences between cells infected with AUTS2-targeting siRNA compared to 
control (non-silencing siRNA).  
 
A previous microarray analysis conducted prior to our experiments, (performed by Dr 
Desrivieres) in which the gene expression profile was looked at in undifferentiated, 
predifferentiated, 3 days differentiation and 7 days differentiation revealed a number of genes 
involved in synaptogenesis and axonogenesis such as SNAP25, SYN1, NRXN2, INA, ELMO1 were 
positively correlated with AUTS2 expression across all the differentiation stages analysed 
(unpublished data) although a batch effect for found in the triplicates. The plan was to repeat 
the experiment without obtaining a batch effect by performing the triplicates simultaneously 
and the idea was to see how the expression of these genes would change if AUTS2 expression 
was silenced. Microarray analysis was carried out at the undifferentiated stage, during 
differentiation, 3 days and 7 days differentiation. Disappointingly, analysis of AUTS2 mRNA 
expression specifically the medium and long isoforms which are targeted by the siRNA showed 
no AUTS2 knockdown effect in any of the stages of differentiation and this finding was 
confirmed by qPCR analysis. Even more surprising was the finding that microarray analysis 
showed no significant changes in global gene expression profile between any of the 
differentiation stages despite the morphological changes observed during the differentiation 
process. As discussed earlier this could be due to heterogeneous cell population even within 
the biological replicates resulting in variation in gene expression profiles. These incongruities 
were found in a similar experiment conducted by another student in our group. qPCR results 
confirmed that the siRNA did not knockdown AUTS2 in this cell line. In hindsight, before 
conducting microarray experiments, it would have been advisable to analyse AUTS2 expression 
to verify knockdown in this cell line even if this had already been done in a different cell line.  
 
Although the above chapters aimed at finding out the role of AUTS2 in neural function, clearly 
further research is required. Based on publically available online data for human and rodent 
AUTS2 gene expression, a few interesting comments, on the possible function of AUTS2 during 
development have been outlined below. Of course information obtained from these resources 
have to be interpreted with some caution.  
 
Looking at rodent gene expression in GenePaint which is a well established collection of in situ 
hybridisation experiments of the mouse developing brain for E10, E14.5, E15.5, post natal 
stages P7 and P56. This database showed that Auts2 is highly expressed in the developing 
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neocortex of the mouse brain.  Although it would be very useful to look at Auts2 expression at 
all these different stages, unfortunately, data for Auts2 expression is only available for E14.5. 
Nonetheless, this data shows that Auts2 is relatively highly expressed in the developing 
neocortex in agreement with previous in situ hybridisation findings (Bedogni et al., 2010b). 
Additionally, these results show that T-box brain 1 (Tbr1) is highly expressed in the same 
region which is not surprising as it transcriptionally activates neocortical Auts2 expression 
(Bedogni et al., 2010a). Given that several lines of evidence associate Tbr1 with neocortical 
differentiation, it is probable that Auts2 may also be involved in this process.  For example, 
Tbr1 was shown to be important for the transition of intermediate progenitors to post mitotic 
neurons in the neocortex (Englund et al., 2005; Bedogni et al., 2010a). Furthermore, Tbr1 
mutant mice display profound defects in frontal differentiation, and Auts2 expression was also 
reduced along with two other genes implicated in brain development Bcl2, Rorb and Reln 
(Reelin), a gene known to regulate neuronal migration and positioning in the brain.  
The neocortex is a brain region involved in higher brain functions such as motor commands, 
sensory perception, spatial reasoning, regulating thought and emotional processes and 
language. It has been shown that aberrant neocortical organization and circuitry may result in 
cognitive dysfunction and increase propensity to neuropsychiatric disorders (Valiente & Marin, 
2010; Rubenstein, 2011). It is now well known that the cognitive abilities unique to humans are 
due the large size of the neocortex compared to other species. In rodents the neocortex is 
smooth while in primates, it contains folds and grooves (sulci and gyri) to increase surface area 
and which has evolved to perform higher brain functions. 
 
Despite the differences in structural features and cognitive abilities of the rodent and human 
brain, analysis of the human brain transcriptome was carried out. This data, obtained from the 
Human Brain transcriptome database (Kang et al., 2011) contains gene expression profiles 
associated with neurodevelopmental processes such as synaptogenesis, dendrite 
development, cell proliferation and axonogenesis. In addition, it contains gene expression 
trajectories of specific genes in different human brain regions before and after birth 
specifically ranging from developmental stage post-conception week 5.7 (when the neural 
tube starts to form) through to 82 years of age. Data is generated from 57 developing and 
adult post-mortem brains from males and females of multiple ethnicities. Expression profiles 
are shown for six different brain regions (neocortex, striatum, hippocampus, mediodorsal 
nucleus of the thalamus, amygdala, cerebellar cortex) starting from 4 weeks post conception 
until 82 years of age. The data generated showed that AUTS2 is expressed post and pre-natally 
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(Figure S2, supplementary materials). Despite the small sample size, the various brain regions 
analysed such as neocortex, hippocampus, striatum, mediodorsal nucleus of the thalamus, 
cerebellar cortex all shared a similar expression patterns for AUTS2.  Interestingly, its 
expression peaks briefly during 10-13 week post conception, a period when cell proliferation 
and migration are key cellular processes. Furthermore, this database contains information on 
general gene expression profiles of co-expressed genes involved in specific biological processes 
such as cell proliferation, synaptogenesis, axon formation and myelination with distinct spatio-
temporal expression patterns are provided in the database. A systematic search to see if 
AUTS2 expression pattern matched that of any of these modules was performed. Intriguingly, 
the expression pattern of AUTS2 resembles that of DCX, doublecortin, a gene important for 
neural migration but also proliferation and differentiation. In light of the above findings, it is 
tempting to speculate that AUTS2 may be involved in these cellular processes. Further support 
for this view, comes from the observation that Auts2 is highly expressed in the subventicular 
zone, the area of the developing brain in which neurons are generated and from which they 
migrate (Bedogni et al., 2010a). Very recently, it has been shown that AUTS2 silencing in 
zebrafish using morpholinos (antisense technology), resulted in small head size, reduced 
neuronal number and locomotor dysfunction (Oksenberg et al., 2013) further supporting its 
role in neurodevelopment and brain function. Interestingly, PCGF3, one of the proteins with 
which AUTS2 was isolated using Tandem Affinity Purification as described in Chapter 4, also 
shared a similar expression trajectory of AUTS2 (see Figure S3 in supplementary materials), 
suggesting it may interact with this protein to execute its function. However, this is only 
speculation based on the above data; they only give clues that point to AUTS2 function.  In 




6.2 Project limitations and future directions 
Limitations specific to each study has been discussed in detail in the relevant sections. There 
are some limitations to this project as a whole that should be noted. Here, a discussion is 
presented on what could have been done differently if the project was to be done again. An 
issue that concerns the thesis as a whole, is producing accurate gene quantitation by properly 
normalising the qPCR data. Throughout this thesis, only one internal control gene has been 
used. There is growing evidence that normalising to a single housekeeping gene can introduce 
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large and variable errors in the analysis as the expression of these genes vary depending on 
the tissue types, experimental conditions and time points. Thus it is important to ensure 
reliable and accurate results, normalising based on multiple reference genes is required 
(Vandesompele et al., 2002). GeneNorm is a commonly used software that uses an algorithm 
to determine the most stable reference gene from a group of tested candidate housekeeping 
genes in a particular sample (Vazquez-Blomquist et al., 2012). If I had to repeat the projects in 
this thesis, I would use Genorm or a similar algorithm-operated software to normalise qPCR 
data. 
 
In Chapters 4 and 5, where AUTS2 cellular and molecular functional characterisation was 
sought, there are number of things I would have done differently. I would design shRNAs 
targeting human AUTS2 as I did for D2R and D3R. Ideally the shRNA would target all AUTS2 
three isoforms so that there would be no compensatory mechanisms, for example, increase in 
expression of the short isoform to compensate for the lack of expression of its longer 
transcript counterparts. In terms of in vitro experiments, the shRNA designed to knockdown 
the three isoforms of AUTS2 can be tested for its silencing efficiency (at RNA as well as protein 
level using the antibody characterised in Chapter 4) in a neural cell line that expresses this 
gene at high levels. For example, commercially available human neural cell lines can be used to 
not only test if the shRNAs silence AUTS2 but also investigate the consequence of various 
cellular processes such as cell survival, proliferation and differentiation on these cells. Human 
embryonic stem cell- and feotal- derived neural progenitors have been used to investigate 
neural proliferation, differentiation and even migration in vitro previously (Delaloy et al., 2010; 
Li et al., 2012). For example, ReNcell VM (Millipore, UK) is an immortalized human neural 
progenitor cell line with the ability to readily differentiate into neurons and glial cells. ReNcell 
VM was derived from the ventral mesencephalon region of human fetal brain which has been 
immortalized by retroviral transduction with the v-myc oncogene (Liedmann et al., 2012). 
Several publications have used this cell line to investigate differentiation potential upon 
specific gene manipulation (Hubner et al., 2010; Lange et al., 2011). I would carry out 
immunostaining in undifferentiated cells such as Sox1 and Nestin as well as differentiation 
markers such Tuj1 (neurons) and GFAP (glia) to investigate the differentiation potential in this 





Additionally, I would look for AUTS2 expression level (during various stages of differentiation) 
using the antibody I validated in Chapter 4. In the case where AUTS2 is expressed at a specific 
stage in differentiation, I would test for the silencing efficiency of AUTS2-targeting siRNA that I 
designed as explained above. If the siRNA significantly silenced AUTS2, I would then go on to 
investigate its effect on differentiation using the abovementioned differentiation markers. I 
would also conduct proliferation assays using BrdU assays for example. In the case that AUTS2 
is expressed in all stages of differentiation, I would systematically knock down AUTS2 at each 
stage and investigate the abovementioned cellular processes. Furthermore, co-expression 
analysis as outlined in Chapter 5 can be performed to investigate expression profiles of genes 
involved in neurogenesis and brain development in order to determine a possible molecular 
pathway through which AUTS2 may exert its function.  
 
Ultimately, in vivo findings would further our understanding of the contribution of this gene in 
mediating behavioural traits. Thus, manipulation of Auts2 expression in the brain will enable us 
to investigate the consequence of its absence in the developing brain on behaviour in mice. 
The Knockout Mouse project (KOMP) repository is an initiative to generate null mutation mice 
for every gene in the genome. Reference to its database showed that a knockout mice for 
Auts2 is not yet available. Indeed, knockout mice can be generated using lentiviral mediated 
gene delivery (Singer et al., 2007). It would be interesting to not only perform a battery of 
behavioural paradigms on these mice in order to study their cognitive, emotional and other 
behavioural function compared to their wild type counterparts. It would also be interesting to 
compare differences in brain sizes, overall brain architechture, cell proliferation, migration and 
differentiation between mutant and wild type mice both pre-natally and post-natally. Findings 
from this would indeed further our understanding on the contribution of AUTS2 in brain 




6.3 Concluding remarks 
The pathways leading from a specific gene to behaviour are complex. It is important to 
genetically dissect the molecular mechanisms which mediate behavioural traits in order to 
understand the underlyinging basis of neuropsychiatric disorders. To sum up, using dopamine 
receptors, this thesis has shown how lentiviral mediated gene delivery in vitro and in vivo can 
be used to delineate the role of different gene isoforms in distinct brain regions to investigate 
behaviour. The present series of findings also aimed to functionally characterise AUTS2and 
have highlighted the need to further investigate its importance in brain function and 
behaviour. It is hoped that the findings presented here may form the basis for future studies 
aimed at further elucidating the functional role of  candidate genes such as AUTS2, and thus 



























 Figure S1: Relatively high neocortical expression of Auts2 in the developing mouse  
In situ hybridisation at mouse embryonic stage 14.5 obtained from GenePaint (Visel et al., 
2004), www.GenePaint.org which contains gene expression patterns on tissue sections by RNA 
in situ hybridisation at mouse embryonic stages E10.5,  E14.5, E15.5 and post-birth stages P7 
and P56. This figure shows that mRNA expression of Auts2 is present in several tissues such as 
the cartilage of limbs and soft tissues of the nasal cavity in the mouse embryo but 
comparatively high expression is seen in the developing brain especially the neocortex as well 






























Figure S1: In situ hybridisation analysis of the mouse embryo E14.5 generated from GenePaint 
database (Visel et al., 2004) for A) Auts2; B) Tbr1; C) Drd3.  
For reference, the developing tissues of the embryo are labelled in D. Auts2 is expressed in the 
developing mouse brain, specifically the progenitor neurons of the neocortex. Tbr1 is highly and 
specifically expressed in the developing neocortical region while Auts2 is moderately expressed in the 
same region and is also detected in other regions such as the cartilage in the limbs. For comparison, 





























            











Figure S2: Expression trajectories of A) AUTS2 B) DCX in the developmental stages of the 
human brain.   
These figures are generated from ‘The Human brain transcriptome’ database. The solid vertical line 
between period 7 and 8 indicates birth.  The developmental stages range from post conception week 5.2 
to 83 years of age. DCX is doublecortin which is a microtubule-associated protein vital for neuronal 
migration. NCX: Neocortex; STR: Striatum ;HIP: Hippocampus; MD: Mediodorsal nucleus of the thalamus 
AMY: Amygdala; CBC: Cerebellar cortex 
 
 











Human AUTS2 is expressed at its peak when proliferation and migration are key 
processes 
The Human Brain Transcriptome Database (http://hbatlas.org (Kang et al., 2011)) gene 
expression profiles associated with neurodevelopmental processes such as synaptogenesis, 
dendrite development, cell proliferation and axonogenesis. In addition, it contains gene 
expression trajectories of specific genes in different human brain regions before and after 
birth. Data is generated from 57 developing and adult post-mortem brains from males and 
females of multiple ethnicities. A systematic search was carried out to compare AUTS2 




development in order to pick out any correlation that may point out to its role in development. 
Figure S2, (A) depicts the expression trajectory of AUTS2 in 6 different brain regions starting 
from 5.7 weeks post conception until 82 years of age generated from 57 developing and adult 
post-mortem. The brain regions analysed are: neocortex (NCX); striatum (STR); hippocampus 
(HIP); mediodorsal nucleus of the thalamus (MD); amygdala (AMY); cerebellar cortex (CBC). It 
can be seen that generally, AUTS2 is highly expressed in the human brain during the lifetime 
although its expression is higher in the prenatal stage of the developing brain compared to 
postnatally. Its expression peaks at period 3 (between 10 and 13 weeks post conception) 
representing the early foetal development period, and gradually decreases after birth until it 
stabilises at the end of period 12 corresponding to adolescence. Also evident is a generally 
small rise in the expression pattern in young adulthood (period 13, represented between 20-40 
years of age). Interestingly, the overall expression pattern of AUTS2 closely matches that of a 





Figure S3: Expression trajectory of PCGF3 in the developmental stages of the human brain.  
This gene is involved in the regulation of embryonic development although its mechanisms are unknown. 
Recently, AUTS2 was found to interact with the protein through tandem affinity purification (see Chapter 
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